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Biobanking of residual human biological materials (HBMs), usually obtained from surgeries, 
is crucial for the advancement of science and public health and improves current treatment 
of various diseases. However, biobanking of residual HBMs comes with ethical, social and 
legal implications (ELSI) that require attention.  This thesis will focus on residual HBMs tissue 
repository, which is considered as a biobank. 
 
The current ethical paradigm and academic debates have focused on informed consent and 
ownership of residual HBMs, and subsequent discussion on the rights of patients through 
benefits sharing, returning of results from the research and profit sharing when the residual 
HBMs are commercialised.  In this thesis, I will attempt to critique this paradigm and its’ 
application in the Singapore context.  
 
A key aim of this thesis is to contribute to the knowledge with regards to patients’ 
knowledge, attitudes, preferences and expectations in donating residual HBMs for research.  
This study will also examine the current approach to consent in a major healthcare 
institution in Singapore compared with other consent regimes, in relation to preferences 
expressed by patients when contributing their tissues.  
 
The outcome of a 3-part explanatory sequential research using mixed methods design is a 
main component of this thesis. It comprises of a systematic literature review, a quantitative 
research using consent forms for a period of ten years (from 2002 to 2011) in a major 
Singapore hospital and a qualitative interview of 100 patients who had contributed HBMs to 
the hospital’s tissue repository.   The empirical results have been analysed in comparison 
with previous reports in academic publications on ethical issues of tissue repositories and 
vi 
 
biobanking, with primary focus on informed consent and the relationship between residual 
HBMs repositories and patients.   
 
I defend in this thesis that specific informed consent is neither morally meaningful nor 
important to the donors of residual HBMs. A regime of general consent with mediated 
communication and respecting donor intent is proposed, together with the establishment of 
a moral institution with proper governance, safeguards and control for the collection, 
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Chapter 1. Introduction 
Biobanking of residual human biological materials (HBMs), usually obtained from surgeries, 
is crucial in biomedical research for the advancement of science and public health. Research 
results obtained from studies involving HBMs invaluably improves drug discovery, clinical 
management and current treatment of various diseases. However, biobanking of residual 
HBMs comes with ethical, legal and social implications (ELSI) that require attention.  
 
The current ethical paradigm and academic debates have focused on informed consent and 
ownership of residual HBMs and subsequent discussion on the rights of patients through 
benefits sharing, returning of results from research and profit=sharing when the residual 
HBMs are commercialised.  In this thesis, I will critique this paradigm and its’ application in 
the Singapore context.  
 
In the discussion of informed consent, opinion leaders within biobanking disciplines have 
proposed various regimes, which include the mode of informed consent and type of 
information required to render it valid.  Some experts have also suggested a highly explicit 
and structured approach to taking specific informed consent while others have suggested 
implicit, presumed or general consent.  These options are described later in this Chapter. 
 
The aim of this thesis is to contribute to Singapore and international knowledge with regards 
to patients’ knowledge, attitudes, preferences and expectations in donating residual HBMs 
to tissue repositories for research.  This study also examines the various models of consent 
currently used and compares them with a broad consent regime that is arguably more 
consistent with preferences expressed by patients when contributing their tissues. 
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This thesis also reviews the development of informed consent in tissue banking (as well as 
biobanking more generally), with comparisons to the notion of informed consent that is 
considered necessary in clinical trials and medical management. It will discuss current ethical 
requirements of informed consent in tissue banking in Singapore, together with other 
important ethical issues that have not been adequately discussed in this context.  
 
Informed consent is meant to protect human subjects from harm.  The prevailing paradigm 
of informed consent is characterized by providing specific and sufficient information about 
risks, all known uses of samples collected, benefits to participants, rights to ownership of 
HBMs, withdrawal of participation and its consequences.  However, in the context of 
biobanking of HBMs, this paradigm does not work well since these biobanks that collected 
tissues are unlikely to be fully certain of the types of future research that will use these 
tissues.  For example, biobanks that collected HBMs 20 years ago were not in a position to 
describe the type of genetic research that is now conducted using the collected HBMs.  This 
limitation is further described in Chapter 2, together with the current tissue banking 
situation in Singapore, and the experiences and preferences of Singaporeans as observed in 
my empirical research.  
 
This thesis will draw on and apply the findings from systematic literature reviews and two 
empirical research projects, which were conducted with the objective of understanding 
patients’ perceptions, attitudes and experiences on tissue banking and their preferences on 
informed consent.  The empirical results in Chapter 3 will be discussed in relation to 
academic publications on ethical issues of tissue banking, with focus on informed consent 
and the relationship between tissue repositories (and biobanks more generally) and tissue 




My empirical findings indicate that specific informed consent is not morally meaningful or 
important to contributors of residual HBMs contributors.  Rather, a broad consent regime 
with the right to withdraw from participation is proposed, and supported by a governance 
regime whereby tissue repositories serve as moral institutions with stewardship 
responsibilities over stored HBMs. These include proper control and safeguards for the 
collection, storage, distribution and use of residual HBMs in tissue repositories to promote 
accountability and gain public trust.  
 
I defend the view that specific informed consent is neither morally meaningful nor important 
to the contributors of residual HBMs to tissue repositories.  To reiterate, a regime of broad 
consent with emphasis on mediated communication, together with the establishment of a 
moral institution characterized by proper governance, safeguards and control for the 
collection, storage, distribution and use of the HBMs will better meet ethical goals and 
reasoned public expectations.  The theoretical basis in support of these propositions will be 
presented and discussed in chapter 4. 
 
1.1 The need for Human Biological Materials for research 
In the year 2009, the Times magazine listed HBMs in tissue repositories and biobanks as one 
of “10 Ideas Changing the World Right Now.”1  The report concluded that HBMs were 
transforming the manner researchers and medical professionals gain a better understanding 
of diseases and discover strategies to treat these illnesses.  HBMs have been identified as 
                                                          
1 PARK, A. 2009. 10 Ideas Changing the World Right Now. Time. 
http://content.time.com/time/specials/packages/article/0,28804,1884779_1884782_18847
66,00.html assessed on 0902013 
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crucial to the core research infrastructure of tissue repositories for advancing medicine and 
public health.2  An example would be the identification of disease-specific information or 
biomarkers revealed by comparison of DNA sequences between tissue samples derived from 
patients and healthy donors which would assist researchers in improving treatment success 
through the identification and significance of genomic and proteomic difference between 
healthy and diseased individuals.3  HBMs have since become an important source for 
academic medical research and the development of diagnostics and therapeutics.4  
 
The practice of collecting and storing HBMs for research has been documented since the 
beginning of medical science.5  There are however variations in the definition of HBMs which 
are sometimes collectively referred to as human ’tissues’, human ‘bio-specimens’ or ‘bio-
samples’.   The term ‘human biological materials’  includes any human materials removed or 
derived from the body, such as solid body tissues, organs, blood, cord blood, other bodily 
fluids and their derivatives, secretions, body parts, biopsy specimens obtained for diagnostic 
purposes, organs removed during surgery, foetuses, gametes and embryos, and DNA/RNA 
                                                          
2 GOTTWEIS, H., GASKELL, G. & STARKBAUM, J. 2011c. Connecting the public with biobank 
research: reciprocity matters. Nat Rev Genet, 12, 738-9. ibid. ibid. ibid. 
3 BALKO, J. M., COOK, R. S., VAUGHT, D. B., KUBA, M. G., MILLER, T. W., BHOLA, N. E., 
SANDERS, M. E., GRANJA-INGRAM, N. M., SMITH, J. J., MESZOELY, I. M., SALTER, J., 
DOWSETT, M., STEMKE-HALE, K., GONZALEZ-ANGULO, A. M., MILLS, G. B., PINTO, J. A., 
GOMEZ, H. L. & ARTEAGA, C. L. 2012. Profiling of residual breast cancers after neoadjuvant 
chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med, 18, 
1052-9. 
4 GODARD, B., SCHMIDTKE, J., CASSIMAN, J. J. & AYME, S. 2003. Data storage and DNA 
banking for biomedical research: informed consent, confidentiality, quality issues, ownership, 
return of benefits. A professional perspective. Eur J Hum Genet, 11 Suppl 2, S88-122. ibid. 
5 ALLEN, M. J., POWERS, M. L. E., GRONOWSKI, K. S. & GRONOWSKI, A. M. 2010. Human 
Tissue Ownership and Use in Research: What Laboratorians and Researchers Should Know. 
Clin Chem, 56, 1675-1682. 
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and cells, from either living or dead persons.6  These materials are commonly obtained 
either during routine surgical and medical diagnostic procedures or via direct contributions 
by individuals when they participate in clinical research.  The term “Human Biological 
Materials” is also used by the Council of Europe in its recommendation on “Research on 
biological materials of human origin”7, the National Bioethics Advisory Commission (USA) in 
its report on Research Involving Human Biological Materials: Ethical Issues and Policy 
Guidance, and Canada’s Tri-Council Policy Statement on Ethical Conduct for Research 
Involving Humans.8  Singapore’s Bioethics Advisory Committee (BAC), established to address 
the ethical, social and legal issues of bio-medical research in Singapore, chose to use a more 
commonly accepted term, “human tissues”, in their reports on human tissues research.  
They defined human tissues as “all kinds of human biological materials derived from living or 
cadaveric donors including solid body tissues, organs, foetuses, blood and other bodily fluids 
and their derivatives, cord blood, embryos, gametes (sperm or eggs), or any part or 
derivative thereof.” 9   Based on this definition, the BAC’s made referenced to “human tissue” 
to encompass both human biological materials and human tissues, which include whole 
embryos, sperms and eggs, in a strict biological sense.  In essence, the definition of “human 
tissues” by Singapore’s BAC is similar to those in US and EU guidelines.  This thesis will use 
                                                          
6 MESLIN, E. M. & QUAID, K. A. 2004. Ethical issues in the collection, storage, and research 
use of human biological materials. J Lab Clin Med, 144, 229-34; discussion 226. 
7 The Council of Europe's Recommendation (2006)4 on research on biological materials of 
human origin.  Accessed on 1 may 2014 
http://www.coe.int/t/dg3/healthbioethic/Activities/10_Biobanks/default_en.asp 
8 HELFT, P. R., CHAMPION, V. L., ECKLES, R., JOHNSON, C. S. & MESLIN, E. M. 2007. Cancer 
patients' attitudes toward future research uses of stored human biological materials. J Empir 
Res Hum Res Ethics, 2, 15-22. 
9 BAC, S. 2002. Human Tissue Research: A report by Bioethics Advisory Committee Singapore. 
November 2002. Section 2.1, Page 3 
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the term “human biological materials” (and abbreviated as HBMs), which includes human 
tissues and all biological materials of human origin.   
 
In the context of this research, HBMs are usually collected using different strategies. Some 
HBMs are specifically collected from healthy volunteers for the sole purpose of research and 
others are collected from patients after diagnosis, surgery or therapy.  In the second 
scenario, residual or excess residual HBMs obtained in the course of diagnosis, surgery or 
medical management of patients that were originally collected for non-research purposes, 
were sometimes stored and subsequently used for research.10  Residual HBMs are the most 
frequent and convenient source of HBMs as large quantity of materials were collected as 
biological wastes after a surgery or procedure.11  The discussion and research on residual 
HBMs in this thesis will exclude whole reproductive organs, embryos, eggs, sperms and 
other reproductive cells and tissues, which have different ethical impacts and issues.  The 
use of patients’ residual HBMs stored in tissue repository is distinct from other biobanking 
projects in which the tissue is specifically collected from healthy volunteers.12  In this part of 
thesis, we will focus on the ethical issues for the collection and use of residual HBMs for 
research by an institution or tissue repository.   Some have argued that the use of residual 
HBMs poses no ethical issue, but from the scandal involving Alder Hey Hospital in the UK,13 
                                                          
10 GEFENAS, E., DRANSEIKA, V., SEREPKAITE, J., CEKANAUSKAITE, A., CAENAZZO, L., GORDIJN, 
B., PEGORARO, R. & YUKO, E. 2012. Turning residual human biological materials into 
research collections: playing with consent. J Med Ethics, 38, 351-5. 
11 GIESBERTZ, N. A., BREDENOORD, A. L. & VAN DELDEN, J. J. 2012. Inclusion of residual 
tissue in biobanks: opt-in or opt-out? PLoS Biol, 10, e1001373. 
12 RIEGMAN, P. H. & VAN VEEN, E. B. 2011. Biobanking residual tissues. Hum Genet, 130, 
357-68. 
13 SQUE, M., LONG, T., PAYNE, S., ROCHE, W. R. & SPECK, P. 2008. The UK postmortem organ 
retention crisis: a qualitative study of its impact on parents. J R Soc Med, 101, 71-7. 
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unauthorized organs retention and other similar cases of non-consensual storage and use of 
residual HBMs proved otherwise.   
 
Residual HBMs, such as cancer or diseased tissues removed by surgery, have emerged to be 
an important and rich resource for biomedical research and clinical studies.  These 
specimens are typically utilized by biomedical researchers to gain a deeper understanding of 
mechanisms of cellular and molecular processes of diseases such as cancers that could 
ultimately be translated into improvements in diagnosis and treatment to prolong the 
survival of cancer patients.14  Through genomics and proteomics research, scientists may 
uncover molecular clues to the cause of a particular cancer type, or target a specific protein 
found specifically in diseased but not in healthy individuals as a form of personalized 
treatment of an otherwise untreatable condition.  New molecular techniques on residual 
HBMs, coupled with advances in information technology, are now transforming the research 
arena with high-throughput robotic systems that can utilize HBMs for tissues microarray 
(TMA) testing.  TMA consists of multiple paraffin blocks in which up to one thousand 
unrelated tissue cores from different patients, are assembled in an array fashion to allow 
high-throughput histological analysis of disease biomarkers and protein expression.  The 
residual HBMs used in TMA, are leftover formalin fixed paraffin-embedded (FFPE) tissues 
that are originally used for diagnosis and have been compulsorily stored in the hospital as 
part of archival pathological record.15  The requirement of large quantities of HBMs for TMA 
                                                          
14 OOSTERHUIS, J. W., COEBERGH, J. W. & VAN VEEN, E. B. 2003. Tumour banks: well-
guarded treasures in the interest of patients. Nat Rev Cancer, 3, 73-7. 
15 WOLFF, C., SCHOTT, C., MALINOWSKY, K., BERG, D. & BECKER, K.-F. 2011. Producing 
Reverse Phase Protein Microarrays from Formalin-Fixed Tissues. In: KORF, U. (ed.) Protein 
Microarrays. Humana Press. 
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has since raised concerns over potential shortages of residual HBMs for cancer and other 
research.16   
 
Clinical treatments and new drug developments have progressed and benefitted from the 
numerous research studies on residual HBMs obtained from patients after surgical 
procedures.17   Residual HBMs are crucial in improving the efficacy of clinical studies as they 
present an alternative to in vivo animal models thus reducing the need for animal testing in 
clinical research.18  Traditionally, drug development requires animal testing for toxico-
efficacy research before clinical trials can be conducted on human subjects.  With residual 
HBMs collected from patients, newly invented chemical compounds can be safely tested on 
established human cell lines, as in vitro models, generated from residual HBMs without 
exposing patients to physical harm or as an alternative to the sacrifice of laboratory 
animals.19  The intrinsic benefit of using HBMs instead of laboratory animals for screening 
and testing of new drug compounds is that when utilizing HBMs models, it is likely to yield 
results that are more representative of the effects of the new compound on an actual 
human subject. This is something that cannot be achieved in laboratory animal testing. 
Several studies have shown that positive results on safety and efficacy of the new compound 
obtained from animal models (e.g. mice and monkeys) couldn’t be replicated in human 
                                                          
16 SCHMIDT, C. 2006. Tissue banks trigger worry about ownership issues. Journal of the 
National Cancer Institute, 98, 1174-1175. 
17 ASHBURN, T. T., WILSON, S. K. & EISENSTEIN, B. I. 2000. Human tissue research in the 
genomic era of medicine: balancing individual and societal interests. Arch Intern Med, 160, 
3377-84. ibid. 
18 OOSTERHUIS, J. W., COEBERGH, J. W. & VAN VEEN, E. B. 2003. Tumour banks: well-
guarded treasures in the interest of patients. Nat Rev Cancer, 3, 73-7. 
19 BERUBE, K. A. 2013. Medical waste tissues - breathing life back into respiratory research. 
Altern Lab Anim, 41, 429-34. 
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models.20  These collections of residual HBMs also enable scientists to determine cellular 
toxicity by experimenting on the extracted tissues, before conducting Phase I clinical trials 
on actual human subjects.  Residual HBMs can also be utilized to validate in vitro scientific 
findings,21 to identify potential new biomarkers for diagnostic and/or prognostic values,22 
and to determine the suitable treatment regimen for patients in personalized medicine.23 
 
There has been an increasing demand for HBMs, in recent years, due to scientific 
advancement of new research and increase in awareness of HBMs’ value in research.24    A 
survey of 700 cancer researchers showed that 47% of researchers had difficulty finding 
HBMs of sufficient quality and 81% of them reported that their scope of work was limited 
due to shortage of HBMs, whereas 60% said they questioned the statistical evidence in the 
findings of their studies, due to insufficient HBMs.25 Thus, having access to a larger number 
of HBMs for research, will create better research opportunities with the ultimate goals of 
advancing medical science and public good.  
 
                                                          
20 SHANKS, N., GREEK, R. & GREEK, J. 2009. Are animal models predictive for humans? 
Philosophy, Ethics, and Humanities in Medicine, 4, 2. 
21 ZATLOUKAL, K. & HAINAUT, P. 2010. Human tissue biobanks as instruments for drug 
discovery and development: impact on personalized medicine. Biomark Med, 4, 895-903. 
22 HEWITT, R. E. 2011. Biobanking: the foundation of personalized medicine. Current Opinion 
in Oncology, 23, 112-119 10.1097/CCO.0b013e32834161b8. 
23 PARKINSON, D., DRACOPOLI, N., PETTY, B., COMPTON, C., CRISTOFANILLI, M., DEISSEROTH, 
A., HAYES, D., KAPKE, G., KUMAR, P., LEE, J., LIU, M., MCCORMACK, R., MIKULSKI, S., 
NAGAHARA, L., PANTEL, K., PEARSON-WHITE, S., PUNNOOSE, E., ROADCAP, L., SCHADE, A., 
SCHER, H., SIGMAN, C. & KELLOFF, G. 2012. Considerations in the development of circulating 
tumor cell technology for clinical use. Journal of Translational Medicine, 10, 138. 
24 HAWKINS, A. K. 2010. Biobanks: importance, implications and opportunities for genetic 
counselors. J Genet Couns, 19, 423-9. 
25 ASHBURN, T. T., WILSON, S. K. & EISENSTEIN, B. I. 2000. Human tissue research in the 




Large scale research biobanks are being prospectively established, with the purpose of 
storing residual HBMs collected for research purposes, together with information on donors’ 
lifestyles and health status to aid studies on relationships between disease, genes and 
donors’ environments.26  Genetic research can help improve global health through greater 
understanding of the basic mechanism of the disease, susceptibility and resistance, thereby 
guiding the development of preventive intervention of such disease.27   A greater 
understanding of the effects of genetic variation on response to drugs allows researchers to 
help develop cures for malaria, HIV, tuberculosis, cancers and other diseases.28   From 
genomic analysis, prognosis and treatment response to certain chemotherapeutic drugs, 
personalized treatment can then be tailored once researchers have identified specific 
disease markers by comparing data from HBM contributors who respond to treatment with 
non-responders.29   
 
This thesis will focus primarily on the collection and use of residual HBMs in research and 
define the term “residual HBMs” as materials taken from the patient in the course of a 
diagnostic or therapeutic procedure, which can be stored and subsequently used for 
research.30   
                                                          
26 SHICKLE, D. 2006. The consent problem within DNA biobanks. Stud Hist Philos Biol Biomed 
Sci, 37, 503-19. 
27 RISCH, N. J. 2000. Searching for genetic determinants in the new millennium. Nature, 405, 
847-56. 
28 WEATHERALL, D. J. 2003. Genomics and global health: time for a reappraisal. Science, 302, 
597-9. 
29 ZATLOUKAL, K. & HAINAUT, P. 2010. Human tissue biobanks as instruments for drug 
discovery and development: impact on personalized medicine. Biomark Med, 4, 895-903. 
30 VAN VEEN, E. B., RIEGMAN, P. H., DINJENS, W. N., LAM, K. H., OOMEN, M. H., SPATZ, A., 
MAGER, R., RATCLIFFE, C., KNOX, K., KERR, D., VAN DAMME, B., VAN DE VIJVER, M., VAN 
BOVEN, H., MORENTE, M. M., ALONSO, S., KERJASCHKI, D., PAMMER, J., LOPEZ-GUERRERO, J. 





1.2 Description of residual HBMs in Research 
Biobanks routinely collect and store different types of HBMs.  HBMs can be obtained from 
different parts of the human body; from different types of subjects depending on whether 
the contributor is a healthy volunteer or patient; for different purposes of removal of 
materials depending on whether it is primarily intended only for research; or for different 
uses of HBMs collected.  This thesis will focus on residual HBMs obtained from surgical 
activities or collected as pathological archived materials, and used for future research.  
 
1.2.1 What are residual human biological materials? 
As explained above, residual HBMs refer to materials taken from patients in the course of a 
diagnostic or therapeutic procedure, which can be stored and subsequently used for 
research.31  Gefenas et al. further clarified that residual -HBMs are materials removed during 
surgical treatment or biological material leftover after diagnostic testing. 32   The leftover 
materials are originally supposed to be processed as medical wastes and disposed, if they 
are not used for research. In the published literature, residual or leftover HBMs may also be 
                                                                                                                                                                      
PASSIOUKOV, A., LEJEUNE, S., THERASSE, P. & OOSTERHUIS, J. W. 2006. TuBaFrost 3: 
regulatory and ethical issues on the exchange of residual tissue for research across Europe. 
Eur J Cancer, 42, 2914-23. 
31 VAN DIEST, P. J. 2002. No consent should be needed for using leftover body material for 
scientific purposes. For. BMJ: British Medical Journal, 325, 648-651. 
32 GEFENAS, E., DRANSEIKA, V., SEREPKAITE, J., CEKANAUSKAITE, A., CAENAZZO, L., GORDIJN, 
B., PEGORARO, R. & YUKO, E. 2012. Turning residual human biological materials into 
research collections: playing with consent. J Med Ethics, 38, 351-5. 
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referred to as ‘residues from medical procedures’, ‘surplus materials’, ‘body waste’, ‘medical 
waste’, ‘excess clinical material’, ‘redundant tissue’, or ‘leftover tissues’, etc.33  
 
In addition to the surgical leftover materials, Gefenas et al. also used the term ‘residual’ to 
refer to previously stored biological materials in pathological diagnostics archives. Such 
collections may be found in a variety of healthcare institutions including hospitals, pathology 
laboratories, tissue banks, blood banks and genetic laboratories.  For example, residual 
archived HBMs include diagnostic collections of pathology slides, existing collections of 
biological materials taken for non-research purposes during different stages of diagnostic or 
therapeutic procedures, like formalin-fixed, paraffin embedded tissues, which have been 
used for primary diagnosis and subsequently archived and stored by hospitals or their 
research institutions.34    
 
The use of such residual archived HBMs for research purposes is only allowed when extra 
histological sections are available or when the archived materials are no longer needed for 
diagnostics purposes.  In most countries, such diagnostic materials are compulsorily and 
legally kept in archived storage for a stipulated period and it is a professional duty to keep 
the original diagnostic sample lesion intact for further verification. The College of American 
                                                          
33 BROCHHAUSEN, C., ROSSRICKER, N. & KIRKPATRICK, C. J. 2007. Biological waste, 
ownership and personality - future perspectives for the secondary use of human tissue in the 
view of national and international regulations. Pathology Research and Practice, 203, 404-
404.  And  RIEGMAN, P. H. & VAN VEEN, E. B. 2011. Biobanking residual tissues. Hum Genet, 
130, 357-68. 
34 GEFENAS, E., DRANSEIKA, V., SEREPKAITE, J., CEKANAUSKAITE, A., CAENAZZO, L., GORDIJN, 
B., PEGORARO, R. & YUKO, E. 2012. Turning residual human biological materials into 
research collections: playing with consent. J Med Ethics, 38, 351-5. 
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Pathologists recommends a minimum of 10 years for the retention requirement of paraffin 
tissue blocks.35 
 
1.3 Sources of HBMs 
HBMs are usually collected and stored using 2 different strategies: (1) as materials 
specifically collected for one specific research use, which can later be research leftover 
samples or research residual HBMs after the specific research has been completed; and (2) 
as surgical leftover or residual HBMs obtained in the course of medical management of 
patients, including clinical care, diagnostics (e.g. health screening), therapy and transplant.36   
 
The most common purposes of harvesting or collecting HBMs are for clinical diagnosis, 
medical treatment and health screening.  These HBMs are usually stored as pathological 
samples after diagnosis is made, as part of the clinical records.  Surgical excess tissues or 
clinical residual HBMs, which are not required for diagnosis, have been an important source 
of materials for medical education and research. Residual HBMs samples from research are 
valuable, especially when they are accompanied with genomics and proteomics information 
that may save time and effort for other researchers who wish to use tissues for their own 
research.  By systematically transferring residual HBMs from previous research projects to a 
repository, the value of such residual HBMs can then be maximized through systematic 
                                                          
35 FITZGIBBONS, P. L. 2011. Are there barriers to the release of paraffin blocks for clinical 
research trials? A College of American Pathologists survey of 609 laboratories. Arch Pathol 
Lab Med, 135, 870-3. 
36 GIESBERTZ, N. A., BREDENOORD, A. L. & VAN DELDEN, J. J. 2012. Inclusion of residual 
tissue in biobanks: opt-in or opt-out? PLoS Biol, 10, e1001373. 
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distribution, allocation and governance.  
 
During surgery, some biological samples are removed from the body to aid in diagnosis 
and/or treatment of the patient’s medical condition.  In majority of these cases, not all 
tissues removed are needed for the primary use of clinical diagnosis and selection of 
treatment for the diagnosed condition. Excess leftover or residual tissues are normally 
discarded if they are not kept for future research. After clinical diagnosis, the diagnostic 
samples are stored as part of the medical records, normally within the pathology 
department of the hospital. These residual materials are normally discarded or destroyed 
when no further analysis is required.   Although the primary use of surgically removed HBMs 
is for medical diagnosis of living patients (in clinical/ diagnostic pathology) or deceased 
persons (in autopsy specimen collections), these specimens are also useful for secondary 
uses such as biomedical research, education and training.37   
 
HBMs are commonly stored in various premises in research hospitals, academic institutions 
and commercial research corporations, either at site of collection as an individual surgeon’s 
personal research collection or an organized storage commonly known as  ‘Tissue 
Bank’, ’Tissue Repository’, or ‘Biobank’.38  The Organisation for Economic Co-operation 
(OECD) defines biobanks as “structured resources that can be used for the purpose of 
genetic research, which include: (1) human biological materials and/or information 
                                                          
37 VERMEULEN, E., SCHMIDT, M. K., AARONSON, N. K., KUENEN, M., VAN DER VALK, P., 
SIETSES, C., VAN DEN TOL, P. & VAN LEEUWEN, F. E. 2009. Opt-out plus, the patients' choice: 
preferences of cancer patients concerning information and consent regimen for future 
research with biological samples archived in the context of treatment. J Clin Pathol, 62, 275-
8. 
38 CAMBON-THOMSEN, A., RIAL-SEBBAG, E. & KNOPPERS, B. M. 2007. Trends in ethical and 
legal frameworks for the use of human biobanks. Eur Respir J, 30, 373-82. 
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generated from the analysis of the materials; and (ii) extensive associated information.”39  
The UK Biobank Ethics and Governance Council states that “the most robust contemporary 
definition of ‘biobanks’ is rich collections of data plus bio-specimens, specifically developed 
as resources for research”.40  A research biobank or tissue repository is set-up and governed 
by either an institution or corporation for non-specific future research conducted by 
qualified researchers within its organization. The objective of such biobanks is to focus on 
and accelerate research, providing infrastructure for researchers to build a valuable resource 
for future research use.  
 
Some biobanks have a comprehensive standard operations procedure (including informed 
consent procedures) and standardized protocols, which allow ethical re-contact and 
collection of related medical information of the participants and patients who have donated 
their tissues for research.41   Different institutions and biobanks, however, have differing 
protocols observed by institutions for the ’banking’ of residual HBMs, especially in 
Singapore.42 
 
Individual clinicians and researchers may set up their personal collection of tissues for 
research. This is normally on an ad-hoc basis or for one-time use, and tissues collected are 
used specifically for their own research, normally stored in their laboratory and not shared 
                                                          
39 OECD 2009. The Organisation for Economic Co-operation and Development: Guidelines on 
Human Biobanks and Genetic Research Databases. 
40 UK Biobank Ethics and Governance Council. Report on Public meeting of the UK Biobank 
Ethics and Governance Council, 11th June 2007 (2007). 
41 MCGUIRE, A. L. & BESKOW, L. M. 2010. Informed consent in genomics and genetic 
research. Annu Rev Genomics Hum Genet, 11, 361-81. 
42 CHAN, T. 2012. The Closure of the National Bio-bank in Singapore. Asia-Pacific Biotech 
News Journal., 16, 40-43. 
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with other researchers who are not related or collaborating with the collectors. If these 
collections are not systematically collected, well stored and processed, they will lose their 
value for future research use due to doubts on sample and data integrity. When 
these ’private’ collections become too large, some of these researchers may convert their 
collections to ’biobanks’ and allow other researchers to use the collected HBMs, if permitted 
by their institutions and funding agencies.  Alternatively, they may donate their collections 
to an established biobank when their funding for storage is exhausted.   Before the 
establishment of institutional biobanks, most researchers with privately stored HBMs either 
discarded them after one use or kept them indefinitely, not knowing the function of these 
residual HBMs after their research is completed. Such HBMs from research are normally not 
shared or stored for future research, and thus results in much wastage if they are discarded 
after a single research use, as substantial funds have been spent to collect, store and process 
them.    
 
Surgical leftover or residual HBMs are most valuable and an easily accessible source if they 
are stored in biobanks for the purpose of future biomedical research.43 With the pooled 
storage of research and clinical residual HBMs stored in well-established biobanks, 
researchers are no longer required to directly approach patients or wait for new patients to 
be diagnosed each time they embark on a new study.  Residual HBMs can be stored either as 
untreated fresh frozen tissues or as Formalin-Fixed Paraffin-Embedded (FFPE) tissues in the 
form of paraffin blocks, stained or unstained sections in pathology laboratories. 
 
                                                          
43 VOIDONIKOLAS, G., GINGRAS, M. C., HODGES, S., MCGUIRE, A. L., CHEN, C., GIBBS, R. A., 
BRUNICARDI, F. C. & FISHER, W. E. 2009. Developing a tissue resource to characterize the 
genome of pancreatic cancer. World J Surg, 33, 723-31. 
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Since the late 1990s, biobanks have become an important resource for HBMs supporting a 
variety of contemporary research studies, which include genomics and personalized 
medicine.44  Due to the increasing demand for larger quantity of residual HBMs from surgery 
and diagnosis, this mode of collection in biobanks has become an important source of 
research materials.   The collection of residual or leftover HBMs, if performed ethically and 
professionally, will ease the current shortage of human biological samples for research.  
Research biobanking is an active initiative by a research institution or organization to 
prospectively collect HBMs from healthy volunteers and patients for current research.  These 
HBMs can also be stored for future research if there are leftovers and patients have given 
permission for such research use at the time of collection.   Biobanks may also be disease- 
specific, like the Cancer Tissue Bank, which stores leftover cancer tissues for research 
specialized in the identification or discovery of new biomarkers affiliated with such cancer.45    
Disease-specific biobanks are usually associated with either an affiliated hospital or a 
research institution, and they may collect samples representing a variety of diseases.  Large-
scale population-based biobanks are also established to store HBMs of healthy volunteers 
meant for studies that investigate the interaction between genes and environment /lifestyle 
in epidemiological and public health research.46  This thesis will focus on residual HBMs 
tissue repository, which is a type of biobanks. 
 
                                                          
44 HOEYER, K. 2008. The ethics of research biobanking: a critical review of the literature. 
Biotechnol Genet Eng Rev, 25, 429-52. 
45 OOSTERHUIS, J. W., COEBERGH, J. W. & VAN VEEN, E. B. 2003. Tumour banks: well-
guarded treasures in the interest of patients. Nat Rev Cancer, 3, 73-7. 
46 HOEYER, K., OLOFSSON, B. O., MJORNDAL, T. & LYNOE, N. 2004. Informed consent and 
biobanks: a population-based study of attitudes towards tissue donation for genetic 
research. Scand J Public Health, 32, 224-9. 
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1.4 Informed consent for Biobanking of residual HBMs for research 
Research results obtained from studies utilizing residual HBMs from biobanks can greatly 
improve current treatment of various diseases.  However, biobanking of residual HBMs is 
accompanied with many ethical, legal and social issues.47  Budimir et al. conducted a 
systematic review of all publications on ethical aspects of human biobanks.  The ethical 
issues identified from 154 articles included informed consent, privacy and confidentiality of 
the subjects, returning of results to the donors, ensuring and sustaining public trust, use of 
children and incompetent adults as study participants, commercialization of HBMs, roles of 
ethics review boards, data exchange, benefits sharing, ownership of the biological samples 
and data, legislative framework for biobanks and other emerging social issues.48   One of the 
main issues discussed in this thesis was the need to define the type of consent deemed 
applicable for residual HBMs for biobanking.  Informed consent in particular has been noted 
as being a highly discussed ethical topic in journal publications.49  Opinion leaders have 
proposed various regimes of informed consent including the mode of consent-taking and 
type of information needed to render an informed consent valid.  Some experts have 
suggested a highly structured and specific informed consent process, while others 
considered that implicit, presumed or general consent would suffice.  Zubin Master et al. 
systematically reviewed 470 publications and found no evidence of consensus on any 
consent regime for biobanking,50 although all authors agreed that contributors should not be 
                                                          
47 BUDIMIR, D., POLASEK, O., MARUSIC, A., KOLCIC, I., ZEMUNIK, T., BORASKA, V., JERONCIC, 
A., BOBAN, M., CAMPBELL, H. & RUDAN, I. 2011a. Ethical aspects of human biobanks: a 
systematic review. Croat Med J, 52, 262-79. 
48 Ibid. 
49 Ibid. 
50 MASTER, Z., NELSON, E., MURDOCH, B. & CAULFIELD, T. 2012. Biobanks, consent and 
claims of consensus. Nat Methods, 9, 885-8. ibid. 
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exposed to additional privacy and other risks without their consent.  We will review the 
various consent regimes for biobanking in the following chapter. 
 
1.4.1 Types of Consent 
Current established informed consent regimens in tissue banking of residual HBMs include 
explicit types like specific consent, tiered consent, general or broad consent, and implicit or 
presumed consent. Each of these regimes is considered below.   
 
Specific consent  
Specific consent is also known as project-based consent, where tissues requested for are 
only used in a specific project. Participants actively participate in the consent-taking 
process and explicitly consent to the contribution of HBMs by filling out a form. Specific 
written consent is regarded as offering the highest guarantees to the participant, in 
terms of specific assurances on the terms of participation.  It is most appropriate in 
studies that contain some level of risk, such as when participants disclose personal or 
sensitive information. For this reason, experiments and in-depth interviews in particular 
commonly rely on written consent. However, specific consent is also appropriate for 
studies with no risk above those of daily life, when the participants are exposed to 
deception, or any experimental treatment, if researchers consider the need to provide 
participants with as much information as possible at the point of consent to be 
important. Information provided will often include specific uses of the HBMs, specific 
period of storage and whether the donors will be re-contacted for consent to the use of 





Tiered consent  
Tiered consent is considered as broader consent (when compared to specific consent); 
where patients agree to a menu of options, which may include broad or specific consent 
for future use such as whether it is for a related or unrelated disease, time period, 
commercial uses, genetic conditions and so on.  Participants can choose from a list of 
different choices and level of participation. In addition, they can specifically decline 
certain future research applications.  For example, participants can choose not to allow 
their HBMs to be used for cosmetic products or cloning.   
 
Broad consent (or open consent)  
Broad consent is also known as one-time open consent or generic consent for all future 
uses of tissues. Here, participants consent to a less limited range of options such as 
future types of research and time periods.  Participants are given the explicit choice to 
opt-out during the initial consent process or to withdraw at any time after they have 
consented.  Broad consent is different from blanket consent in that the latter allows 
donated HBMs to be used for all purposes without any control or restriction.51   Broad 
consent permits some specific requirements (such as right to withdraw) and limitations 
on the future use of samples, whereas blanket consents does not allow any restrictions 
on future research studies.  For example, if specific types of research are known to be in 
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conflict with the fundamental values of contributors, such as studies on human cloning, 
these can be precluded in the initial broad consent.52 
 
Presumed consent or implicit consent     
Presumed consent is also known as opt-out or implied consent. Patients are informed 
that their specimens will be used for future research unless they deny permission by 
opting-out. Patients must actively opt-out if they do not wish to donate their tissues.53 
Participants are informed of the research or the collection of the HBMs for future 
research, and are considered to agree to participate unless they specifically decline or 
explicitly refuse to be included. In other words, when the patients allow their specimens 
to be collected for diagnostic purposes, they are presumed to have consented to 
research participation   
 
Precautionary consent     
The term ‘precautionary consent’ was used by the Council of Europe and the German 
Ethics Committee,54 and explained as seeking broad consent for research use of bodily 
substances collected for diagnostic or therapeutic purposes.  In the event of any 
concrete future research plans which requires the use of the retained samples, this 
                                                          
52 WENDLER, D. 2013. Broad versus Blanket Consent for Research with Human Biological 
Samples. Hastings Center Report, 43, 3-4. 
53 VERHEIJDE, J. L., RADY, M. Y. & MCGREGOR, J. 2009. Presumed consent for organ 
preservation in uncontrolled donation after cardiac death in the United States: a public 
policy with serious consequences. Philos Ethics Humanit Med, 4, 15. 
54  Council of Europe and the German Ethics Committee Rec(2006)4,9 
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precautionary consent will suffice, in order to avoid the need and the trouble to seek 
re-consent or the waiver of consent by an ethics committee.55  Similarly, the Irish 
Council for Bioethics also found it acceptable to routinely ask the patients for consent 
for possible future research use of “tissue or organs removed during surgical treatment 
or surplus biological material left over after diagnostic testing”.56 
 
Consent norms and policies in research ethics require that participants in research must be 
fully informed.57 However, in a tissue banking context, due to the long-term nature of 
storage of HBMs in biobanks, it is impossible to predict the nature and risk of all future 
research at the time of collection.  Furthermore, the large number of participants makes it 
impossible to obtain detailed specific consent or re-consent for every future research, thus 
making specific consent impracticable in many instances.58  The regime of tiered consent, 
where participants can choose from a checklist of preferences like types of research or 
institutions allowed to use their stored HBMs, requires significant amount of administrative 
resources and also limits the usefulness of stored HBMs.59  It is also difficult to rely on 
presumed or implied consent for prospective collection of residual HBMs, given that 
informed consent is the "norm” for use of HBMs in research. 
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1.5 Current Guidelines on Biobanks in Singapore  
In the following chapters, I will present and discuss the status of biobanking in Singapore, 
and its ethical governance.  I will primarily focus on Singapore’s Bioethics Advisory 
Committee (BAC) report on Human Tissues Research, which was released in November 2002, 
and the current situation more than a decade after its first implementation. Biobanks and 
tissue repositories in Singapore must comply with BAC’s recommendations, as they are 
adopted by the Ministry of Health, and enforceable by professional councils of healthcare 
professionals.  In this thesis, the National University Hospital (NUH) Tissue Repository will be 
the key research focus, and is further illustrative of the current biobanking situation in 
Singapore. Various points discussed in this section will be emphasized and elaborated in the 
chapters that follow. 
 
1.5.1 BAC Guidelines on Tissue Banking 
As indicated above, Singapore’s national guideline for human tissue banking and biomedical 
research was released in November 2002 by the Bioethics Advisory Committee (BAC).  
Currently, this is the first and only guideline on human tissues research published in 
Singapore.  These Human Tissues Research guidelines have been revised in a draft report in 
2012, however the final version has not been released when this chapter was written. 
 
The BAC‘s report on Human Tissue Research focused mainly on two key issues: (1) respect 
for and welfare of the donor, and (2) confidentiality. As noted above, human tissue is 
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broadly defined in this report.60 According to the guidelines, researchers and tissue banks 
are required to obtain “full, free and informed consent of the donor” before either taking or 
accepting any HBMs for research, and must ensure confidentiality of the contributor's 
personal information during collection, storage, and use of human biological materials for 
research. Contributors of HBMs should be adequately informed, and free from any coercion 
or undue influence. They should be able to understand and appreciate the risks, potential 
benefits, and alternatives of contributing their HBMs and have either ’competence’ or have 
the ‘mental capacity’ to make a valid decision.  This may include comprehension and 
retention of the information provided.  HBMs may be collected for either clinical tests, 
diagnosis or treatment or specifically for one research and only residual materials from such 
collections can be transferred to a tissue repository for storage in anticipation of its future 
use in research.  The BAC guidelines further stressed the importance of informed consent as 
autonomy-based governance, especially in cases where residual tissue is from either 
therapeutic or diagnostic purposes, which can be used for research.61   
   
1.5.2 BAC - An outright gift model for tissue donation 
The BAC has proposed that consent form should state the contribution of residual HBMs as 
either an “outright gift” or donation without any conditions,62 and that all tissue samples 
contributed for research use must be given either without any personal or direct benefit 
from the contribution or claim to property and future rights on the HBMs. This unconditional 
                                                          
60 BAC, S. 2002. Human Tissue Research: A report by Bioethics Advisory Committee 
Singapore. November 2002. 
61 Ibid, Section 8.9. 
62 Ibid, Recommendation 1.D and Section 8.5. 
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gift excludes future provision of information to contributors on either any medical condition 
or predisposition discovered in the course of research, unless it has been earlier agreed 
upon during the informed consent process. Contributors should be informed of 
the ’unconditional gifts’ arrangement and if they disagree, their contribution of residual 
HBMs should not be accepted.  
 
The outright gift model allows the accepting organisation or the ’donee’ to have total control 
over the gifted HBMs. Accepting organisation of the donated HBMs would prefer the 
“outright gift” model as the mode of contribution because they can have complete control 
over the use and disposal of the HBMs any way they wanted without further consultation or 
consent from the contributors.  The most obvious difficulty or disadvantage with outright 
gifts is the total loss of ownership and control of the gifted property by the contributors, as 
donors.  The donors have no control or decisional rights over the HBMs once they are 
donated as outright gifts and they have to bear the risk of their donated materials being 
used for researches which they do not support (for example, cloning) or risk being identified 
through genetic research. 
 
The ’gift’ model of donation is also stated in the Medical Therapy, Education and Research 
Act (MTERA).  The MTERA, however, make provision for the use of only the bodies of 
deceased persons or parts thereof for purposes of medical or dental education, research, 
advancement of medical or dental science, therapy and transplantation, and for other 
related purposes.  Any person who is not mentally disordered and who is 18 years of age or 
above may give all or any part of his body for any of the purposes specified in section 7 of 




The BAC views that participation in research should be on an altruistic basis, and this 
includes contributing HBMs for research. Here, the benefit can be practical since research 
institutions need not be unduly concerned with the outcome of the research or with 
encouraging social participation and contribution to the common good. Some disadvantages 
include questions of fairness to the participants and extent of accountability on the part of 
the research institution.  My empirical research findings in Chapter 3 will discuss this aspect 
further. 
 
1.5.3 Recommendation on Governance and regulations 
The BAC recommended that all research tissue banks ought to be statutorily approved and 
licensed, and advised the setting up of a statutory board to oversee and license institutions 
and companies carrying out human tissue research and banking thus making it necessary 
that all such research activities be approved and monitored.63    Recommendation 2 of the 
BAC report stated that research tissue banking should only be allowed in institutions 
approved by appropriate authorities, and not by private individuals.  They further 
recommended that a statutory authority must be set up to provide statutory regulation and 
supervision of research tissue banking, and that institutions must have transparent and 
appropriate systems, and standards for the ethical, legal and operational governance of 
research tissue banking.64 The significance of this recommendation and its special relevance 
to this thesis will be discussed in Chapter 4. 
 
                                                          
63 Ibid, Section 11.4 and 11.5. 
64 Ibid, Recommendation 3. 
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1.5.4 Where are we now in terms of Biobank governance? 
Whilst this thesis supports autonomy-based governance and accepts the importance of 
informed consent, in terms of respect of autonomy and a contributor’s right to choose,65 I 
argue that informed consent alone does not carry much moral value and may not be 
effective in protecting participants from harm.  Specific informed consent, in particular, 
provides participants with a choice on whether or not to donate their HBMs unconditionally 
and this consent type limits future use of HBMs that is undetermined at time of donation. It 
is argued that greater emphasis should be placed on effective governance of management of 
a biobank or tissue repository, transparency on the use of stored HBMs and frequency 
statutory monitoring of its operations. The subject of governance will be elaborated on in 
Chapter 4.    
 
Current ethical governance on the use of stored residual HBMs in Singapore still lacks 
transparency, accountability and monitoring.  The BAC’s recommendations on statutory 
regulations, governance and supervision still have not been implemented.  Contrary to BAC’s 
recommendation, there is no statutory authority body to regulate and supervise all human 
tissue research in Singapore, and institutions and companies carrying out human tissue 
research and banking, are not transparent with their safeguards and there is no clear system 
of accountability over the collection, storage, distribution and use of residual HBMs.  Further, 
there is a gap between the corresponding institutional duties and a contributor’s rights in 
biobank research. This is evident especially in the absence of ethical governance of biobanks 
in terms of transparency and accountability, the inconsistencies in the issues of consent, 
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ethical governance and right of withdrawal.  These issues have negative repercussions on 
public trust and long-term support, which are pivotal to the success of biobanking projects.66  
For example, the BAC guidelines stipulated that only institutions and companies approved by 
appropriate authorities and not by private individuals could set up tissue banks and be 
permitted access to residual tissues.  A reason for the BAC’s concern is that individual 
researchers may not have enough resources, expertise and motivation to properly maintain 
the tissue collection.  The BAC is evidently interested to avoid an incident such as Alder Hey 
from occurring in Singapore.  Unfortunately, without the presence of such an authority body, 
individual researchers in institutions and private companies can set up their own private 
collections of HBMs thus storing HBMs in their research laboratories for personal use, 
without supervision, governance or control.  This shortfall in governance has been noted in 
the position paper on ’Human Tissue for Biomedical Research: Tumour Banks’, written by 
the Chapter of Pathologist Committee (2001-2002), of the Academy of Medicine, Singapore 
for the BAC.  Section 3.4 of the paper stated: “It has been common practice to store 
collection of tissues (including blood, blood products and body fluids) on completion of the 
project, with a view to use these for future yet to be specified projects.  The principal 
investigators may also ‘share’ samples with other researchers.”   These investigators have 
their own storage for HBMs that they collected and not discarded after the completion of a 
research project.  The main concern is that in the original protocol of the research and  
consent provided by the contributors did not clearly reflect that the HBMs would be stored 
in archive indefinitely, and shared with other researchers or used for future research.   
Ethically, an investigator must first obtain informed consent from the participants if he or 
she wants to store such materials and use them for future research either by themselves or 
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by others. All future researches must also be approved by an independent research ethics 
committee or IRB. 
 
Until a statutory research tissue banking governance authority is established in Singapore to 
assure protection of donors in tissue research and guidelines or regulations for the 
management of biobanks in medical research are established and/or harmonized, the 
responsibility of ethical governance is shouldered by the IRB and biobank administrators, 
who may not be in the position to resolve deficiencies of the current regulatory or 
governance framework. Existing governance issues include lack of participant protection and 
uncontrolled use of biological samples, and potential security breaches that could 
compromise the privacy and confidentiality of data held by a biobank.67   
 
1.5.5 Role of the Institutional Review Board (IRB) in tissue research 
The IRB is empowered by its affiliated institution and the Ministry of Health to review all 
human subject research. IRBs have the mandate from respective institutions to approve, 
reject, propose modifications, or terminate any proposed or ongoing research involving 
human subjects conducted by researchers within the institution,68 using considerations set 
forth according to BAC’s third report entitled Research Involving Human Subjects: Guidelines 
for IRBs in Singapore.  However, it is debatable whether IRBs are the most appropriate 
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bodies to evaluate research projects involving biobanks.69  Most IRB members fail to 
understand their roles as the safeguard and control of HBMs in biobanks,70 and are not well 
versed in the ethical issues and operations of a biobank.71   IRBs are not established solely to 
oversee biobank research but all research involving human subjects conducted within the 
institution. It may therefore be expected that IRBs are overwhelmed with different types of 
human subjects research and this situation can be aggravated by conditions such as 
manpower constraint.72 Auray-Blais et al. presented a survey of 43 research ethics boards 
and IRBs in Canada, demonstrating difficulties for IRBs in reviewing and managing research 
projects with biobanks and a high percentage of rejection of protocols involving the use of 
HBMs stating that “the risks of discrimination and stigmatization being a recurrent issue.”73  
Overly- cautious IRBs may however hinder research on HBMs.  Further, the effectiveness of 
an IRB in the monitoring of biobank governance and control is also doubtful since it is only 
mandated to receive annual continuing review reports from approved projects.74  Auray-
Blais et al. also reported on the burden on IRBs attempting to evaluate research projects 
involving the use of storage samples in biobanks and demonstrated difficulties for IRBs to 
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manage research projects with biobanks.75  McHale et al. mentioned that despite good 
intentions, neither conventional research ethics committees nor IRBs can provide an 
effective solution to the legal and regulatory challenges arising from biobanks. They further 
proposed the setting up of either a specialist ethics or biobank ethics and governance 
committee to focus on ethics and governance and also provide oversight in relation to the 
operation of biobanks.76  However, they cautioned that without a formal legal status for 
biobank ethics committees, these committees are ’toothless tigers’ and thus unable to 
‘formally bite’ and hold a biobank accountable.  This discussion will be further elaborated on 
in Chapter 4. 
 
In the next chapter, I will discuss the consent taking process of a major biobank in Singapore. 
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Chapter 2. Human Biological Materials: Abandonment, Donation 
or Participation in Research? 
The focus of this Chapter is on the consent regime of a major hospital and tissue repository 
in Singapore.  It is in this context that the need of informed consent is traced to legal 
discourses on property and on fundamental rights, and their subsequent impact on the 
ethics of consent taking.  Various consent regimes have since emerged, and the consent-
taking process of the hospital being studied in my research could be regarded as a form of 
broad or even ‘precautionary’ consent. However, the hospital’s tissue repository relies on 
the notion of donation.  I argue that the ‘general or broad consent’ regime is a combination 
of legal theory on property and fundamental rights, which emphasizes respect for persons 
and individual choice.  In important ways, the notion of donation goes beyond general 
consent.  The differences between these two approaches are discussed in the context of 
Singapore, and current notions of informed consent in relation to biobanks are presented 
and critiqued.   
 
Currently, there are two main research tissues repositories in Singapore, namely, SingHealth 
Tissue Repository (STR) and National University Hospital Tissue Repository (NUH TR). These 
tissues repositories collect HBMs from healthy volunteers, patients and post mortem 
cadaver for use in population based studies, clinical research or disease-specific diagnosis 
and treatment.  
 
STR was established by SingHealth, the largest healthcare group in Singapore, and comprised 
a network of 2 hospitals, 5 National Specialty Centres and 9 Polyclinics. It is the largest 
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research tissue repository in Singapore.77 STR operates under the guidance of the STR 
Committee, comprising clinicians practicing in local hospitals, research scientists, as well as 
lawyers and the Chairman of SingHealth Centralised IRB. The STR Committee oversees the 
development and implementation of institutional bio-specimen banking policies and 
guidelines, and reviews and approves requests to collect and access specimens.    
 
The NUH TR was established by the National University Hospital (NUH), which comprised the 
National University Hospital (NUH), along with Yong Loo Lin School of Medicine, the Faculty 
of Dentistry and Saw Swee Hock School of Public Health of the National University of 
Singapore (NUS). The common governance structure was intended to create synergy to 
advance health by integrating clinical care, research and education in Singapore.78 NUH TR 
was guided by the NUH TR Steering Committee, which oversees the development and 
implementation of institutional bio-specimen banking policies and guidelines whereas 
another committee, the NUH TR Scientific Review Working Committee, reviews and 
approves requests to collect and access specimens.79 
 
Until 2011, the Singapore Biobank (SBB) was the third research tissue repository in 
Singapore. It was established in 2002 as a national tissue bank by Singapore’s government-
lead Agency for Science, Technology and Research (A*STAR) and Ministry of Health. The SBB 
was first known as the Singapore Tissue Network (STN) and changed its name to SBB on 1st 
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April 2010. SBB collected bio-samples directly from researchers, NUH TR and STR. SBB was 
designed to be a core research infrastructure to support Singapore’s Biomedical Sciences 
Initiative and facilitate bench-to-bedside translational research, as well as population based 
epidemiological research. In September 2011, the closure of SBB was announced to the 
surprise and dismay of biomedical researchers and research institutions in Singapore, for 
various reasons, which include funding shortage, low utilization rates, problems in collection 
of HBMs and lack of trust.80 
 
In the following section, we discuss the consent regime of NUH TR and another consent 
regime of NUH with regards to residual HBMs from surgery.  The latter regime relies on 
general consent and, very loosely, the notion of abandonment of residual HBMs from 
surgery.  In contrast, NUH TR relies on ‘donation’ – an approach that is consistent with 
national ethics policy but with at least one important qualification.  The notion of donation 
goes further in being broader than what general or broad consent permits.  It relates to the 
giving of HBMs toward one or more purposes, and may even be conceived as having the 
character of a ‘charitable’ purpose.  It is in this context that the various regimes of consent 
set out in Chapter 1 are discussed and critiqued.  For reasons set out in Section 2.5 below, 
both approaches (i.e. general consent and donation) are better than a specific consent 
regime.  As outlined in Chapter 3, empirical data is provided in support of this argument.  
However, I argue that the requirement of informed consent is insufficient to safeguard the 
welfare and interests of patients as research participant.  The BAC’s recommendations on 
human tissue research imply this point, and many systems-level issues have still remained 
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unanswered.  Some of these issues will be considered at the end of this Chapter, and further 
elaborated on in Chapter 4. 
 
2.1 Consent Regimes in NUH for Biobanking 
2.1.1 NUH – A Singapore example  
NUH has been collecting and storing residual HBMs from patients over many decades.  Two 
separate consent-taking processes are used: one in relation to the donation of residual 
HBMs from all surgical procedures - for medical research, education and study purposes, and 
another for the specific storage of both residual HBMs and associated medical information in 
NUH Tissue Repository (NUH TR), mainly for research purposes.  In both consent-taking 
processes, patient is assured that (1) whether he/she decides to give consent or not, it will 
not affect the standard of medical care he/she will receive; (2) no additional HBMs will be 
removed beyond what is therapeutically necessary; and (3) the residual HBMs are stored 
only after information for diagnosis and treatment has been extracted.  The consent in both 
processes may be characterised as broad consent, but with important differences as NUH TR 
is also concerned with donation of residual (and non-residual) HBMs.  The contribution of 
residual HBMs from all surgical procedures seems to give effect to the concept of 
‘abandonment’, whereas the language of ‘donation’ is relied on by NUH TR detailed 
informed consent, which allows donor the right to withdraw consent after agreeing initially.  
Both consent processes will be analysed further later in this chapter. 
 
2.1.2 Consent-taking for storage and use of residual HBMs from surgeries 
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During pre-operative counselling, all patients admitted to NUH are provided with a copy of 
surgical consent form, which contains a simple paragraph to obtain broad consent for 
specified uses of their residual HBMs.  The aim of this consent process is to provide general 
information to prospective donor about the choice of contributing surgically removed 
residual HBMs for research, education and study purposes, and only after they are no longer 
required for the medical care of donor.   
 
Consent-taking for the use of residual HBMs not required for medical management, occurs 
simultaneously with consent taking for surgical intervention, as both are components of the 
same Surgical Consent Form (Figure 1. Consent for Operation/Procedure).  Hence, a patient 
can decide how his/her residual HBMs should be disposed of at the point of consent taking 
for a recommended surgical intervention. 
 
FIGURE 1: SAMPLE OF NUH CONSENT FORM 
 
NUH Consent for Operation/Procedure 
(version MAQ-FORM-GEN_00)
I *agree / * do not agree to 
allow the remainder of any 
tissues removed not required 
for my medical management, 
to be used for medical 
research, education and study 
purposes.  I understand that 
only excess tissue remains 
after all the necessary medical 
tests are completed will be 
used, and no extra tissue will 




Patients can opt to either agree or disagree (by deleting the non-applicable option labelled 
with asterisks in the section) for their residual tissue to be used for research and education.  
If a patient refuses to provide consent, the surgical excess HBMs that are not required for 
diagnosis will then be destroyed as biological wastes.  This refusal is recorded in the medical 
records, so that the same patient will not be asked to donate her HBMs to the NUH TR at a 
later stage. 
 
There is no explicit statement on withdrawal of consent or for use of medical records in this 
consent form.  Consequently, any residual HBMs donated through this process are 
anonymised tissue and can be used in research without any further restriction.  In practice, a 
‘consent’ nurse (if consulted) will assure patients that their medical care will not be affected 
if they declined.   
     
2.1.3 Consent-taking for the banking of residual HBMs and medical information 
with NUH TR  
Due to various factors including shortage of storage space, quality of HBMs, amount of 
residual HBMs after diagnostic tests and funding limitations, not all HBMs are ‘banked’ into 
NUH TR.  Approximately 10% of all residual HBMs are usually found suitable for banking in 
the NUH TR.  Hospital administration considers it too burdensome to obtain informed 
consent from every patient for the storage of residual HBMs, as most of them would not be 
banked.  Furthermore, residual HBMs obtained from surgery (but not banked with NUH TR) 




The selection of suitable residual HBMs for ‘banking’ is primarily determined by a pathologist 
from the NUH TR, who reviews daily scheduled surgeries to identify potential residual HBMs 
suitable to be stored for future research.  This selection is based on existing or anticipated 
research needs and that NUH TR is established as a cancer tissue repository primarily aim on 
the collection of residual cancer tissues for research purposes.  After patients have 
consented to donate residual HBMs, these tissues are collected at the pathology department 
only after the completion of diagnostic tests.  Collected tissues are then stored in pathology 
archives, either as paraffin-embedded tissue blocks for diagnostic purposes or frozen tissue 
materials obtained from leftover surgical diagnosis.  
 
For HBMs found suitable for storage in NUH TR, a separate consent will then be requested 
from selected patients.  This process involves a more detailed discussion with a trained 
‘informed consent’ nurse from NUH TR.  During discussion, the nurse will explain contents of 
the NUH TR ‘Participant Information’ pamphlet (set out in Appendix 2), which include 
description on the nature of donation, potential users of the donated HBMs, accessibility of 
HBMs to commercial companies, non-return of research results, potential risks and harm 
from donating, and no personal benefits for any research discovery.  Patients are also 
informed that they can contact NUH TR if they change their minds and wish to withdraw 
from NUH TR after signing the consent form.  NUH TR will then destroy any unused samples, 
as the collected biological sample(s) will not be returned to the patients for bio-safety 
reasons.  Patients will again be provided with an assurance that no additional tissues will be 
removed and that only residual tissues from diagnosis and surgery will be collected after full 
diagnosis is established.  They will also be informed that future research utilising their HBMs 
must first be approved by an IRB before NUH TR releases them.  In addition to the IRB, a 
NUH TR Steering Committee, comprising senior clinicians and surgeons from the hospital, 
governs subsequent access, use and distribution of stored HBMs.  Before any HBMs are 
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released from NUH TR, the Steering Committee must ensure that the proposed research has 
good scientific merits and has been given ethical approval.  As noted earlier, consent will be 
sought for use of medical data, as well as additional HBMs such as blood, hairs, nails and 
urine (which are not strictly residual).  At this stage, the patient may seek clarifications from 
the nurse and can still refuse to ‘bank’ his/her residual HBMs (and related medical 
information) in the NUH TR, despite having previously consented in the Surgical Consent 
Form. 
 
For residual HBMs meant for banking with NUH TR, a computerized tracking system links the 
consent status of residual HBMs using individualised barcodes to avoid storage of residual 
HBMs without the requisite consent for use of medical data (i.e. leftover surgical tissue 
donated as anonymised HBMs).  Once a patient consents to the banking of his/her residual 
HBMs with NUH TR, this system will link the individualised barcode to patient’s hospital 
identification number on all of his/her medical investigations and diagnostic results.  After 
the medical data corresponding to the residual HBMs are obtained, identifiers will then be 
coded via a coding system.  All banked specimens are issued a NUH TR code number and 
identifiers are removed and stored in a separate database, to prevent disclosure of any 
personal identifiers to researchers when they request for HBMs (and accompanying 
information).  The database with patient identifiers, that are linked to NUH TR code numbers, 
are kept by an institutionally designated information trustee, which is audited quarterly.  
 
As both consent processes (in relation to residual surgical HBMs and NUH TR) do not impose 
serious limits on the range of research applications or duration of storage, they may be 
categorised as general or broad consent (following the categorization set out in Chapter 1).  
This is consistent with the recommendations of BAC, although we should note that the 
system of governance proposed by BAC, has not yet been fully implemented (to be discussed 
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in relation to governance in Chapter 4).  The practicality of general consent is easy to 
understand, especially when informed consent has been regarded – at least in common law 
jurisdictions – as central to the lawful taking and use of HBMs.  Given that it is impractical, 
and certainly impossible, to specify the range of research applications during consent-taking 
and avoid the need of having to seek re-consent later on, the BAC has gone further to 
encourage researchers to persuade research subjects to donate HBMs for research.  In effect, 
general consent to collect and use a tissue, and a conditional donation of tissue, are broadly 
similar in outcome.  Where informed consent has not been properly obtained, such taking or 
use is unlawful, unless the HBMs are regarded as ’abandoned’ or otherwise approved by 
legislation.  As we will discuss later, there is no serious difference in terms of the legal 
consequences between HBMs that have been donated for research and those that were 
regarded as ’abandoned’.    
 
2.2 Abandonment in Property Law 
When biological materials are removed during surgery, it is assumed that most patients no 
longer want such residual HBMs.  It is uncommon that people ask about the status of their 
removed HBMs,81 and this is also shown in my empirical research in the next chapter.  The 
removed HBMs became either of secondary importance or of a lesser interest to the 
patients in comparison to the diagnosis and prognosis of their medical condition. When 
patients go into surgery, they do not undergo the procedure for the purpose of donating 
HBMs to research and do not think much of  the “diseased” or excised HBMs with the 
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exception of diagnosed results (such as if the excised tissues is either benign or malignant). 
Most patients undergoing medical or surgical procedures would have no further interest in 
their removed HBMs. To some individuals, it would be termed as ‘abandonment’ of these 
unwanted ’waste’ materials.  From a property law perspective, it has been argued that such 
residual HBMs have been ’abandoned’ as unwanted materials. 
 
Such an argument of ’abandonment’ of surgically removed tissue was illustrated in the case 
of John Moore v University of California.82  Mr. John Moore consented and underwent 
treatment and surgery for hairy cell leukaemia at UCLA Medical Center under the clinical 
care of Dr. David Golde.  Tissues from his removed cancerous spleen were later developed 
into a cell line, which was then commercialised by Dr. Golde, without Moore’s knowledge, 
information, permission or consent.  Mr. Moore eventually sued the UCLA Medical Center, Dr. 
Golde and his team of researchers for breach of fiduciary duty and conversion for the use of 
his ‘property’ for commercial benefit without consent.83 The court initially ruled in favour of 
Mr. Moore but the decision was subsequently reversed by the courts of appeal.   
 
Additionally, there was no specific law that regulates the relationship between patients as 
source of HBMs and biobank when the Moore case was heard.  The concept of property law 
was used together with other existing laws, such as the Uniform Anatomical Gift Act (UAGA), 
which regulates the use of body parts for research and donation of body parts of individuals 
after death. 84  The Supreme Court of California found that Mr. Moore had no property rights 
to his discarded organs and cells since they no longer belonged to him after they were 
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removed from his body.  The court ruled that Mr. Moore did not have ownership rights in 
the newly generated cell line that was established from his removed organs, or in its patent 
rights. For this reason, a cause of action for conversion could not be sustained.85  As Mr. 
Moore did not claim his excised spleen immediately after his surgery, he had actually 
abandoned his excised organ.  Mr. Moore decided to sue to regain his rights of ownership 
only after he realised that there was a patent filed and the cell line was commercialised.  
Justice Broussard of the Supreme Court of California stated that “in common scenario, the 
patient has abandoned any interest in the removed organ and is not entitled to demand 
compensation if it should later be discovered that the organ or cells have some 
unanticipated value.”86  If individuals enjoyed property rights over their bodily tissues, 
individuals could then sell their tissues for biomedical research purposes, and a range of 
different transactions between donors and scientists would be possible.87  However, existing 
regulations, such as Section 7054.4 of the Health and Safety Code, prohibit “commercial 
exploitation” and the buying or selling of human organs, and defined “scientific use” as “not-
for-profit scientific use”.  These made it impossible for property rights to be granted to 
Moore in relation to his organ, as it would be illegal to profit from such rights.88 
 
The court also mentioned that it would be a great burden for research physicians if they had 
to ensure that each tissue sample was obtained through extensive informed consent 
procedures.  Further, the court stated that if the research physician needed to obtain 
specific information each time they collected a tissue sample, the progress of research 
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medicine would be significantly hampered.89  The appeal case was subsequently terminated 
due to the demise of John Moore during the legal process and Mr Moore's claim for the lack 
of informed consent on the use of his tissues and breach of fiduciary duty of researchers 
were legally unanswered with the termination of this case.90  
 
Another similar case that involved property rights and informed consent was the case of 
Greenberg et al. v Miami Children’s Hospital Research Institute et al.  The Greenberg case re-
visited the Moore’s case, when a group of individuals involved in a research on Canavan 
disease entered into collaborations with Dr Reuben Matalon and the Miami Children’s 
Hospital Research Institute (MCH) to identify the gene responsible for the disease.91  Dr 
Matalon successfully isolated the gene and secretly filed a patent application without 
Greenberg’s consent, which led to Greenberg, suing Dr Matalon and MCH.  Relying on the 
diverse nature of contributions to medical research, MCH argued that if every contributor 
had the right to decide on how and to whom the research results could be used or made 
available to, medical research would be impossible. Basing its rationale on the Moore 
decision, the defendants argued that short of an explicit agreement on property rights in the 
outcome of research, it should not be assumed that contributors of HBMs retained any 
property interests in these materials. In other words, it was argued that the plaintiffs did not 
have a right to exercise control over the commercialization of the patent, as they retained 
no recognized interests in the HBMs contributed to research. This case was ultimately 
settled through a confidential agreement. MCH was still able to license its patent and collect 
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royalties in relation to the use of clinical testing for Canavan disease, which it had developed. 
However, licence-free use of the Canavan patent in research directed at finding a cure for 
the disease was allowed as a compromise.92  
 
In these two cases, the legal concept of abandonment was implicitly used to support a policy 
position.  Abandonment is an act of either surrendering, deserting or relinquishing property 
or contract rights or giving up of something, which we are entitled.  It is normally an act of 
intention and thus a permanent decision.  In the Moore decision, majority of the judges 
agreed that a removed body part, by its nature, could never constitute ’property’ for the 
purposes of a conversion action.93  However, Justice Broussard in his dissent on the 
conversion cause of action in the Moore decision, stated that when a “patient consented to 
the use of his removed organ for general research purposes and the patient's doctor had no 
prior knowledge of the scientific or commercial value of the patient's organ or cells, I would 
agree that the patient could not maintain a conversion”94 He further added he could not 
agree when “the unauthorized use of excised organ or cells, even against a party who knew 
of the value of the organ or cells before they were removed and breached a duty to disclose 
that value to the patient.”  In this case, when a patient does not know the value of his organ, 
and decided not to claim ownership and abandoned the organ to the disposal of the hospital, 
would this abandonment out of ignorance and lack of information still be valid? It can be 
argued that by withholding information from patients, especially when the researchers know 
that there is value in the materials and patients are intentionally misled (through non-
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disclosure) into abandoning them is unethical and maybe even illegal under the common law 
(for conversion).95  I agree that although there can be no property rights to the removed 
organs, researchers must not be allowed to obtain the excised HBMs using deception, 
concealment and fraudulent practices.  To ensure transparency in the collection of residual 
HBMs, researchers need to obtain informed consent and permission from patients when the 
medical procedures are being conducted.  The court in the Moore decision also upheld 
Moore’s claim for “cause of action for breach of fiduciary duty and lack of informed 
consent.”96   
 
In a third case, Washington University v. Catalona, research participants donated HBMs to Dr 
William Catalona, a clinician researcher at the Washington University (WU), by signing a WU 
Genetic Research informed consent form.97  The HBMs would be stored in WU’s biobank.  Dr 
Catalona resigned from WU and wanted to transfer his collected samples to his new 
employer in Northwestern University.  He wrote to his research participants requesting for 
their permission to release the WU retained sample to him.  The court ruled that the 
research participants “parted with any semblance of ownership rights once their biological 
materials were excised for medical research”.98 
 
The ’abandonment’ of the removed tissues was also discussed in studies focusing on 
expansion of  biobanks’ collection of research tissues and discourses of handling medical 
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waste as a way of legitimizing biobanking activities.99  Within biobanking discourses, the 
term ’medical waste’ was often used when tissues samples that would otherwise be 
discarded after an operation or a procedure, were collected as waste and subsequently used 
for research.100  The ‘waste’ discourse is closely related to the abandonment discourse in 
that both discourses imply that the contributor cannot lay claim of ownership once the 
waste material is no longer privately valued by its ‘owner’ (as defined by Porter).101  The case 
of Mr. John Moore highlighted that removed tissues were viewed by the courts, in relation 
to the scientific production of knowledge and economic development, as abandoned ’waste’.  
In the Catalona  decision, the court further ruled that the right to withdraw only meant that 
research participants had ceased providing HBMs pursuant to a research protocol and WU 
could either destroy the materials, or store indefinitely without further use or remove all 
identifiers and use the anonymized HBMs in ’exempted’ research.102  
 
Most patients do not know the value of their HBMs, and ‘abandon’ the HBMs for disposal by 
the hospital, due to ignorance and lack of information.  It cannot be concluded that it is done 
intentionally since they do not have such knowledge before.  Most of the time, there is no 
need for a thorough examination of the reasons behind an intention to abandon. In other 
words, a simple intent to ’abandon’ will be enough, unless there is fraud, deceit or similar 
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unlawful conduct on the part of the wrongdoer. Furthermore, a successful action in legal 
conversion does not imply that the patient will have a claim over a patent derived from his 
organ.  In reality, it is difficult for the hospital or a researcher to clearly indicate whether a 
patient’s residual HBMs will subsequently give rise to commercial profits, and the extent 
that is owed to the patient. Although Justice Broussard’s dissent has ethical persuasion, the 
injustice that Mr. Moore suffered is also not difficult to appreciate.  Jeffrey Potts wrote in 
support of Mr. Moore’s cause of action for the physician’s failure to gain the patient’s 
informed consent and argued for the need of expanded disclosure to the patients in the 
spirit of promoting greater transparency.103  Others have also argued for the action of 
battery to include instances where physical wrongdoing occurred without the person 
concerned having been sufficiently informed.104  However, it is quite a different matter to 
say that an individual should suddenly acquire property interests in his or her HBMs for the 
reason of preventing unjust enrichment on the part of the wrongdoer.  Clearly, no hospital 
or researcher should obtain HBMs through deception, concealment or fraudulent practices.  
In most of such jurisdictions, a range of legal recourses for such transgressions exists.  For 
more ambiguous situations, a fair system of research governance should at least ensure 
clarity of expectations, responsibilities and entitlements on all parties involved.  Arguably, 
property-based notion of HBMs is one of two most profound influences that the Moore and 
Greenberg decisions have had on research ethics and research governance of residual HBMs. 
Another critical element, which was mentioned earlier, is the legal emphasis on informed 
consent. As we shall consider in the next section, the underlying rationale for this 
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requirement rests on a property-based theory or property law, but more so on fundamental 
rights. 
 
The Moore case has been influential in giving emphasis to certain values such as informed 
consent and the preclusion of property rights in the body. These legal values have been 
influential in shaping US bioethics, as a number of bioethicists have observed. Bioethics in 
Singapore has been heavily influenced by leading scientific jurisdictions, particularly the US 
and the UK, among others. Important lessons have been learnt on the need for informed 
consent, and some problems with overemphasis of informed consent. There is no 
established legal case on the use of HBMs in Singapore.  Singapore legal system follows 
common law ruling and thus US and UK legal cases may have indirect implications in 
Singapore.   Major areas of law – particularly administrative law, contract law, equity and 
trust law, property law and tort law – are largely judge-made, though certain aspects have 
now been modified to some extent by statutes.  The Singapore court regularly draws on 
oversea common law cases, with considerations on the local contextual and sociocultural 
norms.    The recent public consultation on the Human Biomedical Bill has brought the 
attention on the use and ownership of human tissues in research.  According to one author, 
this issue is normally overlooked by Singapore and leftover tissues have been used for 
research without requiring specific consent from the patients.105   
 
2.3 Legacy Tissue and the Rejection of Implied Consent 
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The centrality of informed consent is perhaps best illustrated in the BAC’s rejection of 
implied consent as justification for the use of legacy HBMs.  The BAC observed that, whether 
in Singapore or elsewhere, the “existence of large collections of tissue samples accumulated 
over the years for which no specific or adequate consent for research investigations has 
been obtained” posed a special difficulty.106  An example of legacy tissue is the old collection 
of diagnostics sample tissues originally collected for diagnostic purposes in relation to 
conditions, such as cancer.  Given the age of the collection, there is a strong likelihood that 
the patients might have died or can’t be traced for consent.  By virtue of their sheer size and 
range of coverage, the BAC recognised that legacy tissue collections are often very valuable 
to academic and commercial researchers. 
 
As these patients do not have property rights in their residual HBMs retained as legacy 
tissues, it may be argued that implied consent has been provided as these materials are 
simply left at the disposal of the institutions concerned.107  The implicit understanding was 
that the institution could collect and store all residual HBMs for its own purpose, unless a 
patient explicitly refused or expressed that he/she did not want the residual HBMs to be 
stored in the tissue repository or otherwise used in future research.108  Specific refusal must 
be expressed each time a procedure is performed or a blanket refusal must have been 
articulated for all the medical procedures during the treatment period.  In comparison with 
presumed consent in organs transplantation, Forsberg et al. stated that the use of presumed 
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or implied consent would increase the amount of HBMs available for medical research, if the 
known purpose of the institution were to build a large collection of HBMs for research.109  
Informed consent need not be explicitly requested from each patient when biobank and 
institutional researchers presume that patients intend to contribute to medical 
advancement through biobanking for future research to improve future health and 
treatment of patients.  Such an approach will save time, effort and expense in having to 
obtain informed consent from every patient.  
 
Reliance on implied consent could also represent a positive endorsement of donation of 
residual HBMs as a good thing to do.  It has been argued that formal acceptance of this 
approach could lead to donation becoming a norm, build trust in the system and thereby 
increasing donation rates.110  However, the difficulty with implied consent is that some 
patients may either not be able to or not have the opportunity to refuse consent.  Arguably, 
this problem may be mitigated, by allowing patients to withdraw their HBMs from the tissue 
bank at any time without having to provide any reason.  Those in favour of implied consent 
further argue that the risk of harm from donation of residual HBMs is rather low (as privacy 
risks can be reduced by maintaining stricter confidentiality requirements) and there is no risk 
of physical harm, as no additional procedure will be performed on the patients.  Overall, the 
benefits of implying consent for the donation of HBMs outweigh the risk to these individuals, 
especially when safeguards and controls are in place for the collection and subsequent use 
of the HBMs.  More generally, adoption of a presumed or implied consent regime could be 
supported by applying an essentially utilitarian approach. 
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Although the BAC did consider that a reasonable and consistent good stewardship to allow 
reasonable and respectful research use of legacy tissues collected in good faith, its rationale 
was not based on implied consent.  While it did recognise that greater public good could be 
achieved in allowing a responsible research use of legacy tissue, it would be illusory to imply 
consent when research use might not have even been considered at the time which HBM 
was obtained.  Rather, the principle of reciprocity was relied upon as justification.  As the 
BAC noted elsewhere, the current proven medical treatments are a result of medical 
research on someone else's previously donated tissues.111  To promote and support social 
good through medical research to discover new treatments for future patients, current 
patients should be expected to demonstrate solidarity in being willing to contribute their 
residual HBMs for research, as they have benefitted from the contributions of past 
patients.112  On the issue of consent, the BAC noted that legislative intervention might be 
necessary to “cure the defect stemming from the problems with the lack of consent.”113  In 
the UK, the Human Tissue Act served as such a legislative intervention, although a similar 
legislation has yet to be enacted in Singapore. 
 
2.4 Rights-based Jurisprudence 
Based on both Greenberg and Moore cases, the courts were reluctant to grant property 
rights over tissues, primarily on public policy reason that parts of the human body should not 
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be commercialised.114  In the case of residual HBMs, if a patient does not ask for his/her 
removed tissue after the surgery, to be retained or returned after the surgery, it will then be 
effectively considered as abandoned.  The patient can have no claim of ownership over it, 
and the hospital is free to dispose or use it for research or any other purpose.  Some experts 
have argued that, if no property rights are assigned to the excised tissues, informed consent 
or permission to use the residual HBMs would be legally redundant and unnecessary, and 
these residual materials should be used in medical research for the advancement of 
science.115  However, this could encourage an ethically problematic practice of not informing 
patients about how their residual HBMs will be used or disposed of.  A good case on point is 
the Alder Hey scandal.116   
 
In 1999, Alder Hey Children's Hospital in Liverpool UK, was discovered to have retained 
unauthorized organs from post-mortem of deceased patients.  These unauthorized retention 
of organs triggered public anger and distress, when Alder Hey and other hospitals within the 
National Health Service UK were found out to have retained deceased patients' organs 
without detailed family consent and approval.  A public inquiry was conducted to uncover 
the retained organ scandal, which involved unauthorised removal, retention, and disposal of 
human tissue, including children’s organs, during the period 1988 to 1995.117  The scandal 
                                                          
114 BAC, Human Tissue Report, Section 9.6, at page 28. 
115 FORSBERG, J. S., ERIKSSON, S. & HANSSON, M. G. 2010. Changing defaults in biobank 
research could save lives too. Eur J Epidemiol, 25, 65-8. 
116 BARNES, L., MATTHEWS, F. E., BARBER, B., DAVIES, L., LLOYD, D., BRAYNE, C. & PARRY, B. 
2005. Brain donation for research: consent and re-consent post Alder Hey. Bull Med Ethics, 
17-21.; ENGLISH, V. & SOMMERVILLE, A. 2003. Presumed consent for transplantation: a dead 
issue after Alder Hey? J Med Ethics, 29, 147-52. 
117 BARNES, L., MATTHEWS, F. E., BARBER, B., DAVIES, L., LLOYD, D., BRAYNE, C. & PARRY, B. 




subsequently led to the set-up of the Retained Organs Commission, an independent 
commission that catalogued and returned 105,000 organs retained by hospitals in England.  
The Human Tissue Act 1960 was subsequently revised in 2004 to overhaul all existing 
legislations regarding the handling of human tissues and created the Human Tissue Authority 
in the UK.118   This scandal also heightened the need for informed consent for collection and 
use of HBMs, and it was during the same period that Singapore hospitals saw the need to 
implement informed consent for the collection of leftover tissues, starting from NUH in 1 
April 2002. 
 
While it is evident that a person has no legal claim over his/her body or body parts as 
property, in a sense that they can be disposed for commercial gain, he/she is recognised to 
have some control over them.  Broadly drawn from human rights theory, the requirement of 
informed consent is now accepted as the basic requirement for protecting patients and 
research subjects.119  For informed consent to be valid the person concerned must have a 
good understanding of what is being asked of him/ her, has decision-making capacity and 
any decision made must be voluntary.120  Past research abuses where human subjects were 
intentionally or unintentionally harmed in human experimentation or simply kept ignorant 
of risks that would have concerned them, served to reinforce the need of informed consent.  
Famously, informed consent is enshrined as a fundamental requirement in the Nuremburg 
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Code created in response to the Nazi experimentations.121  This was also adopted by the 
World Medical Association in the Declaration of Helsinki.  More recently, research scandals 
such as the Tuskegee syphilis study122 and other events like the retention of organs from 
demised children in Alder Hey (as discussed above) emphasise its continuing relevance, 
particularly where biobanking is concerned.123  It should therefore not be surprising that the 
requirement of informed consent was emphasised in both the Moore, Greenberg and 
Catalona decisions. 
 
More recently, lawsuits relating to the retention and use of residual blood samples from 
new-born screening in the US continue to illustrate the central importance of informed 
consent. Many state governments in the US (through their department of health) collect 
blood samples from most infants born in the country each year, with the goal of detecting 
and treating a variety of potentially serious conditions.  All 50 states, including the District of 
Columbia, operate new-born screening programmes.  New-born screening is mandatory in 
49 states, and most of the 4 million infants born each year in the United States undergo 
new-born screening.124  The Texas Department of State Health Services (DSHS) has been 
collecting new-born blood samples from babies born within the state since the 1960s.  Texas 
                                                          
121 POST, S. G. 1991. The echo of Nuremberg: Nazi data and ethics. J Med Ethics, 17, 42-4.; 
COHEN, B. 1990. The ethics of using medical data from Nazi experiments. J Halacha 
Contemporary Society, No. 19, 103-26. 
122 ROY, B. 1995. The Tuskegee syphilis experiment: medical ethics, constitutionalism, and 
property in the body. Harv J Minor Public Health, 1, 11-5. 
123 STJERNSCHANTZ FORSBERG, J., HANSSON, M. G. & ERIKSSON, S. 2011. Biobank research: 
who benefits from individual consent? BMJ, 343, d5647.; WAUGH, P. J. 2004. Getting ethics 
into practice: comparing Alder Hey with Tuskegee is not helpful. Ibid.329, 513; author reply 
513.; CURTIS, H. Ibid.Getting ethics into practice: Tuskegee was bad enough.;  
124 LEWIS, M. H., GOLDENBERG, A., ANDERSON, R., ROTHWELL, E. & BOTKIN, J. 2011. State 
laws regarding the retention and use of residual newborn screening blood samples. 
Pediatrics, 127, 703-12. 
55 
 
currently tests for 28 disorders including cystic fibrosis, endocrine disorders, fatty acid 
disorders, and genetic testing for hemoglobinopathy, phenylketonuria, and galactosemia.  
Leftover HBMs, in this case – new-born blood samples – were stored for future research. 
 
In March 2009, a group of parents formed the Texas Civil Rights Project and filed a lawsuit in 
US District Court, claiming that the state’s collection and storage of the leftover new-born 
blood samples without the consent of the parents amounted to “an unlawful search and 
seizure” and violated the privacy rights of the parents and their children.  In their lawsuit, 
the parents argued that there was no legal authority for the hospitals to keep the blood 
indefinitely without consent.  Under the settlement, the state agreed to destroy 5.3 million 
samples it has collected from 2002 when the Department of State Health Services began 
storing the blood. Similar actions were filed in other US states.  In Minnesota, another 
lawsuit was spearheaded by the Citizens’ Council for Health Freedom in St Paul demanded 
that the state obtained written informed consent to collect, store or use new-born infants’ 
leftover blood samples.125  The court ruled that Minnesota’s Department of Health must 
destroy 1 million new-born blood samples in November 2011 and to pay nearly $1 million in 
legal costs.126  Based on these events and developments, there is a great challenge to collect 
and store leftover diagnostic HBMs for future research without informed consent.  While 
consent and permission for storage and use are needed, I argue that this is not a suitable 
regime of consent for biobanking in the next section. 
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2.5 ‘Donation’: Beyond Abandonment and Fundamental Rights 
In the Moore decision, the court considered a further approach.  Since Mr. Moore did not 
ask for the return of his organ or demand compensation prior to the removal of his excised 
HBMs, he could be regarded as having made a gift of it to his physician.  During the hearings, 
however, there was no evidence that Mr. Moore specifically intended to donate his excised 
residual HBMs and it could not conclude that Mr. Moore voluntarily gave his residual HBMs 
away.127  Although the Supreme Court ruled that Mr. Moore had no ownership interest and 
property rights in his excised residual HBMs, he did have some other rights over it.  As 
a ’bundle of rights’, some types of personal property: “(1) may be sold but not given away, (2) 
while others may be given away but not sold, and (3) still others may neither be given away 
nor sold.”128  In the case of HBMs, the court ruled that while the sale of organs and tissues 
was prohibited by law, they could be transferred as a gift.129  This transfer of HBMs does not 
amount to a sale of commodity when no ‘valuable considerations’ were given in exchange 
for them. 
 
When a person donates something, whether it is money or tissue, he/she willingly transfers 
the possession of the item, for a purpose other than his/her own profit or benefit.  Such a 
purpose may be an altruistic intention to donate to a specific cause or for a specific 
condition.  This cause is what makes donation a morally significant action, and it includes 
giving to charity or medical research.  In the case of patients who choose to donate their 
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residual HBMs to a biobank, it is a gift towards the generation of knowledge for medical 
purposes.   
 
By treating tissue donation as a gift, most patients voluntarily transfer control over the 
excised HBMs to the tissue banks to benefit a cause or purpose.  This action need not be 
purely motivated by true altruism, in a sense that most patients will decide that they have 
no use of the excised HBMs and will expect it to be thrown away.  They may thus be willing 
to give the residual HBMs away for a worthy cause, rather than to have them discarded as 
medical waste.130  This is unlike a truly altruistic cause of unconditional giving even when the 
gift is valuable to the donor.  A patient may explicitly make a donation or gift to the biobank 
if he/she wishes to contribute to future research.  This explicit wish to donate residual HBMs 
to the biobank may be expressed as part of consent taking for a medical intervention or as a 
separate process.  Where the former is concerned, this can be achieved by adding a 
checkbox to the pre-existing consent form authorizing residual HBMs to be transferred to a 
biobank for future research use.  As we have considered, the consent-taking process and 
consent form in relation to NUH TR present an invitation for patients to donate their residual 
HBMs and medical information for collection and future research use.  Where appropriate, 
the donation could extend to additional HBMs.  The nature of the giving is presented as a 
purposive one, and is therefore different from general or broad consent. But can it be 
construed as a conditional gift?  After all, patients retain a right to withdraw, if they wish to 
in the future.  
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As with any other donation, the patient may decide to make an unconditional or conditional 
gift with the residual HBMs.131 An unconditional gift of residual HBMs would allow any 
researcher to use the specimens for any research, whereas a conditional gift would specify a 
patient’s preference, for example, that the donated residual HBMs could only be used in 
future breast cancer research and nothing else.  This condition may be acceptable for a 
tissue bank for breast cancer research, but a general biobank may not be able to comply 
with such a specific condition.  Thus, a biobank must be certain that it has the capability to 
commit to, and comply with, the conditions that govern the use of residual HBMs, should it 
decide to accept donation on a restricted or conditional basis.  Where NUH TR is concerned, 
no such limitation of purpose is provided for.  There is also no explicit restriction on the 
duration for retention of HBMs and associated information.  It may also be relevant to note 
that, up to the completion of my empirical research, no patient has withdrawn consent.  
Thus, the status of residual HBMs collected by NUH TR is best understood as materials 
donated for the purposes of research.  The right of withdrawal, while not entirely consistent 
with the nature of the gift, is arguably an undertaking provided by NUH TR as institutional 
goodwill to honour any such request, if they should arise.  In other words, the right to 
withdrawal is an expression of freedom of choice and transparency rather than a 
characteristic associated with the HBMs.  This aspect of NUH TR’s policy will be further 
discussed in Chapter 4. 
 
2.6 The Illusion of ‘Fully’ Informed Consent 
                                                          





Based on these events and developments, it is legally challenging to just rely on 
abandonment or implied consent for prospective collection of residual HBMs, given that 
informed consent is the ‘gold standard’ for use of HBMs in research.  Informed consent is 
required by key international guidelines on research ethics (like WHO, CIOMS, HUGO and 
UNESCO guidelines on tissue banking) before any tissues are removed and stored.132  The 
difficulties rest on how much patients and potential research subjects should be ‘informed’.  
Where biobanks are concerned,133 the issue has been framed as whether fully informed 
consent is possible and practicable at the point of collection where the nature of future 
studies is unforeseeable when consent is first obtained.134  The main challenge in this part of 
consent-taking process is that, the eventual purposes for the utilisation of the stored HBMs 
are not always foreseeable at the time of collection.  
 
In the case of Havasupai Tribe of Havasupai Reservation v Arizona Board of Regents, 
secondary use of DNA samples first collected for diabetes studies, was subsequently used for 
migration patterns and mental illness.  The original ’Diabetes Project’ was consented to by 
the Havasupai participants and intended to include health education, collecting and testing 
of blood samples, and genetic association testing to search for links between genes and 
diabetic risk.135  After several years, the Arizona State University (ASU) researchers then used 
the blood samples containing DNA, for other unrelated studies such as studies on 
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schizophrenia, migration, and inbreeding, all of which are taboo topics for the Havasupai.  
These subsequent research projects were conducted without individual identifiers and 
without re-consent, but with IRB approval from ASU.136  The Havasupai tribe claimed that 
they consented only to the use of the HBMs for diabetic research, and not to other research 
uses, even though they signed a consent form to “study the causes of behavioural/medical 
disorders”.137  They claimed that the dignity of its tribe members and community reputation 
were compromised by these secondary research applications.  The case was eventually 
settled out of court with the Arizona University’s Board of Regent agreeing to pay $700,000 
to 41 of the tribe’s members, returning the blood samples and providing other forms of 
assistance to the impoverished Havasupai.138  The Havasupai case illustrates the restrictive 
nature of informed consent that is specific to one type of research application and failed to 
respect the sensitivities of the tribes and their members.  
 
According to Onora O’Neill, informed consent relies on two ethical tests: legitimate uses of 
human tissue must not inflict gratuitous injury, and must not override the consent of those 
whose tissues are used.  Any use of human tissue that either injures gratuitously or removes 
tissue without consent is an abuse.139  But the requirements for a detailed and full-informed 
consent have been criticized by Onora O’Neill.140  She argued that the ethical justifications 
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for informed consent in medical treatment, human research and use of human tissues, have 
been supported by poor arguments and exaggerated claims.141  Four major limitations of full 
informed consent have been set out as: (1) Some patients may lack competency to 
understand the information provided, e.g. the very young or old, very ill, demented or 
mentally impaired, unconscious or confused, bodily discomfort or merely frail, or in medical 
emergency; (2) informed consent is useless in selecting public health policies, which are 
uniform throughout the population; (3) medical treatment of one individual may use 
personal information of his family and relatives without their informed consent; and (4) 
people who are under duress or constraints, like prisoners and soldiers, the vulnerable and 
dependent that normally have the mental capacity to consent are still unable to refuse at 
the point of consent. 
 
Onora O’Neill further cautioned that: “It is important not to lay exaggerated weight on some 
mythical notion of ‘fully’ informed consent, and to take account of the particular difficulties 
that arise in the case of those - children and others - who are not legally competent to 
consent.”142  O'Neill supports the need for consent and does not support the waiver of 
consent or the use of implied or presumed consent, where patients are not asked for 
consent but presumed that they have agreed if they have not opted-out or objected.  In her 
opinion: “Inaction may be evidence of failure to notice or understand what is going on; 
acquiescence may reflect mere idleness or adaptive preferences, mere cynicism or 
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frightened awareness that dissent has costs.”143  She further stated that “consent that is 
uninformed (for example, based on ignorance or deception) does not legitimate; consent 
that is not free (for example, based on duress or manipulation) does not legitimate.”144 
“Misinformed” consent with the purpose to deceive or coerce patients into donating their 
tissues or forcing the patients to donate their tissues under duress should be illegal. 
 
With the advent of personalized medicine and genomics research, medical and scientific 
research and practice are making ever more varied use of human tissue.  The cases of 
unscrupulous or unacceptable use of human tissue reported, even by a small handful of 
researchers or doctors, may bring important medical and scientific activities into disrepute, 
and lead to public demand for restrictions on the uses of human tissue calling for a betrayal 
of trust.145  Thus, informed consent may not offer adequate protection for the patients and 
does not necessarily promote trust.  O’Neill added that informed consent, while essential, is 
not enough to show that use of human tissue is acceptable.  As we shall see, the empirical 
findings of this thesis (reported in the next Chapter) support her position. 
 
For different reasons, it would often not be possible or practicable to re-contact the patients 
or research participants who have contributed residual HBMs for consent.  For example, 
samples of HBMs collected in the 1980s could now be used for genetic research (including 
whole genome sequencing), which was an unknown type of research at the time of 
collection.  Where research using retained and banked HBMs is expected to be socially 
beneficial and where no risk of harm to the individuals, some have argued that the concept 
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of abandonment could still be relied upon, provided that they have also expressed 
agreement for their tissue to be stored and used in research.  One such approach is 
recommended by the Nuffield Council on Bioethics.  
 
The Nuffield Council explored the relationship between the HBMs contributors and the 
removed excised tissue, and especially the issue of whether the person retained any right of 
control over it, or if the consent to surgical removal was regarded as implying abandonment 
of the tissue.146  In the case of removal of tissue from patients in the course of their medical 
treatment,147 the Nuffield Council held that “consent to treatment should constitute 
abandonment of tissue, and that the possibility that tissue might then be archived or stored 
and subsequently used in the treatment of the patient or others, or in medical research and 
education, should be indicated in general terms in standard consent procedures.” 148  This 
concurs with the Moore decision and related cases, and may explain NUH’s consent taking 
for the storage and use of surgical residual HBMs for research (as discussed in the beginning 
of this chapter).  Similar to NUH, many biobanks or tissue repositories now specify, in 
consent-taking, that agreement to contribute and store tissue is also an agreement to the 
use of such tissue in research as the biobank or repository consider appropriate (and 
typically subject to ethics review and approval).  
 
Another approach has been to use general or broad consent in a way described by some as 
‘precautionary’. As discussed in chapter 1.4.1, ‘precautionary consent’ was used to seek 
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broad consent for research use of residual HBMs.  The broad consent was requested as a 
form of precaution and in the event of any future research plans on retained samples, this 
precautionary consent would suffice, in order to avoid the need and trouble to seek re-
consent or the waiver of consent by an ethics committee.149 This was accepted by the 
Council of Europe and the German Ethics Committee.  The Irish Council took into 
consideration that “such consent by its nature would have to be a broad consent, as the type 
of the research was completely unknown at the time [when it was taken from the 
subject]”.150  I am of the view that precautionary broad consent should accordingly be 
sought, in case a need arises in the future for the research use of stored HBMs.  This option 
is an extension of the strategy of broad consent, and is administered to all patients and 
research participants, for the ease of consent-taking and is less burdensome in terms of 
detailed or ’full’ information that these individuals will otherwise have to deal with.  The 
latter is especially problematic with patients, who are often under physical discomfort and 
emotional stress, as their main concern would be the therapeutic outcome, rather than with 
research participation or the fate of the excised residual HBMs.  Many patients also lack 
technical and scientific competency to understand biobanking and the nature and types of 
research that could be conducted.  They are also unlikely to fully appreciate and understand 
the benefits and risks entailed, which is demonstrated in my research (discussed in Chapter 
3). Some patients may feel stressed when asked for additional informed consent (in addition 
to consent for their medical procedure) before their surgery.  Studies have shown that there 
is no perfect time for taking consent on the collection and use of residual HBMs from 
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patients, since they are likely to be in emotional distress and anxious before the surgery.  
After surgery, patients are invariably physically strained due to surgical pain and need to 
rest.151  In the Chapter that follows, empirical evidence from Singapore derived for this 
thesis presents a finding that is consistent with these observations.  As we shall see, patients 
(no less in Singapore) often decide on the fate of their residual HBMs without much 
consideration but would instead base their decision on mere trust to the establishment, 
professionals and that research would generate knowledge for public good and 
advancement of medical treatment.  Thus obtaining “fully” informed consent for research 
use of residual tissues may not be practicable and ethical, if the vulnerable state of these 
patients is to be taken seriously. 
 
Consent for future research use, even if by broad consent, should be more appropriately 
understood as a means of promoting transparency and respecting a person’s autonomous 
decision on their choice to donate of the residual HBMs after surgery.  Such permission or 
consent should explain the usefulness of these otherwise discarded HBMs.  Individuals who 
have any objections (for whatever reasons) to having their residual HBMs stored and used 
for research would be given the opportunity to refuse consent.  Although being ’informed’ is 
crucial, in that permission for storage and use of residual HBMs should be given or refused 
based on the information provided, such information should be understandable and 
comprehended by the patients at that moment they were asked.  It is almost always not 
helpful to provide patients with a long list of unverifiable and overly detailed information.  
Rather, reliance on basic general information that is comprehensible and pertinent is more 
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likely to empower patients to determine for themselves their willingness to be involved 
(through contribution of their HBMs) in research.  A clear and simple general informed 
consent or permission is more likely to encourage trust, whereas a ten-page consent form 
with technical jargons, terms and conditions with exclusion clauses, will cause further 
confusion and mistrust. 
 
2.7 Informed Consent is an Inadequate Safeguard  – the importance 
of statutory governance in biobanking 
As we have considered earlier in this chapter, most tissue repositories would have informed 
prospective donors that their HBMs will be banked for future and unspecified research in the 
form of a general consent.152  The BAC goes further to emphasise donation towards a more 
generic purpose and by adopting this approach, the donation could be understood as being 
even more open-ended that that of general consent. 
 
The recommendations of the BAC did not stop at outright donation of residual HBMs. It also 
recommended that all research tissue banks (including biobanks) ought to be statutorily 
approved and licensed, and advised the setting up of a statutory board to oversee and 
license institutions and companies that carry out human tissue research and banking, 
making it necessary that all such research activities be approved and monitored.153 In 
addition, the BAC proposed that research tissue banking should only be conducted by 
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institutions approved by the appropriate authorities and not by private individuals,154 and 
institutions must have transparent and appropriate systems, and standards for the ethical, 
legal and operational governance of the research tissue banking.155  
 
While recognizing the importance of informed consent,156 the BAC is correct that this 
autonomy-based governance does not offer adequate protection of research participants 
from harm.  Informed consent provides patients with a choice on whether or not to donate 
their HBMs unconditionally, but once the donation has been made, an effective system of 
governance on a biobank’s operation must be in place to ensure accountability and 
transparency.  Currently, the system of ethical governance of the use of residual HBMs in 
Singapore still lacks transparency and accountability.  The BAC’s recommendations on 
statutory regulations, governance and supervision are still not implemented.  Contrary to 
BAC’s recommendation, there is still no statutory authority being set up to regulate and 
supervise all human tissue research in Singapore. Further, institutions and companies that 
carry out human tissue research and banking are not transparent with their safeguards. 
There are also inadequate measures in place to ensure accountability in the collection, 
storage, distribution and use of donated HBMs.  These issues will have implications for 
securing the public trust and long-term support that the success of biobanking depends 
on.157  However, due to the absence of statutory authority, individual researchers in 
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institutions and private companies could still set up their own private collections of HBMs 
and storing HBMs in their own research laboratories for their own use, without any clear 
supervision or governance and control. 
 
While the IRB is empowered by the institution and Ministry of Health to review all human 
subject research, it has the mandate from the institution to approve, reject, propose 
modifications to, or terminate any proposed or ongoing research involving human subjects 
conducted by researchers of the institution,158 and applying the guidelines of the BAC.159 
However, the role of the IRB in the monitoring of biobank governance and control is 
restricted since it is only mandated to receive annual continuing reports from approved 
projects.160 McHale et al. mentioned that conventional research ethics committees or IRBs 
could not provide an effective solution to the legal and regulatory challenges arising from 
biobanks.  They proposed the setting up of specialist ethics or biobank ethics and 
governance committee, with legislation, to focus on ethics and governance, and to provide 
oversight in relation to the operation of biobanks.161 Properly situating informed consent 
within a system of research ethics governance is discussed in Chapter 4.  In the Chapter that 
follows, empirical data is presented in support of the proposition that informed consent is in 
itself an inadequate safeguard of patient welfare and interests. The nature and content of 
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these welfare and interests are elucidated (in the context of Singapore), with a view to 





Chapter 3. Research on donation of residual biological samples 
and consent given for secondary use 
 
3.1 Background  
The research value of residual HBMs in tissue repositories or biobanks has been earlier 
discussed in Chapter 1.  However, the scientific potential of HBMs cannot be achieved unless 
ethical challenges can be effectively addressed.  Of these challenges, there is still no clear 
consensus on an appropriate standard for informed consent, according to Budimir et al 
(2011) in their systematic review on the ethical aspects of human tissue repositories and 
biobanks.162   As discussed in Chapter 2, the general requirement of informed consent is not 
disputed.  However, it remains unclear how much information must be provided in order for 
consent to be sufficiently ‘informed’ and whether lack of sufficient information will render 
the consent invalid. This has been a subject of debate and some scholars have argued for 
‘fully’ informed consent, which is equivalent to the model of specific consent within a 
classificatory system of consent-taking presented in Chapter 1.  For instance, Tom 
Beauchamp argued that the pervasive view in U.S. bioethics is that if consent is taken, it 
should be an adequately informed consent and that a broad consent is not sufficiently 
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“informed”. 163  Others have criticised this proposition to be illusory, and have instead gone 
further to propose approaches in implied consent or general consent.164   
In Chapter 2, it is argued that broad consent is to be preferred, provided that it is instituted 
within a broader system of governance that promotes accountability, transparency and trust. 
A further distinction has been made between the contribution of HBMs through broad 
consent and one that is essentially through donation. While there will be few practical 
differences between the two means of contribution, donation is arguably least restrictive in 
that the giving is predicated on purpose (typically altruistic) rather than on explicit 
informational specifications, no matter how general. 
 
This chapter reports on a systematic literature review and two empirical studies that have 
been conducted to uncover the purposes and motivations that underscore the contributions 
of HBMs to NUHTR.  The demographics, knowledge, attitudes, preferences and expectations 
of patients with NUH as contributors of their residual HBMs are documented, analysed and 
compared (at a thematic level) with corresponding published data from outside of Singapore.  
These preferences, experiences and expectations are also related to key themes that have 
been identified from a systematic literature review as: (1) Reasons for donation; (2) Degree 
of information to be provided in consent-taking; (3) Pre- or post-surgery consent (and when 
to take consent); (4) Right to withdraw; (5) Privacy and Confidentiality of Medical 
Information; (6) Governance, safeguards and controls; and (7) Access and uses of tissues.  In 
addition, my empirical qualitative study shows that there is a statistically significant 
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relationship between social demographics and the likelihood that a patient will contribute 
HBMs to research.  Demographic differences among patients do matter, and these are often 
not accounted for in consent taking.  For instance, a certain level of information associated 
with a specific consent regime is provided on the assumption that all patients recruited for 
the study have the same informational needs.  Overall, this study shows that arguments in 
favour of ‘specific informed consent’ are misguided, as most patients are not concerned with 
being fully ‘informed’.   Depending on the situation, patients are more likely to get confused 
by practices necessitated by specific informed consent. If they are to be burdened with a 
high level of details in consent taking, such an approach is more likely to encourage distrust 
and limit meaningful participation.  
 
This study has been designed as an explanatory mixed-method research that was 
implemented in three sequential phases. It began with a comprehensive systematic review 
(CSR) of the literature from 1990 to 2010, regarding donors’ preferences and perceptions of 
tissue repositories and biobanking as Phase I.  The CSR provided an overview of the 
published information concerning patients’ experiences with, and expectations of tissue 
banks and biobanks internationally.  This was followed by a quantitative analysis of the 
Surgical Consent Forms of NUH over a period of 10 years and a qualitative study involving 
100 NUH patients, conducted as Phases II and III respectively. The findings in Phase III of the 
research study have been matched and contrasted with the key themes derived from the 




This mixed-methods research methodology was selected as it enabled in-depth exploration 
into the different purposes and motivations to tissue donation.165  Both quantitative and 
qualitative methods are used, as neither is sufficient and comprehensive on its own to 
capture the trends and details of perceptions, preferences and expectations with regards to 
tissue banking.166  By utilizing both quantitative and qualitative research, the strengths of 
both methodologies are incorporated by enabling triangulation, and providing a more 
comprehensive analysis and account.167 
 
As a component of a sequential explanatory design, the qualitative findings serve to explain 
and interpret the quantitative results.168  Initially the consent rate (numeric quantitative 
data) of NUH patients was analysed and derived through the quantitative study using 
statistical analysis. The quantitative study took into account certain demographic factors, 
including ethnicity, religions, age groups, genders and types of organs involved, while the 
qualitative interviews drew out the reasons underlying the patients’ participation, their 
understanding of the risks and benefits of participation and their expectations and attitudes 
towards tissue banking research.  Analysis of this quantitative data, in combination with 
results from the CSR, facilitated the formulation of research questions for the qualitative 
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study (in Phase III).  Qualitative interviews (text data) of NUH HBMs donors were then 
analysed to help explain and elaborate on the consent rate obtained in Phase II.  
 
The qualitative study thus built on the quantitative results, by explaining why patients 
donated their HBMs (and medical information) to NUHTR, and what their preferences, 
motivations and expectations were. 169  Combining quantitative and qualitative sets of 
information can produce insightful results to learn more about patients’ opinions, 
preferences and attitudes in tissue donation 170  and provide a richer account of the study 
population.171  They could also be useful in informing policy-makers in the formulation of 
future policies and good practices in tissue donation, as these findings are thematic-based 
and practice-oriented. This aspect is elaborated on in Chapter 4. 
 
3.2 Research Objective 
As an explanatory mixed-method research implemented in three sequential phases, the 
main objective of the study reported in this Chapter is to understand and present the best 
available empirical evidence on the perceptions, motivations, expectations and experiences 
with donating HBMs to NUH TR by patients of NUH. 
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A mixed-methods design172 was conducted in 3 sequential phases, comprising a systematic 
literature review, a quantitative analysis of NUH Surgical Consent Form over a period of 10 
years and a qualitative study involving 100 patients who had donated residual HBMs to 
NUHTR.    
 
A summary of each of the three phases is as follows: 
• In the first phase, a comprehensive systematic review (literature review) was conducted 
using a standardized data extraction and analysis tool from the Joanna Briggs Institute 
Qualitative Assessment and Review Instrument (JBI-QARI) and the review was 
subsequently published in the International Journal on Evidence Based Healthcare, to 
ensure that it meets the standards of peer researchers.173  A comprehensive systematic 
review was conducted on published literature that investigated patients’ experiences on 
the donation of their residual tissues,  patients’ experiences with consent-taking for the 
use of  residual tissues and the different types of consent which influenced their decision 
to donate.  
• In the second phase,  I conducted a quantitative analysis of the consent rate among 
167,329 patients in NUH in relation to the donation of residual surgical HBMs for 
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research, education or study.  A detailed quantitative statistical analysis was carried out 
on filled Surgical Consent Forms over a period of  ten years (from 2002 to 2011), and 
matched with the patients’ demographics, including ethnicity, religion, age groups and 
type of surgery.   
• The third phase encompasses a qualitative study involving 100 patients from NUH who 
had donated HBMs to NUHTR for research. The questionnaire was designed to further 
understand patients’ preferences, experiences and attitudes in relation to their donation. 
The thematic results generated were then compared with qualitative research collected 
from elsewhere in the world (and through the CSR in Phase I of this study). 
 
Ethical approvals for both the quantitative research of NUH consent forms and qualitative 
interviews have been obtained from the National University of Singapore – Institutional 
Review Board (NUS-IRB).  Details on NUS-IRB application and approval are discussed below 
and enclosed in APPENDIX 5. 
 
3.3.1 Overview of mixed method research design 
 
Phase 1: Comprehensive Systematic Literature Review 
A systematic literature review was carried out to critically appraise, synthesize and present 
the best available evidence related to the perceptions, experiences and knowledge of 
residual biological sample donors and the impact of this experience on the type of consent 
given for future use of these tissues.  This systematic review was conducted in accordance 
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with the Joanna Briggs Institute (JBI) Evidence Based Systematic Review Methodology174 and 
(as noted above) the full text of this systematic review report was published in 2011 in JBI 
Library of Systematic Reviews.   Details of this systematic review are included as APPENDIX 4. 
The search strategy employed in this review was to identify qualitative research results in 
peer-reviewed published studies from 1990 to 2010, on tissue banking and patients’ 
preferences. A three-step search strategy was utilized. An initial limited search of MEDLINE 
and CINAHL was first undertaken, followed by analysis of the text words contained in the 
title and abstract, and of the index terms used to describe the article. A second search using 
all identified keywords and index terms was then undertaken across all included databases. 
Thirdly, the reference lists of all identified reports and articles were searched for additional 
studies.  The databases searched included Pub Med (MEDLINE), CINAHL, SCOPUS, EMBASE 
and PsycINFO.   The search for unpublished studies included Mednar and PROQUEST. Initial 
keywords used were: (i) “Tissues or Biological Samples or Blood or DNA or Bones and 
Human”, (ii) Consent, (iii) Research or Medical research, and (iv) Qualitative studies or 
qualitative research.  
 
A total of 153 published papers were initially identified following a search of the abstract, 
title, and references of all retrieved papers.  Following a review of abstract and title by 2 
independent reviewers using JBI-QARI assessment tools, 29 papers were deemed 
appropriate to this review topic based on their methodological quality.  Any disagreements 
that arose between reviewers were resolved through discussion or with a third reviewer.  
Out of the 29 papers retrieved for detailed review and examination, seven were excluded, as 
they were not congruent with this review study.  These were mixed method studies, that 
                                                          




were primarily quantitative research with some sections on qualitative discussion, and either 
did not contain illustrations or subjects’ quotation or did not have themes relevant for this 
systematic research.   After applying the respective criteria in the JBI methodology, out of 
the 22 papers identified, 18 were included and four were excluded, as the latter were not 
congruent with the criteria for methodological quality of this review. A total of 131 findings 
were identified from the 18 eligible studies and included in this review.  Qualitative data 
were extracted from these papers using the standardized data extraction tool from the JBI’s 
Qualitative Assessment and Review Instrument (JBI-QARI).175   The Grades of 
Recommendation have been based on the JBI-developed 2006 Grades of Meaningfulness: 
Grade A - Strong support that merits application; Grade B - Moderate support that warrants 
consideration; Grade C - Not supported.  Only Grade A papers are selected for this review.  
Studies that focused on qualitative data including, but not limited to, designs such as 
phenomenology, grounded theory, ethnography, action research and feminist research, and 
qualitative data from mixed-method studies were selected.  This review was not limited by 
any geographical or cultural settings.   Further, this current systematic review provided an 
overview of the patients’ experiences of donation of their residual tissues including patient’s 
experiences with different types of consent for the collection and use of leftover tissues, as 
well as the different types of consent that influenced their decision to donate.  From these 
data, we formulated our qualitative research questions to further explore patients’ 
preferences and attitudes toward tissue donation in the Singapore context. 
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Phase 2: Quantitative Research on NUH tissues consent from 2002 to 2011 
This quantitative research involved statistical analysis of the consent rates of patients at 
NUH, over a period of ten years (from 2002 to 2011), and are matched with patients’ 
demographics which included gender, ethnicity, religion, age group, and type of surgery in 
167,329 filled consent forms.  The consent rates were obtained through monthly computer-
generated reports with detailed breakdown on the number of patients who had either given 
or refused consent under the Surgical Consent Form for their surgically removed residual 
tissues to be used for medical research, education or study.  The reports on consent rate and 
demographics of the patients were provided without any identifiable personal information 
of any individual patient, and were initially meant to be a quality assurance project.  The 
reports were analysed and compiled for a period of 10 years (2002-2011) with ethical 
approval and permission from the hospital’s administration.   The data has been analysed 
using statistical p-value hypothesis test, to determine if the observed effect was statistically 
significant176 (e.g. p<0.05) and not due to chance or sampling error. The null hypothesis is 
based on the proposition that the association between the consent rate and demographic 
factor(s) is not statistically significant.  In statistical significance testing, the p-value is the 
probability of obtaining a test statistic result at least as extreme as the one that was actually 
observed, assuming that the null hypothesis is true. The null hypothesis is rejected when the 
p-value turns out to be less than a predetermined significance level, often 0.05.177  In this 
study, all the null hypotheses have been rejected on the basis that the associations between 
the consent rate and various demographic factors are of statistical significance. The 
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quantitative research titled: “Consent for donating leftover tissues in Singapore” was 
approved by NUS-IRB (Reference code: 10-252E dated 9 June 2010).   NUS-IRB application 
and approval are set out in APPENDIX 5.  
 
Phase 3: Qualitative Study involving HBMs Donors 
Qualitative interviews of 100 NUH patients who had donated HBMs for research were 
conducted with the aim to further understand their preference towards donation of residual 
tissues, the impact of these experiences on level of information required for consent 
purposes, as well as experiences and attitudes towards donation.  The author and consent 
nurses of NUHTR conducted the 100 qualitative interviews from the period of 2011 to 2012. 
Open-ended questions were used during the interviews.  This would allow respondents to 
answer in their own words and to avoid pre-judging responses. This methodology collects 
the opinion, reflection, knowledge, perception and attitude from participants who either 
have donated or have intentions to donate to NUHTR.  With the permission of the 
interviewees, face-to-face interviews were voice-recorded and verbatim transcriptions were 
prepared by the interviewers and compiled in an MS Excel spreadsheet. The responses to all 
questions were then examined using Taylor’s (2006) qualitative thematic analysis method.178  
The initial thematic domains were also identified based on our systematic literature review, 
as well as essences or patterns within the text and key words. New themes were 
subsequently identified after analysing the responses.  Thematic results generated were 
then compared with those collected from other qualitative research selected through the 
                                                          




CSR.179  A relatively large number of interviews (100 in total) were conducted in order to 
ensure that saturation points were reached for each of the emergent themes. This was also 
considered to be necessary as patients were in different states of health during the 
interviews and some of them could be too tired to answer all the questions clearly.180 
The following open-ended questions under the following themes were included in the 
interview: 
• Reason for Donation 
• Degree of Information Needed for Consent-Taking 
• Pre or Post surgery Consent (or When to Take Consent) 
• Right to Withdraw 
• Privacy and Confidentiality of Medical Information 
• Governance, safeguards and controls 
• Access and uses of tissues 
• Recruitment of patients for interview 
The qualitative study recruited English- speaking patients who have been asked to donate 
their leftover tissue.   The NUHTR consent nurse routinely asked patients whether they 
wished to donate their leftover tissues before their scheduled surgery.  After the nurses 
noted their decisions on the donation, the subjects were then invited to participate in the 
qualitative research. Participation was voluntary and the patients could withdraw and not 
answer any questions at any time.  Subjects were approached visited by the research team 
only after their surgery, when they were comfortable enough for the interview.   Verbal 
                                                          
179 AL-BUSAIDI, Z. Q. 2008. Qualitative Research and its Uses in Health Care. Sultan Qaboos 
University Medical Journal, 8, 11-19. 
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informed consent was sought before the interview begun, since many did not feel 
comfortable about signing a document.  This waiver of written informed consent has been 
approved by the NUS-IRB and consent was voice recorded or documented in the field notes, 
for those who refused to have their interviewed recorded.  Each patient participated in a 30-
minute interview at a time convenient for him/her. The interviewers were the NUH tissue 
Consent Nurses together with myself, and the interviews were conducted at the NUH’s 
wards. The interviews were conducted only in the English language and audio-recorded if 
consent was obtained.  Personal information were not collected from the patients but 
demographic information, e.g., age, sex, religion, etc., would be transferred from the initial 
NUHTR Consent Form to the researchers’ records.  Subjects’ identities have been coded on 
the questionnaire and the NUHTR Consent Form.   The data collected, including transcripts 
and audio-recordings, have been stored in a password=protected personal computer at the 
NUHTR for a maximum period of seven years after the last publication. Thereafter, the data 
will be destroyed. 
 
3.4 Ethics Approval for qualitative interview 
The qualitative research entitled:  “Patients’ experiences towards the donation of their 
leftover tissues and the impact of these experiences on the types of consent given for 
secondary use” was approved on 8 August 2011 (NUS-IRB reference code: 11-234), Head of 
NUHTR and Pathology.  The Head of NUS Department of Pathology and NUS-IRB approved 
the quantitative research on consent forms statistics of NUH patients, with assistance from 
the NUH TR team and NUH Computer Centre. Details on NUS-IRB application, approval 
documents, participant consent forms, recruitment materials (e.g. information sheet, 




3.5 Review of Results and Findings 
3.5.1 PHASE 1: Systematic Literature Review 
131 findings were aggregated into 19 categories and grouped under four main findings using 
the meta-synthesis methodology established by JBI, from the 18 eligible studies (1990-2010) 
and included in this review.  
 
The four main thematic findings were synthesized as: 
1. Patients’ contribution of their residual tissues is influenced by many and varied 
factors.  Key factors are benefits to self and others and trust in research and 
researchers;  
2. Patients expect strict safeguards and controls to maintain privacy and confidentiality 
of their data; 
3. The views on ownership and rights to the tissues vary between individual patients; 
4. Patients have different views on the commercial use of their tissues. 
 
From here on, each of the four main synthesized thematic findings are elaborated on and 
discussed. 
 
Finding 1:  Patients’ contribution of their residual tissues is influenced by many and varied 
factors. Key factors are benefits to self and others and trust in research and researchers. 
(See figure 2 for reasons why the donors contributed the HBMs for research.) 
 
More than half of the findings from the review, which was 69 out of 131 sub-findings, 
explained the different reasons why patients were willing to donate their residual tissues for 
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research (Figure 2).  This synthesized thematic finding was the dominant theme in the 
analysis and was therefore an important consideration for researchers and policy makers as 
all 18 selected studies did include findings, which supported the varied reasons that patients 
would consider when donating their biological samples for research.    The qualitative 
evidences from the systematic literature review and its specific quotations are listed in 
APPENDIX 4. 
 
FIGURE 2: SYNTHESIZED THEMATIC FINDING 1 - CATEGORIES AND STUDY FINDINGS 
 
The most common category of this group of findings was “benefits to 
self”.181 182 183 184 185 186 187 188 In this category, some patients donated tissues because they 
                                                          
181 ASAI, A., OHNISHI, M., NISHIGAKI, E., SEKIMOTO, M., FUKUHARA, S. & FUKUI, T. 2002. 
Attitudes of the Japanese public and doctors towards use of archived information and 
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believed there was either a direct or an indirect benefit to themselves.  For example, they 
may have a medical condition for which further research may be of direct benefit, either 
presently or in the future.  This group of patients would thus expect that the outcomes, 
conclusion and results of the research (whether accidental findings of a specific individual’s 
tissue or an important finding on the medical condition) be communicated back to the 
participants in the future.189  
 
Trust in research, medical researchers, research organization, and governance of the 
donated tissues was the next dominant category.190 191 192 193 194195 196 197 198 199   Patients 
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claimed to have trust in the public good paradigm of research for societal progress,200  and 
believed researchers were generating public good in the diagnosis and treatment of medical 
conditions. Patients trusted the professionals, who gained their consent to use their tissue 
samples for research.201 They also trusted that their tissues would not be misused202  and 
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exhibited confidence in the research process203 and meaningfulness of the research204  to 
generate new knowledge.  Overall, trust was an important factor in the decision on whether 
they will donate their residual tissues. 
 
A similar category is that of “Benefits to others,” where participants believed that their 
donated tissues will benefit society.205 206 207 208 209 210 211 212 213 214   This category 
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demonstrated the altruistic and solidaristic characteristics of society where patients donated 
their tissues out of their own kindness or gratitude.  Through the donation of tissues for 
research, some patients wanted to contribute to the development of medical science and 
public good, and to promote a greater public interest.215   Because of a “desire to do 
good”216 or because of “seeing donation as an act of reciprocity for having received benefit 
from past research”,217 some patients were willing to donate their tissues in recognition of 
“the good” that the research could bring to others.218  Exact quotes from the literatures are 
enclosed in APPENDIX 4 . 
 
Some people believed that donating their tissues was one way to contribute to medical 
science219  and medical education,220 and considered the tissue donation as “a gift” to 
humanity.  This line of evidence indicated an unconditional gratitude and reciprocity, with 
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some people not even having a specific reason221 222 223 when donating their tissues.  One 
group of patients based their decision to donate (or not to donate) their residual tissues on 
the type of research224 225 226 227  to be conducted. For example, some patients refused to 
donate for either cloning,228 or non-therapeutic research229 or research using stem cells230 as 
they were viewed as “weird” research.231  
 
Many patients felt that as there was “no risk and harm”232 233 234  to the donor, they would 
donate their residual tissues which would otherwise be discarded or destroyed (as it was 
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considered a “waste”235 product of the surgery). However, some patients donated because 
they believed they had a “dependent relationship”236 with the doctors requesting these 
tissues and consequently felt obliged to donate.   
 
Finding 2:  Patients expect strict safeguards and controls to maintain privacy and 
confidentiality.   
The enclosed figure 3 shows a total of 27 sub-findings grouped into four categories to 
support this main finding. 
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FIGURE 3: SYNTHESIZED THEMATIC FINDING 2 - CATEGORIES AND STUDY FINDINGS  
 
 
On the collection and storage of residual tissues, patients believed that research institutions 
should have strict controls and ethical safeguards on these HBMs and their related genetic 
and medical information.237 238 239   Protection of privacy and maintaining 
confidentiality240 241 242 243  were two major concerns of patients. Patients were worried that 
private and confidential medical records and genetic information from tissue identification 
would be leaked into the hands of insurance agents and employers.244  This could result in 
potential economic and financial loss to patients in the future.  Further, they were 
concerned about social and financial discrimination once their medical confidentiality was 
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breached and thus believed that there should be safeguards and controls on the medical or 
genetic information retained by researchers and their organizations.245   
 
Mistrust in research organizations and their governance was one of the main reasons for the 
refusal to donate residual tissues for research.246 247   Others were also concerned about the 
method and timing in which patients were approached for donation.248 249   It was important 
that patients should not feel coerced to donate or be placed in a vulnerable position where 
they felt forced to donate.250  
 
Finding 3:  The views on ownership and rights to the tissues vary between individual 
patients.    
On the storage and use of stored tissues, patients presented differing views on the 
ownership of donated tissues and their rights to use donated tissues for future research.  A 
total of 29 sub-findings were grouped into four categories to derive this main finding (Figure 
4). 
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FIGURE 4: SYNTHESIZED THEMATIC FINDING 3 - CATEGORIES AND STUDY FINDINGS  
 
Eighteen of the 29 sub-findings were related to the issue of informed consent.  Most 
patients (14 out of 18 findings) agreed that residual tissues should not be collected, stored, 
distributed and used for research without the prior consent of 
patients.251 252 253 254 255 256 257 258  Other issues mentioned by patients include query of who 
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should give consent (especially in the case of minors),259  use of the stored residual tissues 
for future research,260 length of time of storage261 262  and the type of research carried 
out.263  The types of consent models, whether broad or specific informed consent, were 
briefly discussed in two articles,264 265  although the authors did not conclude the type of 
consent models preferred by interviewed patients.  Some patients considered that tissue 
samples as property that they owned266  as these were once part of their own body267  and 
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these patients claimed that they have a right to know the fate of their tissues.268 269  These 
patients were not willing to give up the right of ownership of their tissues270 271 272 273  when 
donating to research institutions.  In contrast, some patients said that informed consent was 
neither required nor necessary,274 and thus informed consent was not an issue for them. 
Some patients preferred to be given an option to either opt-out of donation or the 
possibility of withdrawing their donated samples275  from tissue repositories, even though 
they did not think that the materials would be misused.276   
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Finding 4:  Patients have different views on the commercial use of their tissues. 
 (Figure 5 shows a total of six sub-findings grouped into two categories to derive this main 
finding.) 
Patients were divided based on the use of their residual tissues by commercial companies to 
generate profit.  While they were willing to donate for altruistic reasons to a government- 
funded institution for research of public benefit,277 they cautioned that such donations 
should not be used for commercial purposes, because they distrusted 'for-profit' 
organizations.278  They were generally suspicious279 of the profiteering motive of private 
companies compared to the motives of either a government or public institution funded 
tissue bank.  Some viewed the involvement of commercial companies and the access of third 
parties to the tissues as necessary280 and considered this as part of the development of 
drugs, or a "necessary evil",281  to advance technology for research. Such patients also 
cautioned that the use of tissues must be either closely monitored or regulated.282  
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FIGURE 5: SYNTHESIZED THEMATIC FINDING 4, CATEGORIES AND STUDY FINDINGS 
 
 
3.5.2 PHASE 2: Analysis of Consent for Residual Surgical HBMs from 2002 – 2011 
In Phase 2 of the research, data was collected from Surgical Consent Forms of patients who 
either agreed to provide tissue for medical research, education or study (Patient’s consent= 
Yes), or those who declined (Patient’s consent= No).  Forms that were left unfilled (Patient’s 
consent= Null) were regarded as consent being refused, as their HBMs would not have been 
collected for these purposes. 
 
An analysis of data on consent rates for the contribution of residual HBMs in NUH from 2002 
to 2011 was conducted.  The data is then stratified according to gender, ethnicity, religion, 
age groups, paying class and type of surgery performed.  These data fields were existing 
demographics captured in the NUH administrative system for patients’ admission. 
 
Based on our detailed quantitative analysis of 167,329 Surgical Consent Forms of NUH 
spanning a period of ten years (from 2002 to 2011), it has been determined that 73.58 % of 
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all patients were willing to contribute their residual HBMs. The consent forms were originally 
collected for quality assurance purposes to ensure that the informed consent processes 
were properly administered. Subsequently, detailed quantitative statistical analysis was 
carried out on the completed Surgical Consent Forms, and matched with patients’ 
demographics, including ethnicity, religion, age groups and type of surgery.  The following 
demographics have been found to be relevant in considering if a person would agree to 
provide their residual HBMs for medical research, education or study: 
Gender - Men were found to be more willing to contribute their residual HBMs than women.  
Ethnicity -  Chinese patients were more willing to provide consent under the Surgical 
Consent Form, followed by Malay and Indian patients. 
Religion - Buddhists and Non-Denomination Christians were more willing to donate. 
Age groups - Elderly patients of more than 50 years of age were more willing to donate. 
Paying Class - Private patients were more willing to donate. 
Different medical conditions - Patients' donation rate varied with their medical conditions. 
 
Gender 
Within the period of 10 years (from 2002 to 2011), a total of 167,329 patients admitted to 
NUH (Table 1) comprising 95,409 females, 71,916 males and 4 of unknown gender (foetuses). 
Comparisons on willingness to donate were then made between the two genders whereas 
samples of unknown gender were deemed as unclassified and omitted from analysis. The 
data suggested that there were significantly more men willing (at 78.00%) to donate their 
99 
 
tissues when compared to women (at 70.24%) with p<0.05 (using Fisher’s exact test, two-
sided).283   
 
TABLE 1: SUMMARY OF GENDER AND CONSENT RATE FOR THE DONATION OF RESIDUAL 




Based on the sampled population, the willingness to donate appeared to be in the following 
order, from highest to lowest in consent rate: Chinese > Sikh284 > Others > Eurasian > Malay > 
Indian (Table 2). The Chinese (74.78%) and Sikh (74.55%) had the two highest consent rates, 
above the total consent percentage (73.58%; Table 1), whereas the Malays (69.49%) and 
Indians (68.69%) had the lowest consent rates.  
 
                                                          
283 In statistical significance testing, the p-value is the probability of obtaining a test statistic 
result at least as extreme as the one that was actually observed, assuming that the null 
hypothesis is true. Researchers will often "reject the null hypothesis" when the p-value turns 
out to be less than a predetermined significance level, often 0.05.  Goodman, SN (1999). 
"Toward Evidence-Based Medical Statistics. 1: The P Value Fallacy."  Annals of Internal Medicine 130: 
995–1004 
284 The Sikh community is one of the smallest ethnic groups in Singapore and is usually 
considered part of the larger North Indian community. According to the 2010 census, there 






 Response Female (%) Male (%) Unknown (Fetus,%) Total (%) 
No 28389 (29.76) 15819 (22.00) 1 (25.00) 44209 (26.42) 
Yes 67020 (70.24) 56097 (78.00) 3 (75.00) 123120 (73.58) 




TABLE 2: SUMMARY OF ETHNIC GROUP AND CONSENT RATE FOR THE DONATION OF 




From the sampled population in Table 3, the willingness to donate based on religion were in 
the following order, from highest to lowest consent rate: Non-denomination > Buddhism > 
Others > Christianity > Roman Catholics > Sikhism > Islam > Hinduism. Among the religions, 
Non-denomination (75.45%), Buddhism (74.42%), Others (74.15%) and Christianity (73.91%) 
had higher consent rates when compared to total consent percentage (73.58%; Table 1).   
The field ‘Non-denomination’ refers to patients who do not have a religion (or no religious 
affiliation) and the field “Others” refer to those who have a religion but not indicated as a 





Response CHINESE (%)a EURASIAN (%)a INDIAN (%)a MALAY (%)a SIKH (%)a OTHERS (%)a TOTAL 
No  29070 (25.22) 113 (26.7) 4362 (31.31) 5633 (30.51) 1287 (25.45) 3744 (26.41) 44209 
Yes 86207 (74.78) 309 (73.22) 9570 (68.69) 12831 (69.49) 3770 (74.55) 10433 (73.59) 123120 
 Grand Total 115277 422 13932 18464 5057 2868 167329 
        a - % within ethnic group 
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TABLE 3: SUMMARY OF RELIGION AND CONSENT RATE FOR THE DONATION OF RESIDUAL 




Based on the sampled population, the willingness to donate based on age group were in the 
following order, from highest to lowest consent rate: 60-69 > 70-79 > 80-89 > 50-59 > 90-99 > 
below 10 > 10-19 > 20-29 > 40-49 > 30-39 > above 100 (Table 4). The results showed that 
patients between the age groups from 50 to 89 years had higher consent rates when 
compared to total consent percentage (73.58%; Table 1). The age group of between 50 to 59 
years was especially notable as the results showed a steady downward trend from age 





 RELIGION No  Yes  Total 
BUDDHISM  (%)a 9907 (25.58) 28827 (74.42) 38734 
CHRISTIANITY  (%) a 3508 (26.09) 9937 (73.91) 13445 
HINDUISM  (%) a 2023 (31.03) 4497 (68.97) 6520 
ISLAM  (%) a 5551 (30.28) 12782 (69.72) 18333 
ROMAN CATHOLICISM  (%) a 68 (26.46) 189 (73.54) 257 
SIKHISM  (%) a 191 (29.98) 446 (70.02) 637 
NON-DENOMINATION  (%) a 2860 (24.55) 8790 (75.45) 11650 
OTHERS  (%) a 20101 (25.85) 57652 (74.15) 77753 
Total 44209 123120 167329 
    a - % within religion  
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TABLE 4: SUMMARY OF AGE GROUP AND CONSENT RATE FOR THE DONATION OF 




Based on the sampled population, a significantly higher percentage of private-paying 
patients donated their tissues when compared to patients who received subsidized care or 
had other forms of payment methods (p<0.05 using Fisher exact test, two-sided; Table 5).  







AGE GROUP, years No  Yes  
Grand 
Total 
< 10 (%)a 741 (27.3) 1973 (72.7) 2714 
10 to 19 (%)a 1475 (28.07) 3780 (71.93) 5255 
20 to 29 (%)a 3528 (28.28) 8946 (71.72) 12474 
30 to 39 (%)a 6066 (30.61) 13751 (69.39) 19817 
40 to 49 (%)a 8176 (29.44) 19600 (70.56) 27776 
50 to 59 (%)a 9478 (26.08) 26869 (73.92) 36347 
60 to 69 (%)a 6681 (22.81) 22609 (77.19) 29290 
70 to 79 (%)a 5027 (23.38) 16472 (76.62) 21499 
80 to 89 (%)a 2479 (24.46) 7656 (75.54) 10135 
90 to 99 (%)a 513 (27.11) 1379 (72.89) 1892 
> 100 (%)a 45 (34.62) 85 (65.38) 130 
Total 44209 123120 167329 
    a - % within age group 
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TABLE 5:  SUMMARY OF FEE SCHEDULE AND CONSENT RATE FOR THE DONATION OF 
RESIDUAL TISSUES IN NUH FROM 2002 TO 2011. 
 
 
Annual Consent Rate 
Results showed that there was an increasing trend of consent from 2002 (at 61.89%) to 2008 
(at 83.15%) (Table 6). However, a decreasing trend of consent rate was seen from 2009 to 
2011.   The average consent rate over the 10=year period was 73.82%.  There was an upward 
trend observed for positive consent, throughout the ten-year period based on the number of 
participants regardless of either positive or negative consent.  The rate of participants 
increased by 1.76% per annum (95% CI 0.30% to 3.21%) and was found statistically 





 Response Private (%)a Subsidised (%)a Others (%)a Total 
No 14033 (24.02) 30150 (27.70) 26 (31.33) 44209 
Yes 44378 (75.98) 78685 (72.30) 57 (68.67) 123120 
Grand 
Total 58411 108835 83 167329 
     a - % within fee schedule 
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TABLE 6: SUMMARY OF YEARLY ANNUAL CONSENT RATE FOR THE DONATION OF 
RESIDUAL TISSUES IN NUH FROM 2002 TO 2011.   
 
Departments 
Results of consent for contribution of tissue based on department showed that out of the 24 
departments within NUH, 18 had positive consent rate of higher than 50% (Table 7).  
Departments including Laboratory Medicine, Ambulatory Service, Urology, Neonatology and 
University Surgical Cluster were the top 5 in terms of positive consent. On the contrary, the 
lowest 5 included Clinical trial Unit, Diagnostic Imaging, Radiation Oncology, Psychological 
Medicine and Haematology Oncology. Different departments excise different types of 
tissues and thus provide an indication on the willingness to donate based on the type of 
surgeries, the types of tissues removed and the various medical departments involvement in 
the collection of residual HBMs.  Further research is necessary to understand the inter-




 YEAR No Yes Total 
2002 (%)a 4084 (38.11) 6633 (61.89) 10717 
2003 (%)a 4531 (31.80) 9717 (68.2) 14248 
2004(%)a 5345 (32.62) 11043 (67.38) 16388 
2005(%)a 4292 (27.39) 11380 (72.61) 15672 
2006(%)a 4106 (23.99) 13009 (76.01) 17115 
2007(%)a 3933 (21.43) 14417 (78.57) 18350 
2008(%)a 3147 (16.85) 15527 (83.15) 18674 
2009(%)a 4206 (22.39) 14581 (77.61) 18787 
2010(%)a 5152 (28.19) 13125 (71.81) 18277 
2011(%)a 5413 (28.3) 13688 (71.66) 19101 
Grand Total 44209 123120 167329 
    a - % within year 
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TABLE 7: SUMMARY CONSENT RATE STRATIFIED BY DEPARTMENT FOR THE DONATION OF 
RESIDUAL TISSUES IN NUH FROM 2002 TO 2011.   
 
Keys: 
“No” – Patient who refused consent for donation of residual tissues 
“Yes” – Patient who consented for donation of residual tissues 
“Null” – The consent form was not completed, i.e. neither Yes nor No 
 
  
Department No Yes Total % No %Yes 
Clinical Trial Unit 218 72 290 75.17% 24.83% 
Diagnostic Imaging  4113 2005 6118 67.23% 32.77% 
Radiation Oncology  55 33 88 62.50% 37.50% 
Psychological Medicine  29 18 47 61.70% 38.30% 
Haematology Oncology  1273 1045 2318 54.92% 45.08% 
Rehab Medicine      4 4 8 50.00% 50.00% 
Cardiac  812 1080 1892 42.92% 57.08% 
Obstetrics & 
Gynaecology  10620 17066 27686 38.36% 61.64% 
Orthopaedic Surgery  2601 4222 6823 38.12% 61.88% 
Paediatric Surgery  835 1538 2373 35.19% 64.81% 
Emergency Medicine  588 1489 2077 28.31% 71.69% 
Ophthalmology  521 1331 1852 28.13% 71.87% 
Dentistry  302 857 1159 26.06% 73.94% 
Otolaryngology - Head & 
Neck Surgery  3052 8841 11893 25.66% 74.34% 
University Medicine 
Cluster  8992 29971 38963 23.08% 76.92% 
Paediatrics  603 2101 2704 22.30% 77.70% 
Anaesthesia  630 2221 2851 22.10% 77.90% 
Hand & Reconstructive 
Microsurgery  758 2744 3502 21.64% 78.36% 
Cardiac, Thoracic & 
Vascular Surgery  1067 3959 5026 21.23% 78.77% 
University Surgical Cluster 6393 36639 43032 14.86% 85.14% 
Neonatology  15 109 124 12.10% 87.90% 
Urology  725 5578 6303 11.50% 88.50% 
Ambulatory Service 2 113 115 1.74% 98.26% 
Laboratory Medicine  1 84 85 1.18% 98.82% 





Data collected on 167,329 potential donors including their age, gender, ethnicity, religious 
beliefs and fee schedule and statistical analysis were performed (using Odds ratio [OR] and 
95% confidence interval [CI] on the data).  The results are enclosed in Appendix 6 of this 
thesis.   
 
Based on the multivariate statistical analysis,  
1. On Gender, men were found to be more willing to contribute their residual HBMs 
than women. The odds of males in willing to donate the human biological materials 
is significantly higher compared with females (OR = 1.50, 95% CI = 1.47 to 1.54, p < 
0.001). 
2. On Ethnic groups, Chinese patients were more willing to provide consent under the 
Surgical Consent Form, followed by Malay and Indian patients. 
a)     Chinese compared with Malay: The odds of Chinese in willing to donate the 
human biological materials is significantly higher compared with Malay (OR = 1.30, 
95% CI 1.25 to 1.36, p < 0.001). 
b)    Chinese compared with Indian: The odds of Chinese in willing to donate the 
human biological materials is significantly higher compared with Indian (OR = 1.35, 
95% CI 1.29 to 1.42, p < 0.001). 
c)     Chinese compared with Eurasian: OR = 1.08, 95% CI 0.82 to 1.44, p = 1 
d)    Chinese compared with Sikh: OR = 1.01, 95% CI 0.93 to 1.10, p = 1 
e)     Chinese compared with Other Races: The odds of Chinese in willing to donate 
the human biological materials is significantly higher compared with other races (OR 
= 1.06, 95% CI 1.01 to 1.12, p = 0.011). 
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3. On religions, Buddhists and Non-Denomination Christians were more willing to 
donate. 
a)     Buddhism compared with Christianity: OR = 1.03, 95% CI 0.97 to 1.09, p = 1 
b)    Buddhism compared with Hinduism: The odds of Buddhism in willing to donate 
the human biological materials is significantly higher compared with Hinduism (OR = 
1.31, 95% CI 1.21 to 1.42, p < 0.001). 
c)     Buddhism compared with Islam: The odds of Buddhism in willing to donate the 
human biological materials is significantly higher compared with Islam (OR = 1.26, 
95% CI 1.20 to 1.33, p < 0.001). 
d)    Buddhism compared with Roman Catholicism: OR = 1.05, 95% CI 0.71 to 1.53, p 
= 1 
e)     Buddhism compared with Sikhism: OR = 1.25, 95% CI 0.98 to 1.58, p = 0.082 
f)     Buddhism compared with Non-Denomination: OR = 0.95, 95% CI 0.89 to 1.01, p 
= 0.178 
g)    Buddhism compared with Other Religion: OR = 1.01, 95% CI 0.98 to 1.05, p = 1 
4. On age groups, elderly patients of more than 50 years of age were more willing to 
donate.  The odds of patients who were 50 and above 50 years old in willingness to 
donate the human biological materials were significantly higher compared with 
those who were below 50 years old (OR = 1.29, 95% CI = 1.26 to 1.32, p < 0.001). 
5. On types of patients’ payment scheme, private patients were more willing to donate. 
a)     Private compared with Subsidised: The odds of those who had private fee 
schedule in willingness to donate the human biological materials were significantly 
higher compared with those who had subsidised fee schedule (OR = 1.21, 95% CI 
1.18 to 1.24, p < 0.001). 
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b)    Private compared with Other Fee Schedule: OR = 1.44, 95% CI 0.84 to 2.45, p = 
0.244 
 
Base on the analysis in Appendix 6,  an elderly i.e., 60-69 years old,  Chinese man, Buddhist 
who is in the private paying ward, would be most likely to donate his residual HBMs, as 
compared to a middle age i.e., 30-39 years old Indian lady, Hindu  in the subsidized ward), 
who is least likely to donate her leftover HBMs for research.   Further research must be 
conducted to conclude that demographic factors were significant predictors of attitudes 
toward donation of residual HBMs for research.  Based on the annual report on the number 
of consent collected, we were only able to perform chi-square test as listed in Appendix 6.  
One limitation of this study is that we could not perform the multivariate analysis, as we 
could not direct access to the individual patient medical records for confidential reason.  
 
The quantitative research (in Phase II) showed that a majority of the patients admitted to 
NUH (73.58%) was willing to provide their residual surgical HBMs without much information 
provided.  The data also suggests that a decision to contribute residual HBMs from surgery 
was influenced by gender, ethnicity, religion, age groups, paying class and type of surgery 
performed. As explained in Chapter 2, the  results indicate that this is also the pool of 
patients that can be approached to donate residual HBMs to NUHTR. In the description and 
analysis of Phase 3 of the research that follows, 100 patients have been interviewed to 






3.5.3 PHASE 3: Qualitative Study involving NUH Patients 
 
In this phase of research, interviews were conducted with 100 NUH patients who agreed to 
donate their residual HBMs to NUHTR.  As these patients have all expressed agreement in 
the Surgical Consent Form, it was not possible to identify any patient who refused the 
proposed donation.  Attempts were made to recruiting patients who refuse to contribute 
residual HBMs under the Surgical Consent Form, but these invitations to participate were 
declined.  The demographics of the recruited participants (n=100) are described below. 
 
Gender 
Among the 100 donors interviewed, 58 of them were women and 42 were men (see Table 8). 
 
Table 8: SUMMARY OF GENDER OF PARTICIPANTS (N=100) 
 
 
Ethnic Group and Nationality 
Table 9 provides the ethnicity of the participants.  The largest ethnic group was Chinese 
(54%) followed by Malay (18%).  Seventy-five are Singapore citizens of whom 18 were 
Malays, 9 were Indians and 48 were Chinese. The rest are foreigners, comprising 10 
Indonesians, 6 Malaysians, 5 patients from Myanmar, 1 patient each from Bangladesh, 
Philippines, Canada and the UK. 
 
GENDER OF PARTICIPANTS NUMBER 
Female donors  58 









Table 10 provides the religion of the participants.  The largest group was Buddhist (25%) 
followed by Islam (24%) and Christianity (18 %).  The listing follows the existing fields in the 
NUH administrative system for patients’ admission. 
 
Table 10: SUMMARY OF RELIGION OF PARTICIPANTS (N=100). 
 
Age Group 
Table 11 provides the age group of the participants.  The largest group was at age 50-59 
(28%) followed by 40-49 (21%) and 60-69 years(18 %).  The participants were selected 
randomly and not based on age.  NUS-IRB approval was granted for interview with adults 
 
RACE 
  CHINESE (%)a EURASIAN INDIAN (%)a MALAY (%)a SIKH  OTHERS (%)a TOTAL 
 Grand Total 54 (54.00) - 9 (9.00) 18 (18.00) - 19 (19.00) 100 
        a - % within ethnic group 
       
RELIGION Number of participants 
BUDDHISM  (%)a 26 (26.00) 
CHRISTIANITY  (%)a 18 (18.00) 
HINDUISM  (%)a 4 (4.00) 
ISLAM  (%)a 24 (24.00) 
ROMAN CATHOLICISM  (%)a 14 (14.00) 
SIKHISM   - 
NON-DENOMINATION  - 
OTHERS  (%)a 13 (13.00) 
Total 100 






above 21 years and thus those below the age of 21 years were excluded from the study due 
to concerns with proper consent-taking (as they were considered legal minors). The age 
distribution amongst the population is listed below. 
 
Table 11: SUMMARY OF PARTICIPANTS STRATIFIED BY AGE GROUP (N=100) 
 
 
Key Findings from Qualitative Interviews 
This study utilized an interpretive approach (as discussed in Schwandt, 2001) 285 to data 
collection and analysis with the aim of capturing the individual’s constructed knowledge and 
meaning, through a close analysis of their actions and behaviour.  Interpretive research 
denotes an approach to studying social life with the assumption “that the meaning of human 
                                                          
285 Schwandt, T.A. (2000). Three Epistemological Stances for Qualitative Inquiry: Interpretivism, 
Hermeneutics and Social Constructionism. In: Denzin, N.K. & Lincoln, Y.S. (eds:) Handbook of 
Qualitative Research. (2nd ed.). Thousands Oaks: Sage Publications Schwandt, T. A. (2001). Dictionary 
of qualitative inquiry (2nd ed.). Thousand Oaks, CA: Sage. 
AGE GROUP, years Number of participants
< 10 -
10 to 19 -
20 to 29 (%)a 7 (7.00)
30 to 39 (%)a 14 (14.00)
40 to 49 (%)a 21 (21.00)
50 to 59 (%)a 28 (28.00)
60 to 69 (%)a 18 (18.00)
70 to 79 (%)a 11 (11.00)
80 to 89 (%)a 1 (1.00)
90 to 99 -
> 100 -
Total 100
a - % within age group
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action is inherent in that action” (p. 134. Schwandt, 2001) 286.  The results of the data 
analysis are presented as thematic analysis, under seven broad themes for each group of 
questions. The themes are: (1) Reasons for donation; (2) Degree of information to be 
provided in consent-taking; (3) Pre- or post-surgery consent (or when should consent be 
taken); (4) Right to withdraw; (5) Privacy and Confidentiality of Medical Information; (6) 
Governance, safeguards and controls; and (7) Access and uses of tissues.  Key findings from 
the interviews, grouped in the sequence of these seven headings, are summarised below. 
The primary reason for tissue donation for a majority of the participants (92%) are altruism, 
for advancement of future research, helping other people and benefiting future generations. 
Some even donated to prevent waste, having the opinion thinking that HBMs were 
superfluous and of no use to them. 
 
A majority of the participants (81%) did not think or did not know there was any risk 
involved in the donation of residual HBMs, and had implicit trust in researchers and the 
research governance system. 
 
74% of the participants were satisfied with the short and brief NUHTR consent form, and 
indicated that they did not have time to go into the details or that they did not really care. 
Most of the participants (78%) did not think they would withdraw from research 
participation although a few participants indicated that they might do so under certain 
conditions such as unethical research, familial pressure or for religious reasons. 
 
                                                          




Most participants (85%) did not object that researchers accessed their personal and medical 
information, as long as the researchers were under obligation to keep these confidential. 
Most participants were not sure of the safeguards and controls that currently exist with 
regards to residual HBMs. However, a majority of the participants were of the view that IRBs 
or researchers should ensure responsible practices. 
Some participants objected to their tissues being used by commercial companies and foreign 
institutions, mainly for the reason that subsequent benefits may not be equitably distributed. 
 
Our qualitative research on 100 NUH patients showed that majority of the patients 
contributed their residual tissues for altruistic reasons, have trust in the institutions and 
researchers, preferred brief general consent to detailed informed consent with safeguards 
and control, were unaware of risks related to tissue bank research and objected to the use 
of the residual tissues by a commercial company.  
Reasons for donation 
 
Interview Question (1a): Why have you consented to tissue donation? 
All participants interviewed consented to the donation of their residual surgical tissues 
(n=100), out of which 82 were repeated tissue donors and 18 were first time donors.  When 
asked why they agreed to donate their residual HBMs, 56 participants gave one reason, 27 
participants gave two reasons, 9 participants gave three reasons and 1 participant gave four 
reasons.  The reasons were grouped into the following themes using thematic analysis by 
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using Taylor’s (2006) qualitative thematic analysis method.287  The themes from the analysis 
of the interviews were then compared with the findings from the CSR (see Table 12). 
 
Table 12: SUMMARY ON REASONS GIVEN FOR DONATING HBMs 
REASONS TO DONATE THEIR HBMs NUMBER OF FINDINGS IN NUH PATIENTS 
Trust in research and researchers 54 Findings 
Benefits to others 38 Findings 
No use for residual tissue 28 Findings 
*Support education and training 8 Findings 
Agreed to donate without any reason 7 Findings 
No harm or risk to self 5 Findings 
A "gift" 2 Findings 
Benefits to Self 2 Findings 
Reciprocate for benefits received from 
previous research contributions 
2 Findings 
Dependent relationship 1 Finding 
 
 
The reasons participants gave for donating their residual HBMs were mainly that they 
trusted the researchers and they believed the research would benefit others, and that there 
was no other use for the residual HBMs.  Only a few of the respondents believed that: 
donation supported education and training for medical staff; here was no harm to oneself by 
donating; it was seen as a gift; that there would be benefits to themselves; that findings 
                                                          





would inform other research; and that they donated because they believed that they should 
or there may be some negative outcomes to themselves (see Table 12). 
 
TABLE 13: REASONS FOR DONATING HBMS IN CSR AND QUALITATIVE RESEARCH 
REASONS TO DONATE THEIR HBMs THEME FINDINGS IN 
CSR 
THEME FINDINGS IN NUH 
PATIENTS 
Benefits to Self YES YES 
Trust in research and researchers YES YES 
Benefits to others YES YES 
Depending on type of research YES Not reported 
No use for residual tissue YES YES 
Agreed with no reason YES YES 
No harm or risk to self YES YES 
A "gift" YES YES 
Dependent relationship YES YES 
*Reciprocate for benefits received 
from previous research 
contributions 
Not reported YES 
*Support education and training Not reported YES 
Key:   * = themes not reported in systematic literature review 
 
There were 2 new findings from the qualitative data from NUH patients, which had not been 
reported in previous research (references) in any country nor was it found as a theme in the 
systematic review undertaken of the literature in this study. The first theme, ‘support 
education and training’ (8 findings) could be unique because NUH is a teaching hospital and 
patients assumed that their HBMs are used by students for their research and experiments. 
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The second theme, ‘reciprocate for benefits received from previous research contributions’, 
was, however, only reported by two participants and therefore should be viewed with 
caution until other studies confirm this theme. 
 
In contrast, the CSR data suggested that the major reasons to donate would be for benefits 
to self. Additionally the CSR data suggested that the type of research that the tissue was 
going to be used would influence participants on whether they will donate their tissues.  In 
the interviews however, only a few respondents raised this concern. This shows a lack of 
understanding (knowledge gap) of tissue banking and research in general among the local 
patient population.  Apart from these, the other findings were similar between the CSS and 
the interviews conducted. 
 
The reasons participants gave for donating their residual HBMs were mainly that they 
trusted the researchers and they believed the research would benefit others, and that there 
was no other use for the residual HBMs. In contrast, the CSR data suggested that the major 
reasons to donate would be for benefits to self. Additionally the CSR data suggested that the 
type of research that the tissue was going to be used would influence participants on 
whether they would donate their tissues.  In the interviews however, only a few respondents 
raised this concern. This shows a lack of understanding (knowledge gap) of tissue banking 
and research in general among the local patient population.  Apart from these, the other 
findings were similar between the CSS and the interviews conducted. 
 
In addition to the themes already identified in the CSR, two new themes emerged from the 
interviews: “Reciprocate for benefits received from previous research contributions”; and 
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“Support education and training”.  The theme, “Reciprocate for benefits received from 
previous research contributions”. was explained by Participant 8, who stated: 
“I have given consent as I (am) also interested in research and it can help doctors to get 
advancement in this technology. Plus, it will be beneficial for the patient. This tissue is also 
of no use and I do not want to waste it. Hence, if somebody can use then let them use it.”   
 
Additionally Participant 12 noted: 
“Yes I have given my consent. I believe that whatever advanced medication or treatment I'm 
getting now is the result of research from the past. In order for that to be done, there has to 
be people who need to volunteer themselves for research materials. Hence, I should also do 
my part.” 
 
It is clear from these findings that these two participants had agreed to donate based on 
reciprocity. They were grateful for the past contribution of others, and wanted to contribute 
their HBMs as research materials for medical progress that will benefit future patients. 
 
Another new theme that emerged was “support education and training”, since NUH was 
perceived as a teaching and training hospital, and affiliated with the university. Participant 
22 stated: 
“Because I pity the student, they want to study about it.  So I give my permission.” 
 
Similarly Participant 74 also noted: 





Interview Question (1b):  Do you know of any benefits and risk in this donation, and uses 
of your donated tissue/s? 
More than half of the participants interviewed considered the use of their tissues in future 
research and discovery of new treatment as benefits. A few people did not answer and/or 
were unaware of the benefits or risks. A majority of the participants did not think there was 
any risk involved, except surgical risk, and they trusted that systemic safeguards were in 
place to ensure that they suffered no harm.  Based on the results, 41 participants replied 
that there was no risk involved; 40 participants were unsure of the risk involved; 3 
participants mentioned that they did not care about risk as long as there were benefits; 3 
participants were concerned about whether their HBMs would be misused (although the 
participants described this as “abuse”); 2 participants claimed that they trusted the hospital 
to protect their HBMs; and only 1 participant was concerned about privacy issues. When 
asked if there was a risk of misuse, most were unsure the context in what misuse would be. 
Quoting participant P10: 
“I do not know much about the risks and benefits.” 
Participant 8 was similarly confident that there was little risk of misuse: 
“Benefits are the reasons that I have stated before, which are for the medical research and 
diagnosis and treatment of the patient. I don't think that there is any risk as I believe that 
the people who are doing this research will keep and use the tissues properly.” 
 
Interview Question (1c):  What would influence your decision? 
Many decisions to donate were influenced by the knowledge that it would advance medical 
and scientific discoveries; help people with same disease in the future; and constitute 
sharing on the basis of religious belief. 
Participant 36 stated: 
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“Because this sickness of mine is rare. According to Professor X, it is rarely happen like this. 
Sarcoma in the liver. Sarcoma usually doesn't make tumour… doesn't make our leukocyte 
increase. But this… we cannot get it in ordinary tumour. So maybe it will help other people if 
they have same disease like me.”  
Participant 16 stated a similar intent to support scientific progress: 
“I think that there are many things that we need to learn from the medical field. So by 
donating my specimen, I hope that they will be able to find something from it.” 
Religious belief encouraged some participants to donate for the benefit of other, like 
Participant 98: 
“It's because I'm a Buddhist, so the donation is a sense of from our entire experience. We're 
taught to donate each and everything. If we've extra, or even if we don't have extra, we have 
to share ... So I think because of our religions background. We're used to this...” 
 
Some participants claimed that they would not donate if there were risks to one’s health. As 
Participant 79 said: 
“Well, nothing really... I mean what. Like I've said earlier, if it's going to do good, let it be. It 
doesn't involve anything more from me. I don't have to cut off another limb or suffer or be 
deprived of some parts of my organ, just for the donation. Actually it doesn't have bearing 
whatsoever on my well-being so that's being the case, it seem no objection whatsoever, you 
know, to donate whatever has been removed from me and people need to use, go ahead. 
You know, I think it's the same principle as organ donation. If anything happen to me, if my 
organs are needed, so be it, you know. Same principle.” 
Patients were willing to contribute their residual tissues for the purpose of scientific 
advancement and the benefit for future patients. Some cited religious practice and belief as 




Interview Question (1d):  Would you have consented to donate a different organ/tissue 
than the current one? 
For most participants, the type of HBM did not seem to matter if it had to be removed for 
therapeutic purposes. More than half of the participants would still donate if it were a 
different HBM. As Participant 100 said: 
“Regardless of the organ, I would still have given, unless maybe it poses a risk to me, you 
know, more than what...I mean I've already contributed. You know, if I've contributed excess 
and it poses additional risk, then maybe I will start to consider. But if you… there's no risk, 
you know, then of course I'm happy actually in fact that they're using it for, you know, for 
improving science for expanding upon knowledge.” 
Participant 70 also expressed a similarly pragmatic viewpoint:  
“Different organ? That's fine. Since it'll be removed from my body already, right?” 
Some participants did indicate that they would rethink at some point in time in the future, as 
Participant 23 noted: 
“That one I may have to think about it. (Why?) Because those are the things that are like 
different, you see. This is just the stomach that is given away.” 
Religious conviction would stop some Muslim participants from donating organs. Participant 
40 said: 
“I don't think so. Because as a Muslim if I die I want to have completed everything.” 
Participant 39 expressed a similar view: “Yes maybe. I would reconsider. (Why?) If it's a 
different organ I would reconsider because as a Muslim, and I'm being born with everything 
that was being given and if I were to go back to Him, I would want to be as one whole piece.” 
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This finding reflects a rather more traditional thinking among some members of the Islamic 
community, as the Islamic Religious Council of Singapore has issued a religious ruling (or 
fatwa) that did not prohibit the donation of such HBMs.288  
 
Degree of Information to be provided in Consent-Taking 
 
Interview Question (2a): Do you remember that you have earlier agreed to donate your 
left over tissues in the surgical (brief) consent form?  
Almost 95% of the participants remembered that they had agreed to contribute tissue in the 
Surgical Consent Form, but many regarded this as no different from the proposed donation 
to NUHTR. Some participants mentioned that they did not read the consent form fully or did 
not have time to read. Participant 29 explained: 
“Yes I remember. Because I got no time to go through. I am very tired, (before the) 
operation. No time to read this.”  
 
Interview Question (2b):  Do you think that the surgical consent form contain adequate 
information for you to be able to decide on left over tissue donation or would you want 
more detailed information, such as the one in the Tissue repository consent form? Why? 
Only 26% of the participants said that they needed more detailed information, and they 
recalled being provided with the Participant information Sheet by the NUHTR ‘consent’ 
nurse.  The main reason for requesting for more information was to have a better idea as to 
why, how and whom exactly were going to use their tissues.  This view was not specific to 
                                                          
288 Fatwa committee of the Islamic Religious Council of Singapore issued a fatwa, a religious edict, 
allowing Muslims to come under Human Organ Transplant Act (HOTA) in Jul 2007.  Accessed on Aug 
13, 2014 http://www.muis.gov.sg/cms/oomweb/fatwa.aspx?id=14698 
     Hussain, Z. (2008, January 22). Muslims to be included in the Act from Aug 1. The Straits Times. 
Retrieved Aug 13, 2014, from Factiva database.   
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any group of particular educational background or age. This study did not identify any shared 
characteristics among these participants who requested for more information. 
 
The majority (or 74%) of the participants were, in some way or another, satisfied with the 
NUHTR consent form, and did not ask for the information sheet or otherwise refused when it 
was offered.  A variety of reasons were given, ranging from “do not have time to go into the 
details”, “cannot read”, “have already decided to donate”, “medical office explained well to 
me”, “wanted it simple and basic”, to “I do not care”. A number of participants provided 
more reflective responses. Participant 6 said: 
“I think it is sufficient if you ask for my permission in advance. I think the simplified form is 
better as when you are sick, you do not want anything complicated. You will want it to be 
simple and basic.” 
 
Participant 8 was somewhat more nonchalant: 
“I have read through so many things but have not read this form. When you all came some 
time ago, I was still recovering from anaesthesia. I do not know what is written there but 
whatever is written in the form does not affect my decision to donate my leftover tissues.”  
 
Some participants appeared to have decided independently of information that was 
furnished. Participant 13 said: 
“I have already made up my decision and I am very decisive about it.  I am not bothered by 





Participants also mentioned that a detailed consent form could be confusing and that they 
were not in the right frame of mind to be bothered with the residual HBMs as they were 
worried about their medical conditions. Participant P33 candidly responded: 
“I never read.  Don’t remember. Of course (I prefer) the shorter version.  Shorter version, in 
the sense that just goes precisely to the point and let me know what is this. Right now with 
my sickness, I am not in the mood to go for details.”   
 
Pre or post-surgery consent (or When to Take Consent) 
 
Interview Question (3a): When is the best time for someone to approach you to get your 
consent to donate leftover tissue?  
The suggested choices for this question were: (A) Before admission; (B) On admission but 
just before surgery; (C) After the surgery; or (D) After your tissue has been fully analysed. 
Most participants (34%) preferred informed consent to be taken before admission (i.e. 
Choice A) and at the time when information on their surgery was provided. Around 25% of 
participants preferred Option B, or after admission but before surgery as the best time of 
taking consent. 15% of the participants preferred this to occur after surgery (i.e. Option C), 
and one participant preferred Option D, or only after the tissue had been fully analysed. 
 
Most participants preferred consent to be taken before admission as the subjects felt that 
they would be in an anxious state during the admission and operative process.  They were 
also concerned that if consent was taken just before or after surgery, effects like pain, 
anaesthetic or medication could affect their choice to donate. Quoting Participant 9: 
“Before admission, as after operation I may be too tired.  During the admission day, it may 
be too tough.  Before going for the operation, patients may be mentally and physically 




Some participants preferred consent to be taken after surgery, as the subjects believed that 
they would be more relaxed and free of disease anxiety, post-surgery. Other participants 
were of the opinion that the types of surgery or disease could influence their choice on the 
different timings for consent taking. Take the view of Participant 85, for instance: 
“Probably after the surgery because before the surgery, you will be very anxious over the 
surgery, and of course the result. You don’t have actually any time for this consenting.” 
[CH: You have explained Options A and C. How about Options B and D? What reasons were 
given for these choices?] 
 
Interview Question (3b): Who would be the most appropriate person to ask for this 
consent, and why?  
Most of the participants preferred either researchers or doctors (almost equal percentages) 
to take consent. Participants who preferred researchers to take consent stated that they 
believed that researchers would know details of research to be carried out.  However,  
participants who preferred doctors to do so indicated the reasons as trust and the doctors’ 
knowledge of patients’ disease and operative procedure. Participant 6 expressed this view: 
“I think the doctors would be more appropriate as you are dealing with them and already 
have a personal relationship with them.” 
 
Only a few participants preferred nurses because of their friendly attitude. Participant 86 
indicated: 
“The consent nurse. Doctor might not free to, you know. Doctor shouldn't be the one to go 





Right to Withdraw 
 
Interview Question (4): If you change your mind to this donation, what do you think would 
be the best way to do this? Under what circumstances would you want to change your 
decision?  
A majority of the donors would prefer to go back to their doctors and inform them about 
their decision to withdraw consent, if at all. Few participants said they would go back to 
NUHTR or use the contact number provided. A number of participants also mentioned that 
they would call, but did not indicate which telephone number. Others said they would go 
and inform the researchers about their decision if they changed their mind on the donation. 
A few participants said they had no idea whom to contact in the given situation (even 
though this information would have been provided in consent-taking). 
 
Almost 90% of the patients interviewed said they would not change their minds under any 
situation. Those participants who said they would change their mind cited unethical research, 
media news on breach of trust, large number of follow up visits or interviews after donation, 
and tissue not being used for the purposes communicated. One subject also mentioned 
family pressure and religion (for Muslims) as a possible reason for withdrawing participation. 
However, almost all participants shared Participant 71’s view: 
“As long as the research projects have a good objective, I don't see why I should change my 








Privacy and Confidentiality of Medical Information 
 
Interview Question (5):  Would you object or not if researchers, carrying out research on 
your tissue, know about your personal and medical information with an undertaking that 
they would keep the information confidential? Why or why not? 
A majority of the participants do not object if researchers, when conducting research on the 
HBMs, can access the personal and medical information with an undertaking that they will 
keep the information confidential.  To quote Participant 40: 
“I would prefer all details to be kept confidential. As long as it is not being passed on to 
others. I don’t object but as long the researcher keep the information confidential and don't 
pass the personal information away.” 
 
Participant 21 expressed a more hesitant view: 
“I would rather be kept anonymous. For instance, for one part that I understand is 
confidential but the researcher will know, is it? I think I'm a bit ambivalent I should be okay 
but my first preference will be anonymity. But if that's the way do it, I mean I'm fine as well, 
rather than… (pause). Why would there be a need for them to know the individual's 
particulars, except for the age, maybe the types of job they do to see the sort of stress result 
this kind of things?” 
 
Generally speaking, most participants had difficulty understanding the exact nature and 
operation of privacy and confidentiality. However, it was a general expectation among 
participants that they should not be harmed or embarrassed through research participation. 





TABLE 14: SUMMARY ON COMMENTS ON PRIVACY AND CONFIDENTIALITY 
No objections (N= 85) Mostly agreed, if confidentiality is maintained 
 “Faith in researchers and system” 
 “Personal and medical info are necessary for better research” 
 “Ready to provide even more info if required” 
 “Nothing to hide” 
 “I am a commoner, not a celebrity” 
Yes, with objections 
(N=15) 
Confidentiality is not 100% fool proof 
 Info may spill out and spoil some better chances in future life 
 Inadvertent publicity 
 Private person – don’t want people to know personal information 
 
 
Governance, safeguards and controls 
 
Interview Question (6): Who should monitor use of your donated tissue? Are you aware of 
any safeguards and controls for this donation, and what governance would you expect? 
A majority of the participants do not know what safeguards and controls in relation to their 
donated HBMs were, even though effective governance was uniformly emphasised.  Some 
participants mentioned protecting confidentiality, proper documentation and audit with 
standard operational procedures as measures to prevent misuses.  There was no agreement 
as to who should have greater responsibility in ensuring responsible conduct. For instance, 
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some felt that researchers should themselves be responsible. Participant 7 expressed this 
view: 
“I think the researcher should definitely be the one who should monitor the use of the 
leftover tissues. I believe that when the tissues are handed over to the researchers, 
everything should be at the researchers' compound. Everything should be done by them. I 
am not aware of any safeguards. I believe that after the research, it should be handled 
properly as I do not know how deadly the tissue is. So they should dispose the tissue off in a 
good and rightful way, though I am not sure clinically how.” 
 
A majority of the participants did consider IRBs to shoulder most of the responsibility, 
although this point was already communicated in consent-taking. Table 15 provides a 
breakdown of views on who should ensure responsible conduct or prevent misuses of HBM. 
 
TABLE 15: SUMMARY ON PERCEIVED GOVERNANCE 
Types of Monitoring Number of responses 
Institutional Review Board    35 
Researchers   18 
Doctors   10 
A government body   8 
Hospital/institution   10 
Combined   3 




The questions were asked to understand patients’ preference on who should monitor use of 
their donated tissue and during the questioning, we briefly explain the role of various 
choices given,  to allow them gain a better understanding on the types of governance and 
control.  
 
Access and uses of tissues 
 
Interview Question (7): Would you object if following groups of researchers have access to 
your tissues for research, and why? 
Most participants agreed that researchers, scientists and students should be allowed to use 
the residual HBMs for research. There was some resistance to access by commercial 
companies, as the motives of profit-driven enterprises were seen as incompatible with the 
more reciprocal or altruistic sentiments associated with the donation of HBMs for research. 
A summary of stakeholders that should be granted access to residual HBMs for research is 
set out in Table 16. 
 
TABLE 16: SUMMARY ON “WHO CAN USE MY HBMS FOR RESEARCH?” 
Would you object if 
following groups of 
researchers 
Responses (No = No Objection) 
Hospital 
researchers/University 
scientists and students 
No – 100% 
Yes – 0% 
Government funded agency No – 98%  





and drug companies 
No – 69%  
Yes – 31% (profiteering; my tissue for 
students/government; doubt on confidentiality; not for 
free ) 
Overseas researchers & 
institutions 
No – 89% (research is global; better facilities and 
technology overseas)  
Yes – 12% (tissue only for local benefit; overseas results 
may not benefit locals; difficult to monitor) 
 
 
On TRUST in donating HBMs 
Patients who have contributed the residual HBMs expressed the views that they trusted the 
doctors, consent nurses and researchers when they donated the HBMs.   Although most of 
them do not know much about safeguards, controls and governance of research that use 
HBMs, they all said that they trust the institutions to have proper governance systems and to 
protect their privacy and the confidentiality of their medical information.  Patients also 
expressed trust in healthcare institutions and researchers not to exploit their HBMs for 
unintended use, or sell them for commercial benefits.  
 
It is unclear if the patients trust the system in a very general informed manner or if it was 
blind faith. This however could be mixed, as patients said they truly trusted, and have full 
faith that they will not be harmed by donating their residual HBMs otherwise they would not 
have donated their HBMs.  Even when they did not know about the potential risk, they 
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trusted fully and gave their residual HBMs.  The possibilities that their HBMs would generate 
potential public benefits were based on trust, when patients believed that their residual 
HBMs were only given to good researchers, who genuinely conducted scientifically grounded 
research for public benefits and not only for commercial patents or profits. Further research 
can be done to explore this issue on trust on donating HBMs for research. 
 
Trust was often expressed in relation to privacy and confidentiality protection. For instance, 
patients were willing to trust medical professional on medical confidentiality and privacy, 
respect of their rights and proper handling of their HBMs.  The following quotations from 
responses of participants are illustrative.   Participant 21 said: “No, I don't object. Well I will 
trust our Singapore medical personnel to keep it confidential and I think that because, yeah, 
they're using it for research so it's nothing really secretive about it.”  
 
A similar comment was also made by Participant 49: “No I do not object as they are 
supposed to keep it confidential. I trust them.” Participant 89 elaborated on what trust 
involved: “We are ok with doctor and the first one you said IRB, this two is fine. Doctors 
because he knows us well and we much trust our doctor. The IRB, that you have said, it takes 
care of the patient’s right. So I assume that it puts the patients’ health first. Not aware of 
safeguards. (On governance) The thing is that the tissue is something that we don't even 
need in the first place, so you can do pretty much whatever you want with it. Correct. So it’s 
up to you what governance you guys want to do with it.”  
 
Some patients are willing to trust nurse on providing the relevant and concise information 
when taking their informed consent.    Participant 27 said: “It looks like a lot of information. I 
trust the consent person will tell me everything because I really don't like to read, it's quite a 
lot of things. (Interviewer: "So in your own opinion, you prefer a short consent?”)  Concise. 
132 
 
This one (Surgical consent form) looks simpler. That one a lot of words (TR consent form). 
This one (Surgical consent form) looks very simpler, look like sometimes...easily filled up. 
Really very easy to see & I can straight away see whether I will agree or not, then can cancel 
or not. The details are very concise, & I only need the nurse just to tell me what are the 
details; whether to donate or not to donate. If I’m to read myself, most probably I won't 
read.” A similar trust was expressed by Participant 46: –“I don't mind. I think it can be 
anyone representing this Tissue Repository Centre. This is because I trust the person who is 
seeking for my consent.” 
 
Trust was also expressed in relation to researchers. In particular, patients are willing to trust 
researchers on the use of their HBMs for research.  –For instance, Participant 41 said: “The 
researchers should monitor because I have already agreed to donate my tissues to them in 
the first place. Hence, I must be able to TRUST them. (On safeguards) I have no idea on any 
safeguards taken.” 
 
Even when they do not know the specific safeguards and control, patients are willing to trust 
that proper governance is in place on the use of their HBMs for research. This could be that 
the patients trusted the system in a very general informed manner or if it was blind faith, 
with no evidence that there were any knowledge on any prevailing system of governance in 
place.  Participant 43 said: Yes I object as I am not sure what they are going to do with the 
tissues and it might be unethical. I ”trust the governance.” Participant 51 similarly indicated: 
“No need. I don't think so. I think if it's going to be donated, I think I will trust that whoever 
going to use is it is going to use it for research will be beneficial for future cases.”  Participant 
72 expressed trust in relation to doctors: “I think the doctor. Because I trust him. I don't 
know (about safeguards and controls). It's hard to say because I really don't know the 
protocol but protocol about these (about governance).”  While others (like Participant 4) 
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expressed a more general trust in the system: –“In my opinion, once you decide to donate 
your tissues then you should have trust in the system to protect your privacy.” 
 
Patients are willing to trust the institutions on the use of their HBMs for research.  The 
reasons for trusting are different, as these quotes illustrate: 
Participant 83: “ I won't know. I won't change my mind. I trust this institution first and it's 
important to trust this institution because it's for university research. I'm confident to 
donate my tissue.”   
Participant 55: “Ok one thing, if in advance let’s say - when I before admit to hospital, this 
kind of request is given to us. So at least we can look at it more thoroughly. But if you just 
before surgery, then actually you got no time to read it thoroughly. It will depend on the 
person explanation. I trust what’s explanation is same as what on paper. I think if you're 
talking about reading it thoroughly, you got to be a few days before admission.” 
Participant 57: “As long as all trustworthy and ethically correct.” 
 
Interestingly, participants also expressed trust that the tissues would not be used for 
commercial purposes. Participant 13, for instance, said: “It should be fine, as long as they 
follow the guideline. I mean I'll trust you all will do a lot of screening that things are done in 
proper manner. I don't think you will just sell it away, you all won't, right? For purpose for 
advance our medical, you will look into that.” In addition, Participant 13 indicated: “No I 
won't. I mean if they're doing the good job, why not. But somebody, as what you mention, 
must actually check on what they are actually doing…. (On governance) Something like that, 
that's what I said everyone have a part to play. I trust you all will do. I'll trust you will do that.” 
 
It is interesting to note that of the 100 participants involved in Phase III of this study, 81 
patients did not consider compromises to privacy and confidentiality to be risks associated 
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with contributing their residual HBMs.  However, they are willing to donate residual tissues 
for research when there are proper safeguards for privacy and confidentiality.    In other 
words, most patients wanted safeguards and control, even without knowing the specifics of 
what constitutes sound governance.  Hence, where biological materials are used for genetic 
research, confidentiality and privacy issues are clearly identified as risk to self and family, 
religious belief, and potential discrimination,  especially in relation to employment and 
insurance coverage.   
 
A key application of good governance relates to securing a participant’s privacy and 
confidentiality interests.  Protection of privacy and confidentiality of personal information 
were two main concerns of patients in terms of safeguards and control.   From the research, 
patients were worried that their medical records (including genetic information) would be 
leaked to insurance agents and employers.  They feared that this could result in future 
economic and financial loss.   Further, they were concerned about social and financial 
discrimination once their medical confidentiality was breached.   For patients who declined 
to donate, mistrust of research organisations in the handling of private and confidential 
information was a dominant reason. Others were also concerned about the manner and 
timing in which patients were approached for donation. It was important that they did not 
feel coerced to donate or were placed in a vulnerable position where they felt forced to 
donate.  
 
3.6 SOME CONCLUSIONS FROM THE RESEARCH 
3.6.1 Motivations, Attitudes and Perceptions of Singaporean in Tissue banking 
From Phase II of the study, the consent rates among 167,329 patients at NUH for agreeing to 
contribute tissue for medical research, education and study over a period of 10 years was 
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73.58 %.  The dataset on consent was matched with demographics data drawn from surgical 
consent forms and admission records, and more specifically, by gender, ethnic groups, 
religions, age groups, paying class and medical conditions. A statistically significant 
relationship was found between demographic characteristics (or factors) and the likelihood 
of consent.  As noted above: 
• Men were more willing to donate compared to women; 
• Chinese patients were more willing to provide consent under the Surgical Consent 
Form, followed by Malay and Indian patients; 
• Buddhists and Christians were more willing to donate; 
• Elderly patients of more than 50 years of age were more willing to donate; 
• Private paying patients were more willing to donate; and 
• Patients’ donation rate varied with their medical conditions. 
 
The interviews conducted in Phase III of the study did provide some explanations for the 
findings from Phase II.  The majority of the participants believed in altruistic donation, 
advancement of future research as a public good, helping other people and benefiting future 
generations being the prime reasons for donation.  The high consent rate may be attributed 
to the reported motivation among most participants of altruism.   
 
As one might expect, religious belief appears to have been an important influence over the 
decision to donate tissue for at least two reasons.  First, participants who were Buddhists 
and Christians explicitly acknowledged the impact of their religious faiths in making the 
donation.  For many Muslim patients, religious concern was a reason for declining the 
contribution of HBMs.   Second, many participants did not consider the provision of detailed 
information in consent-taking to be the deciding factor on whether to donate.   Risks of 
136 
 
harm were similarly not of special concern.   Rather, sentiments of reciprocity and solidarity 
could often be traced to religious or civic mindedness.    For this reason, some participants 
objected to their HBMs being used by commercial companies and foreign institutions, as 
they were concerned about inequitable distribution of benefits.    
 
Where religion or civic consciousness has not been of influence, the donation may be simply 
attributed to pragmatism, as these participants do not have any use for the HBMs and do 
not think that there is any serious risk of harm.   In fact, there was a high level of trust in 
systemic safeguards and sound governance was in place.   A majority of the patients (81%) 
did not think that there was any risk involved in the donation, and clearly expressed faith 
and trust in researchers and the healthcare system (since NUHTR is associated with NUH and 
not an independent research setup).   Perhaps most indicative of the low emphasis on the 
information aspect of consent is that a majority of the patients (74%) was satisfied with the 
short and brief Surgical Consent Form.  As we have seen, some participants clearly indicated 
that they did not have time to go into the details, or that they honestly did not care.   
Interestingly, most participants (85%) did appreciate that there could be compromises to 
privacy and confidentiality, as researchers could access their personal and medical 
information. Nevertheless, they expressed confidence in the researchers as long as they kept 
the information confidential.  Patients seemed to have found assurance in the high level of 
trust in the system of governance, but again not clearly distinguishing the healthcare setting 
from research. This is most evident as the participants did not seem to be well informed 
about existing safeguards and controls.  
 
3.6.2 Altruism and Trust: Why patients donate their residual tissues 
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The most common reason for donating HBMs has been indicated as benefit either to the 
donors themselves or to others.289  In my research, a majority of the participants reported 
the desire to help other people and to benefit future generations as the prime reason for 
donation.  The dominant influence and intention should be noted by researchers and policy 
makers to secure and support altruism and being critical in maintaining trust.   Our results 
showed that patients donated the residual HBMs with aspirations and intentions in 
contributing to public good, so that researchers could use their HBMs to find cure for 
diseases in the future.  Thus, what happened are not a case of abandonment but an 
intentional contribution of residual HBMs for future research and an entrustment towards 
an altruistic cause. 
 
Trust is often expressed as an expectation among donors that their HBMs will not be 
misused and applied for a good cause.290  Trust is thus an important basis for patients to 
freely donate their residual HBMs for research,291 and a betrayal of trust can lead to lower 
donation rates.292  From our qualitative research, we found that patients who have 
contributed the residual HBMs expressed the view that they trusted the doctors, consent 
nurses and researchers and the institutions.   They trusted the institutions collecting and 
using their HBMs to have proper governance systems and to be capable in protecting their 
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privacy and confidentiality of their medical information.  Patients also expressed trust in the 
institutions and researchers for not exploiting their HBMs for unintended use, or selling 
them for commercial benefits.   The “betrayal of trust”293 was described in some studies 
when the scandal of UK’s Alder Hey Hospital came to light, 294 as described by some 
donors.295  These research findings showed that patients contributed their residual HBMs for 
altruistic reasons and trusted the institutions, particularly since the ideals of informed 
consent are seldom met.  Trust appears inevitable, as there is a “knowledge gap” between 
patient-donors and researchers.  For example, patients would think that “there is no value” 
in their residual HBMs and consider them as surgically removed waste materials, while 
researchers know that such materials are extremely valuable. Most laypersons will not 
appreciate the value, or the risks and benefits associated with donating their residual HBMs. 
 
As we considered in Chapter 2, some people believed that donating their tissues was one 
way to contribute to medical science and medical education, and they considered tissue 
donation as “a gift” to humanity.  This act of giving could be considered as an expression of 
unconditional gratitude, and it was centred about trust. The strong association between 
altruism and trust has also been reported in two other research studies conducted in 
Singapore (between 2003 and 2004) on the donation of HBMs for research.  In the first 
paper (which is included in the systematic review in Section 3.4.1 above), conducted a 
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qualitative research296 interviewing 98 Singaporeans in 12 focus groups. The results from this 
study were used to formulate the second study – a quantitative survey297 - involving 548 
adult Singaporeans to examine their willingness to donate blood samples for research. They 
found that less than half of the sampled populations (49.3%) were willing to donate blood 
samples for genetic research.  Among the willing donors, 84% were willing to have their 
blood stored for future research (49.3% for donating blood specimens and 41.4% for storage 
of the HBMs for future research).  The authors attributed the observed low rates of 
willingness among the general population in Singapore to differences in religious and 
cultural beliefs. Additionally, participants of the survey also stated other reasons such as an 
apprehension about donating blood due to fear of pain and needles (38.1%), fear of finding 
out that they might have a disease (22.3%), no self-benefits (24.8%) and concern on 
discrimination (18.7%). Misconceptions such as weakness (15.4%) and weight gain (9.5%) 
from giving blood samples were reported by a small but significant proportion of 
respondents. Reasons reported for willingness to give blood were for medical progress 
(81.9%), to benefit future generations (81.1%) and for one’s health concerns (66.6%). 
 
In the qualitative focus group research session, the researchers also found differences in 
concerns and issues regarding the donation and storage of blood specimens for genetic 
research from their focus group sessions with the three major ethnic groups in Singapore: 
Malay-Muslim (n=35); Chinese (n=32) and Indian (n=31) Singaporeans. The participants 
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(n=98) were recruited island-wide and stratified by gender, ethnicity and educational level 
(lower education defined as less than 10 years of schooling). There was a total of 12 focus 
group sessions with 7-9 participants in each group. From this research, some Malay-Muslims, 
regardless of their gender and educational level, said that it was against their religion to 
have their blood stored as the blood specimens would outlive the ‘owner’. Some felt it was 
not right to test for genes to predict the future, just as it was not right to buy life insurance. 
They were also concerned about how and why they were selected for population-based 
genetic research and whether genetic tests would be used for discriminating conditions like 
intelligence. A few Malay males did not like the use of the word ‘investigator’ to denote the 
researcher in the consent form. They expressed that it had a negative connotation as if a 
police officer were investigating on the research participant like a ‘criminal’. None of the 
abovementioned concerns was expressed by the other ethnic groups.  These findings relate 
to our quantitative research where Malay patients are less willing to donate the HBMs due 
to lack of trust. 
 
Chinese and Indians generally expressed concern about giving blood to strangers and being 
‘bothered often and inconvenienced’ by participating in research that may require frequent 
follow-up visits. All groups expressed concerns about confidentiality; pain and needle pricks; 
finding out about disease and having no self-benefits. 
 
The findings in these two studies complement my research findings, in the need to take 
serious account of ethnic-specific concerns, design ethnic-sensitive messages and involve the 
public and religious leaders in planning programs to promote community participation in 
research using HBMs.  The centrality of trust and good governance is similarly evident in the 




3.6.3 Lack of consensus on informed consent regime for Tissue banking 
Traditional consent regimes vary from highly specific informed consent to broad consent for 
the use of HBMs.  Consent norms and policies in ethics require that research participants be 
fully informed of the nature and risks involved in research. In Chapter 2, the impossibility of 
‘fully’ informed consent was discussed at some length.   Specifically in the case of tissue 
banking, where the sample population is diverse and a large number of samples are 
collected, mandating specific informed consent as a requirement can be an insurmountable 
challenge.  In the ideal world, specific informed consent provides patients or donors with a 
specific choice on exactly how their HBMs will be collected, stored and used.   Informed 
consent “allows individuals to exercise their fundamental right to decide the scenario on 
how their body, body parts and associated data will be used.”298  A broad consent is still 
informed and valid consent, if properly execute and that the patients know that the HBMs 
are used for research, even without knowing what types of research and when will it be used.   
The lack of specific information about particular uses of the samples does not imply that 
such consent cannot be fully autonomous and so is unethical.299  My research shows that 
broad consent can also be informed consent and the patients knew what they are doing 
when they agreed to donate their residual HBMs.   
 
Where HBMs are limited to specific uses in a research project, the researchers will have to 
discard the HBMs after the research in completed.   Any future use of these HBMs will then 
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require re-consent from patients for new research use.  However, this method was deemed 
not practicable or impossible, especially in a situation where the patient had died.  In 
addition, it could trigger unnecessary emotional distress to patients and family (in the case 
of a deceased donor) to be contacted by researchers, particularly if the initial understanding 
was that the HBMs would be disposed of after use.   Discarding residual HBMs may however 
not be in compliance with the requirements of certain scientific journal, as peer (or scientific) 
verification and data validation are sometimes required after the paper is published.300  
Limiting HBMs to a specific project at a time could also be a waste of valuable resources as 
time, money and effort have been expended in collecting and processing these HBMs as 
samples.301  In addition, their valuable research potential will be lost.302   For these reasons, 
most tissue banks favour the use of general or broad consent. This is the finding of Master et 
al. in their review of existing consent practices in the literature on tissue banking, even when 
they report that there is no consensus on consent regime amongst numerous scholars.303  
Phase I (or the CSR) of my research arrived at the same conclusion, in that there is no one 
superior consent regime.  Based on patients’ experiences and preferences alone, Phase III of 
this study suggests a clear preference for the broad consent approach over specific informed 
consent. However, there are too few studies to point to a clear and absolute choice.304   
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Other studies however are divided on the issue.   For instance, Murphy noted that the 
patient “could be given a choice of either broad or study specific consent at the beginning of 
a research”305 whereas Skolbekken306 concluded that patients preferred “initial consent to 
be active, and the need for explicit and active consent for each new research project was 
perceived as unnecessary”.307   Depending on whether the tissues are identifiable, coded or 
anonymous (with no identifiable patient’s information) at the point of collection and usage, 
preference for a particular consent model or approach may differ.308  Some authors have 
indicated that, where coded and anonymous tissues were used, participants did not consider 
the stringent specific consent requirement to be necessary.  In contrast, this requirement 
would be appropriate for identifiable tissues.309   Due to limited qualitative studies on 
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participant preferences, no conclusion could be made at this point and further research is 
thus necessary.310   
 
3.6.4 Presupposition of Good Governance at various stages of tissue banking 
From Phase III of this study involving NUH patients, different concerns were expressed at 
different stages of handling residual HBMs by researchers and research institutions.  The 
stages of HBMs handling considered were collection, storage, distribution and future use of 
the HBMs, and related concerns that were reported are summarised as follows: 
• During collection or donation of tissues, patients spoke mainly on the different 
reasons for donating their residual HBMs; 
• During processing and storage of tissues in tissue banks or research institutions, 
patients expressed concerns about safeguards and controls on the collection and 
storage of residual HBMs; and 
• Concerns over ownership and equitable distribution of benefits were reported in 
relation to the subsequent distribution, access to and use of tissues.   
 
A common expectation that cuts across these different stages was the expectation of the 
existence of a good system of governance, as well as a system to protect the rights, privacy 
and confidentiality of patients.  Most patients preferred an ethical and effective system to 
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decide on the future use of their donated HBMs.  Institutions and research organisations 
were also expected to be responsible custodians in safeguarding where stored HBMs are not 
misused, and as stewardship in ensuring that research using HBMs are ethically conducted 
and for the public good.   Good governance is hence a critical precondition to trust and 
sustains the willingness to donate. Higher patients’ acceptance and greater positive 
donation rate are important because leftover or residual HBMs have no direct cost to 
patients and research institutions, as they will otherwise be surgical waste to be discarded.  
As a larger research enterprise, tissue banking can only survive if it is able to draw 
contributions of HBMs and related data on one hand, and allow reasonable access to 




Chapter 4. Discussions and Recommendations on Trust and 
Governance 
 
Residual HBMs are usually stored in an institutional tissue repository for future research, or 
in the laboratories of individual researchers (as personal tissues banks) for their specific 
research. These are the two main types of biobanks for residual HBMs.  As discussed in the 
earlier chapter, I argue that broad consent should be obtained from prospective contributors 
of HBMs as it is increasingly difficult to determine the types of research that would require 
the use of HBMs in the future.311 Consent-taking will ensure that tissue contributors are 
aware that their HBMs will be banked in tissue repositories for future and unspecified 
research use. 
 
While recognizing the importance of informed consent, I argue that this autonomy-based 
governance does not offer adequate protection of research participants from harm.  
Informed consent provides patients with a choice on whether or not to contribute their 
HBMs, but once the contribution has been made, an effective system of governance on a 
tissue bank's operation must be in place to ensure accountability and transparency.  
Currently, the system of ethical governance on the use of residual HBMs in Singapore still 
lacks transparency and accountability. The BAC’s recommendations on statutory regulation, 
governance and supervision have yet to be implemented.  More specifically, there is still no 
statutory authority being set up to regulate and supervise all the human tissue research in 
Singapore, and institutions and companies that carry out human tissue research and banking 
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are not transparent with their operational practices and safeguards. There are also 
inadequate measures in place to ensure accountability in the collection, storage, distribution 
and use of residual HBMs.  These issues will have implications for securing the public trust 
and long-term support that the success of tissue banking depends on.   
 
In this Chapter, I will elaborate on my support for broad consent (with a right to withdraw) 
that is supported by a system of governance that is transparent and accountable, and 
constitutes institutions that collect, store and use residual HBMs as stewards. 
 
4.1 Broad Consent as the Preferred Choice in tissue banking  
As discussed in Chapter 2, tissue banking of residual HBMs has added complexity to the 
regime of informed consent, which is an important ethical component in research. The 
current requirement of various levels (or models) of informed consent mainly emphasises 
the informational parameters deemed necessary for donors so that they can voluntarily 
determine whether to donate on their own free will or not.  This ethical safeguard operates 
on the assumption that an individual will carefully deliberate on and assess the information 
provided, and then decide if s/he will voluntarily participate in the research based on an 
understanding of the risks and benefits of the research.  Demographics (like gender, ethnic 
groups, religious belief and age) are accounted for in the informed consent process; ethnic 
group may be important because of the language used in the consent documents; age may 
be important to determine competence; religious belief may be important especially in 
cultural sensitivities study; gender may be of high importance in some male dominated 
community. However, it unclear if the motivation for contributing HBMs has been as closely 
scrutinized, particularly in relation to specific demographic features.  As my study in Chapter 
3 shows, such considerations are significant and important, if patients in Singapore act as a 
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useful point of reference. The requirement for ‘specific’ informed consent as an ethical 
safeguard will typically encompass a long and detailed informational process, depending on 
the complexity of the research envisaged. Based on a ‘specific’ informed consent regime, re-
consent is necessary for every future unknown investigative use of collected HBMs (often 
construed as a form of respect for autonomy). Other forms of safeguards include privacy 
protection laws and anonymisation of personal information to protect privacy and 
confidentiality; ethical review by either a research ethics committee or an IRB represents 
different layers of protection and safeguard against potential misuses of collected HBMs.  
Some of these protections may not be as effective in protecting patients as research 
participants.  For instance, the lack of privacy protection can be further aggravated by 
advanced data matching and re-identification techniques used by bio-informatics.312  Recent 
studies have shown that tissue banks cannot guarantee absolute privacy due to advances in 
information technology processing and data mining tools.313 The strategy to rely on specific 
informed consent (considered in Chapter 2) will either preclude a concerned patient from 
such research participation, or allow the participation at the patient’s own risk since 
information on the possible privacy risk are normally not explicitly stated in the participants’ 
information sheet and informed consent form.  For this reason, specific informed consent 
taken at the time of contribution cannot be adequately applied, as a proper safeguard, to 
any future unknown use of HBMs in tissue banks research.  
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While specific informed consent can be, in theory, instructive for the potential research 
participant, it may impede the operation of tissue banks by creating unnecessary restrictions 
on the future use of collected HBMs and limiting their research application.  It could even 
discourage an altruistic person from contributing HBMs to research, as my findings reported 
in Chapter 3 suggest.  The requirement for a detailed and tedious informed consent process 
fails to give due recognition to the trust that is already manifested by HBM contributors, 
especially when it is presented in a legalistic format. This is more likely to arouse suspicion in 
patients, rather than to help patients realise that there is something important about the 
consent process and to enhance the trusting relationship. In the context of my research, 
such a tedious and long informed consent process also fails to acknowledge the emotional 
distress that patients are likely to be experiencing before surgery.  The patients are willing to 
participate and contribute to tissue banks as long as they trust the researcher.  In many 
cases, patients may also lack the sophistication or interest to understand a proposed 
research in its entire intricate details. For these reasons, as well as those set out and 
discussed in Chapter 3, tissue banks have generally preferred the use of general or broad 
consent for the contribution of residual HBMs for present and future research. This has been 
discussed in the case of NUHTR.  In Chapter 2, it has been argued that there are clear 
justifications to obtain broad consent rather than specific consent. In fact, I have gone 
further to distinguish donation from contribution of tissue through broad consent, and to 
argue that the latter is to be preferred over the former. A reason for this is that contribution 
is more representative of the motivations of donors, and it need not necessarily (although it 
could) be limited by certain requirements. In other words, a conditional contribution to a 
public cause is not any less altruistic than a donation. Over emphasis on informed consent 
obscures important issues about the aims of assembling and using such collections, and the 
risk to contributors especially when the system of governance lacks rigour. Certain details 
may also be obscured in the process, such as allowing the use of HBMs for commercial 
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interests, which may not be consistent with the original altruistic motivation of donors, and 
could amount to a betrayal of trust that the contributors must invest.314 
 
A donation has the character of what the BAC in Singapore has described as an ‘outright gift’, 
with no conditions attached. According to my research findings, altruistic motives are the 
main reasons for patients contributing their residual HBMs. They do it for the good of others 
with no expectation of direct self-benefit, as they want to help in search for better cure and 
treatments. Patients must weigh altruistic motives to advance research against personal 
risks of participation, since donating their residual HBMs do not directly benefit themselves. 
This finding is also discussed by Dr. Lynn A. Jansen, who mentioned that research 
participation can arise out of genuine altruistic motives to benefit others and these are 
different from decisions made as a product of confusion and misunderstanding.315  Most 
patients are willing to contribute, based on a level of trust and the condition that this gift of 
residual HBMs will be applied to advance public good, and on the assumption that they will 
not suffer any harm as a consequence of making this ‘conditional’ gift.  As a sign of respect 
for the trust manifested by the patients, it should not be necessary for the tissue bank to 
specify all possible future uses of the gift.  The tissue bank should demonstrate that it is 
trustworthy to fulfil the donors’ motives and conditions for contributing.  A sound 
governance system should be directed at promoting and sustaining trust among contributors 
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and trustworthiness on the part of tissue bank, by ensuring accountable and responsible 
handling and use of HBMs.316 Trustworthiness is elaborated on later in this Chapter.  
 
Within a framework of trust, the tissue bank serves as a public guardian of residual HBMs, 
and should be able to freely decide on the types of research that are in the public interest 
and can easily gain access to the stored HBMs.  The constant need to re-contact contributors 
for re-consent on new research uses in the future does not show respect for the trust that 
has been given.  Such a need should not arise if the purposes, goals and operating 
procedures of the tissue bank are clear to all parties involved. This is not to say that the 
tissue bank should discourage willing contributors to have greater participatory involvement 
in its work, however, where HBMs have been contributed pursuant to broad consent, the 
trust relationship is disregarded when re-consent is required. The application of broad 
consent does not require re-consent to be sought from contributors of HBMs. As discussed 
earlier, such re-contact for the purpose of re-consent would also be logistically burdensome 
and not practicable especially if the contributors have passed on. 
 
 My research data reported in Chapter 3 indicate that most patients did not want to know 
the specific details of the research that they were contributing to, nor the exact risks that 
were entailed, if there were effective safeguards in place to protect their interests. A general 
understanding that their HBMs would be used for research resulting in public benefits was 
sufficient for the patients, and many gave residual HBMs to NUHTR based on altruism and 
trust in the institutions and researchers. A similar outcome would have been achieved under 
a broad consent regime, where the consent sought was for the contribution of residual 
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HBMs for a broad range of activities, including research. Consider the Surgical Consent Form 
that was discussed in Chapter 2. By signing this broad consent form, donors agree that the 
future use of their HBMs in medical research, education and study is to be decided by 
NUHTR and the institution. A preoccupation with informed consent may even obscure other 
ethical issues about the proper use of the HBMs to reflect the original altruistic motivation of 
the patients and the trust they have invested in the system.317 Decrease in the reliance on 
‘full’ specific informed consent and the inability of researchers to ensure full privacy 
protection for instance would imply a greater need for better and more responsive system 
of tissue bank governance.318   
 
Some authors prefer the use of tiered consent as they consider that, broad consent – 
although pragmatic – to be an unacceptable ethical compromise and not truly informed on 
the grounds of autonomy.319  For instance, Steinsbekk et al. support the use of tiered or 
dynamic consent because they consider broad consent to be paternalistic and advocating of 
top-down governance.  The intent is to give effect to the principle of autonomy, with the 
hope of also increasing user participation.  The proposed ‘dynamic consent’ employs modern 
communication methods to inform, involve, offer choices and obtain re-consent for every 
research project based on available resources.320  Several discussions on fine-tuning the 
tiered informed consent process by some authors have made it impracticable for tissue 
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repositories (and tissue banks) and researchers to execute this in practice.321  Tiered (or 
dynamic) consent involves offering patients a variety of options about the use of HBMs. It is 
logistically difficult for both tissue banks and researchers to implement in consent-taking and 
could be difficult to honour as more complex conditions are added in the selection of the 
types of research to be undertaken.  While sensible in theory, this approach to consent-
taking is inconsistent with the expectations of HBM contributors or research participants. 
We know, from the results reported in Chapter 3, that the general preference of patients or 
research participants is for simplicity and ease of process. As an alternative to the ‘full’ 
informed consent regime, tiered dynamic consent is most unlikely to resolve important 
ethical issues surrounding tissue banking, the protection of patients’ rights and general 
wellbeing, and it is inconsistent with the expectations of contributors; it can only add more 
barriers to the research. 
 
By the analysis presented in this thesis, there appears to be a hierarchy of approaches to 
consent in terms of its informational component. In the order of highest to lowest priority, 
we have:  
• Donation of HBMs, where the informational component is essentially purposive; 
• Broad consent, where the contribution and use of HBMs are limited by minimal 
conditions; 
• Tiered (or dynamic) consent, where the informational component can be onerous 
given that contributors of HBMs must make certain choices;  
• Specific full consent, which is most onerous in terms of its informational 
requirements; and 




• Implied (or presumed) consent, which lacks sound ethical grounding and should not 
be implemented, unless supported by legislation or other forms public endorsement. 
As argued in Chapters 2 and 3, the hierarchy proposed above is justified based on taking into 
serious account the perceptions, motivation and preferences of contributors of HBMs, at 
least in the Singaporean context.  Practical concerns are also taken seriously for reasons that 
have already been discussed at some length.  However, to properly secure public trust and 
safeguard the interests and well-being of donors, tissue repositories and tissue banks must 
themselves act as responsible stewards and are be supported by a system of good 
governance and control. These are elaborated on in the sections that follow. 
 
4.2 Tissue Repository and its institution as Stewards of residual HBMs  
The roles and functions of tissue repositories as research tissue banks have been discussed 
extensively.  These repositories serve as collection centres of HBMs for researchers to tap as 
resources for their research.  The primary objective of a tissue bank is to collect, process and 
store tissues and other residual HBMs for future research use.  My research on the 
perceptions of contributors shows that their acceptance of tissue banks and their willingness 
to donate are influenced by several factors.  These key factors include the understanding of 
the role of tissue banks and their purpose, trust in the institution and tissue bank 
administrators, equitable sharing of benefits, and privacy and confidentiality protection. 
These are consistent with existing requirements on tissue banks to protect the rights and 
respect the preferences of donors, and to minimise risks of harm to donors. 
 
A person is more likely to contribute HBMs if s/he trusts that a tissue bank has a proper 
system of governance in place.  Thus, tissue banks are entrusted with proper handling and 
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use of residual HBMs, including other services that the tissue bank may provide, such as 
extraction of DNA, RNA and/or proteins, which are often needed by researchers. However, 
the specific nature of a tissue bank's responsibilities may not always be easy to articulate 
clearly. From the CSR in Chapter 3, the literature points to a variety of relationships that can 
exist between contributors and tissue banks.  For instance, this relationship could depend on 
the status of the HBMs, whether as ‘outright’ gifts, as abandoned ‘waste’ after surgery, or as 
‘conditional-use’ research materials.  The status of HBM contributors is also relevant, as they 
could be active participants or ’research subjects’, ‘donors’ or ’patients’ who may or may not 
be construed as having abandoned their ‘waste’ tissue (as we have considered in Chapter 2).  
In situations where residual HBMs are unconditional gifts, patients no longer possess 
ownership rights over them. Alternatively, if these residual HBMs are intentionally 
abandoned by patients after surgery, tissue banks should have the right to use them without 
having to obtain consent.322  More often, patients are considered participants in research, 
especially if the HBMs are not anonymised. However, it is not always clear which patients 
are genuinely altruistic, which patients merely abandoned their HBMs, and which patients 
had a mixture of many motivations.  My research demonstrated that most participants are 
aware that they are contributing their HBMs for research and thus, the rules of research 
ethics and human subjects protection apply. Patients may sometimes be considered as 
a ’partner’ of a tissue bank, being party to a provider-researcher partnership for the 
advancement of medical research.323  Whether patients contribute their residual HBMs in a 
donation (as donors), in a case of abandonment (as contributors), in research participation 
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(as research participants) or in a partnership (as partners) for future research, published 
literature and opinion leaders have provided inconsistent descriptions and contrasting 
models of contribution leading to ambiguities in the examination of ethical, social and legal 
implications.324    My research, as discussed in Chapter 3.5.3, demonstrates that these 
residual HBMs contributors care about what becomes of their tissue and expressed a 
continuing interest in the fate of their HBMs.  They know that they have contributed their 
residual HBMs for research and hope that this research will result in future cure for other 
patients or even themselves.  It is not intentional abandonment even though some have 
expressed that the HBMs are donated for good use rather than to simply discard them.  
Contributors expressed preference for a simple broad consent because they trusted the 
institutions, doctors and researchers and did not see the need for active control of the HBMs 
contributed, in a way that dynamic consent attempts to implement for instance.    
 
I argue that as stewards of such tissue repository, trustworthy or moral institutions should 
proactively encourage responsible distribution and use of such collections, and sponsor 
research that reflects publicly agreed priorities and is likely to generate the greatest public 
benefits. The BAC in Singapore supports the notion of donation, that patients should 
willingly ‘donate’ their residual HBMs to tissue banks for the purpose of new research 
discoveries for the benefit of the community.  Given the BAC emphasis on donation, the 
contribution of residual HBMs is to be regarded as a ‘gift’ to the tissue bank and patients 
should be considered as ‘donors’ or ‘residual HBM contributors’.  The recent draft revisions 
to the BAC’s tissue research guidelines use the term ‘custodianship’ to refer to the 
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relationship between tissue banks and the HBMs.325  The term ‘custodian’ is also used in 
paragraph 2.1 of the UK’s document on human tissue and biological samples for use in 
research. This model of custodianship, as a framework for tissue banking research is 
intended to promote fair research access and resolve issues of control and potential conflict 
between tissue banks, investigators, human research participants (human subjects), and 
sponsors.326  From the initial collection of residual HBMs to the final dissemination of 
research findings, tissue banks have a moral obligation to ensure responsible oversight and 
use of residual HBMs collected for research.  The custodial model attempts to ensure 
transparency in research, fairness to contributors of HBMs, and accountability shared by 
stakeholders and researchers involved in tissue bank research.327 
 
Rather than to perceive the role of tissue banks as custodians of donated HBMs, a better 
view is to adopt a ‘stewardship model’.  This may be implemented in different ways, 
including the establishment of a tissue bank oversight committee in leading and taking 
responsibility for research projects that utilise residual HBMs provided by the tissue bank.  
Campbell (1998) stated that when patients donate their organs or tissues, the receiving 
organization has a duty and a responsibility to serve as a trustee of these HBMs and to 
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ensure the protection of the contribution.328  Stewardship embodies responsible planning 
and management of resources of others, which the stewards have been entrusted with.329  
The concept of stewardship is not new and it has been recognised as encapsulating duties 
and responsibilities to shepherd and safeguard these valuable resources.  A conceptual 
framework of the ‘stewardship model’ is published and proposed by Jeffers in Advances in 
Nursing Science, and is substantively similar to the recommendations of the BAC.330  Jeffers 
conceptualises the ethical responsibilities of a tissue bank and its governing institution, as 
managers acting as stewards who are responsible for the assets they receive and to manage 
them in the best interests of the intended beneficiaries.331  When a person contributes 
his/her HBMs, s/he expects and trusts the tissue bank to ensure responsible use and in ways 
that maximise public good. 
 
A stewardship model of governance also includes respect for human dignity, responsibility, 
accountability, service, cultivation, conservation, and protection of the preferences and 
needs of contributors of their residual HBMs.332 Stewardship is a concept with deep roots in 
medical science, ethics and law, and in the practice of data and materials collection, sharing, 
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and analysis.333  Stewardship requires managers to act as trustees of the assets they control 
(in this case, residual HBMs) and they are held to high standards of conduct.334  Where tissue 
banking could be conceived as a public enterprise, the HBMs and accompanying related 
health data should be viewed as public goods to be used for the benefit of patients or public 
causes.335   
 
In the absence of a regulatory authority and legislation like the UK Human Tissue Act in 
Singapore, the role of stewardship falls upon the institution, the tissue bank administrators 
and researchers.  Regardless of whether the residual HBMs were abandoned, donated or 
contributed by research participation, HBMs that NUHTR have received are akin to trust 
property and should be handled accordingly.  As a practical measure, NUHTR could establish 
a committee to ensure that clear and transparent processes are in place for HBMs to be 
applied in ways that maximise public benefit.  In other words, it is critical for the institution 
to assume the role of a moral institution to ensure good stewardship in governing the tissue 
bank for the public good.   
 
4.3 Good Governance 
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As argued above, good governance at an institutional level is in essence good stewardship.   
Research using residual HBMs is different from other research activities because of the 
perpetuity of bio-specimens collected (most HBMs are kept forever by the tissue bank and 
some are immortalized as cell-lines), the emotional and personal factors associated with 
residual HBMs donation, and the uncertain future use of HBMs. Every future use of stored 
HBMs is equivalent to a new participation in a new research and unless a re-consent is given 
for every future use, it would seem that a one-time consent for collection will not suffice.  
Even if re-consent is done on each occasion, informed consent and discussion on privacy, 
ownership and rights do not answer all the ethical and social issues raised by such research 
without the implementation of proper governance of the HBMs.  Governance of tissue banks 
and use of HBMs should take into consideration patients’ concerns, motivations to donate 
and preferences, and protecting them from possible harm. Implicit to good governance is 
the need to give effect to the promise of anonymity, secure privacy and confidentiality and 
ensure that all research use would not lead to any harm to patients.  The governance of 
tissue banks also includes institutional agreements that will meet the expectation of patients.  
Proper safeguards and controls on the use of HBMs by researchers form the foundation for 
the development of governance in tissue bank.  Sustainable and effective governance of 
tissue banks is crucial in resolving some of the ethical problems in tissue banking. The 
principle of ‘first do no harm to donors’ should be of paramount importance of governance 
in tissue banks, based on the research ethical relationship between the researcher and the 
research participant. 
 
As a trustworthy or moral institution, a tissue bank must fulfil its duty to safeguard the 
interests and rights of altruistic participants and ensure that research will be conducted with 
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the most efficient methodology benefitting society.336  The use of HBMs ought to be 
maximized to avoid wastage and used in research to generate public good.  An effective 
governing authority must best scrutinize resource allocation of HBMs to the qualified 
researchers to conduct research for public benefits.  Optimized utilization of HBMs would 
uphold the intention and altruistic interests of donors and justify the funding spent on 
maintenance and operation of tissue banks.  Tissue repositories require substantial 
investments in management and operations and lack of funding will thus affect its 
sustainability, as demonstrated by the closure of the Singapore Biobank in September 
2011.337 
 
TABLE 17:  PROPOSED ‘STEWARDSHIP’ OF RESIDUAL HBMS 
Proper Governance including  
• Ethical review on research and 
access requests 
• Biobanking only by institutions 
• Statutory regulation and supervision 
of bio banks 
 
Moral institutions to ensure that clear and 
transparent processes are in place to ensure 
that for HBMs are to be applied in ways that 
maximises public benefit 
Oversight committees in protecting and 
ensuring responsible use of HBMs.   
• HBMs governance board or council, 
HBMs utilisation steering committee and 
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• Biobank Governing Board 
• Biobank Tissues Allocation 
Committee 
• Biobank Ethics Committee 
 
scientific advisory board with a view 
towards ensuring harmonization of its 
ethics governance with accepted 
international best practice. 
• Research ethics committee or an IRB 
represents different layers of protection 
and safeguard against potential misuses 
of collected HBMs.   
Transparency and Mediated communication 
in Biobanking 
• Biobanks are required to explain to 
patients the status of their HBMs to 
foster trust and enhance participation.  
• Mediated communication rather than 




Accountability to participants and society remains the key principle underlying a moral 
institution, which oversees its tissue repository and proper conduct of research using 
HBMs.338  A moral institution is a trustworthy organization which governs the moral 
behaviour of a set of individuals within a given community; in this case, tissue bank 
operators/administrators, researchers and everyone involved in the handling and use of 
residual HBMs.  Institutions that collect HBMs from patients are responsible for the 
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protection of patients and accountable to them for future use of stored HBMs.  McHale et al. 
stated that “accountability of tissue banks and researchers should not be simply left to the 
individual researchers and organisational integrity, nor be dependent upon whether if 
something went wrong later or an aggrieved research subject decided to litigate” and sued 
the tissue bank. 339   He further cautioned, “Litigation (from the aggrieved subjects) was long, 
cumbersome and expensive, and could ultimately destroy a tissue bank through the 
resultant adverse publicity leading to participants withdrawing en masse.” 340    McHale et al. 
concluded that tissue banks had the duty to establish a proper ethics system and governing 
bodies in order to be responsible and accountable to research subjects. Such governing 
bodies should be able to execute effective sanctions through good practice guidelines, 
policies and established laws that provided appropriate regulatory support.  Gottweis et al. 
also stated that governance of tissue banks was a response to sociocultural challenges and 
required the building of trust, acceptance, and careful political and regulatory negotiation.341  
Due to the unique social and ethical challenges associated with implementation and 
operation of tissue banks, governance has become a complicated architecture and field of 
action involving a multitude of forces and rationalities.342   Conception of accountability, 
usually reinforced with specific requirements for openness or transparency, is broadly 
management based.343 
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Institutions that support and govern tissue banks need to establish stewardship and ethics 
systems to promote intelligent and appropriate governance through accountability, 
transparency and control.   Onora O’Neill is against unintelligent views of accountability, 
which involves administrative bureaucracy and forms filling that have no meaning or 
purpose for research participants. To enable accountability to achieve its aims, one must 
look for intelligent and independent ways of holding professionals and institutions 
accountable.344  She proposed the conception that good governance must include intelligent 
measurable accountability reinforced with specific requirements for openness or 
transparency.345  Good governance would therefore include the forms of accountability that 
best support the relationship of trust allowing people to make intelligent and informed 
judgments about where to place their trust.  O’Neill further stated that accountability 
depended on informed judgment and those lacking the relevant competence could not 
judge complex matters adequately.  This is the case where research participants have a 
‘knowledge gap’ in tissue banking when compared with the tissue bank researchers. 
Research participants are not familiar with tissue banking, or its risks and benefits, as shown 
in my empirical research.  Hence, O’Neill suggested that accountability require independent 
judgment and that good accountability should not rely just on insiders to judge quality of 
performance. 346  By this analysis, it is not good enough for tissue banks to establish for 
themselves their own ethical review systems.  There are limits to self-governance, and 
broader systemic safeguards should be introduced.  This is consistent with the 
recommendations of the BAC, especially for the establishment of an independent regulatory 






authority. However, as we have noted in Chapter 2, this recommendation is yet to be 
implemented in Singapore. 
 
The integrity of the institutional officials, tissue bank administrators and researchers is an 
important component of trust.   Many practical considerations would follow, and some of 
these are discussed here.  Researchers ought to agree to continue to protect the rights and 
privacy of patients and respect HBMs as a valuable research resource. Concurrently, a tissue 
bank has the duty to ensure that stewardship of HBMs is properly assigned and transferred, 
through material transfer agreements, to researchers.  Maintaining a researcher utilization 
record and database will ensure the ethical use of HBMs through monitoring and reports.347 
Researchers using HBMs for research should be trained to handle HBMs as limited bio-
samples and to properly dispose of them with respect after research completion.  The risks 
of breach of confidentiality associated with HBMs research are tied to the confidentiality and 
sensitivity of requested personal identifiers and medical information. If such medical 
information were recorded with neither identifiers nor personal data, the sensitivity of 
information accompanying the HBMs would be less of a concern. But if the medical 
information collected and supplied with the HBMs were both identifiable and sensitive, then 
safeguards to protect confidentiality should be carefully considered by tissue banks, 
researchers and investigators and accompanied with proper ethical review by the IRB and 
other governing authority. When considering a research hypothesis, the investigator must 
first assess the importance of associating the participant with his/her medical information 
and identification.  Some research may require continuous linkage with a patient’s medical 
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records to fulfil research criteria.  For example, a breast cancer researcher may obtain breast 
cancer tissues from mastectomy, and continue to track the patient annually to carry out 
blood testing and review if there is either a relapse or slowing of efficiency of chemotherapy.  
Such a research will then require separate consent for every additional new blood donation 
and access of new medical information. 
 
Tissue banks should have a thorough and effective policy for researchers to address and 
manage research incidental findings (IFs) and individual research results (IRRs) of either 
potential health, reproductive, or personal importance to individual donors.348 It is 
commonly the duty of researchers and their affiliated research institutions to manage and 
decide on IFs and IRRs. However, there are on-going debates about the extent of researchers’ 
responsibilities to inform research participants of IFs and IRRs generated in the course of 
their research. Research discoveries and information may or may not be diagnostically and 
analytically valid, since research laboratories are generally not accredited for clinical analysis 
and thus the IFs and IRRs may not always be clinically conclusive.  In addition, releasing 
clinically un-confirmed research results may cause undue worry to patients.   The worst-case 
scenario will be that the new research findings are not “clinically actionable”, meaning that 
the findings do not allow either the patient or attending physician to prevent or alter the 
course of condition, or treatment of the condition.  For example, the identification of new 
genetic markers associated with certain cancer types in HBMs will cause undue emotional 
distress and may be inconclusive for diagnosis.  With the lack of regulation on return of IFs 
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and IRRs to donors, the option of consenting to return these findings in the initial informed 
consent process must be requested and only released to patients who have earlier opted to 
receive them with the choice of a detailed counselling, on possible clinical implication of the 
research findings.349 Some tissue banks may be designed to irretrievably de-link personal 
data and identifiers at the initial collection stage of HBMs to prevent future re-identification.  
By fully de-linking all personal data, these actions will conclusively hinder the return of IFs 
and IRRs to donors.  In another design, tissue banks code the HBMs at time of collection and 
only provided with either de-identified or anonymous HBMs to researchers. A trusted third 
party (TTP) holds the code used to de-link personal data with HBMs. In such cases, the return 
of IFs and IRRs can only be done when re-identification of coded HBMs are re-linked back to 
patients’ personal data.  
 
As we have considered earlier on in this Chapter, proper discharge of an institution’s 
stewardship responsibilities include the establishment of an ethics committee, HBMs 
governance board or council, HBMs utilisation steering committee and scientific advisory 
board with a view towards ensuring harmonization of its ethics governance with accepted 
international best practice.  Central to good governance of tissue banks, is the requirement 
that confidentiality of donors is maintained throughout.  Many of these measures will 
require investment in administrative, logistical and financial costs.  For example, for the 
purpose of personal data protection, a moral institution should invest in a trusted third party 
computerized secure system to hold the link between donors’ identities and tissue codes. 
The third party system will perform the necessary un-coding and re-coding allowing 
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researchers access to de-identified medical information associated with the tissues.350    
Institutions should also allow results from research using HBMs to be disseminated to all 
participants and, where applicable, to the public, through mediated communication via 
newsletters and websites, which we will discuss in the next Section.  Tissue repositories 
should communicate actively with their contributors when there is new information that 
may be of relevance to them, both through their websites and through regular e-bulletins, to 
promote transparency and accountability. 
 
4.4 Transparency and Mediated Communication in tissue banking 
Transparency is one of the crucial factors of a governance framework for tissue bank 
research, apart from accountability and control.  O’Neill stated that accountability must be 
reinforced with requirements for openness or transparency. 351  Tissue repositories are 
required to explain to patients the status of their HBMs to foster trust and enhance 
participation.  It is through this trust and continued participation that tissue banks can amass 
large numbers of HBMs for future research.  Timothy Caulfield et al. have stated that “given 
the importance of public trust for the recruitment and continued involvement of much-
needed participants, the obtainment and maintenance of public funding, and the 
implementation of any emerging health-related technologies, even a relatively small loss in 
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public trust could have substantial ramifications for the viability and utility of tissue bank 
initiatives.”352   
 
In Singapore, tissue banks are funded by public funds and governmental budgets, and are 
thus accountable to the funding agencies, taxpayers and contributors. Large substantial 
support from public funding entities has been channelled to set up and maintain these tissue 
banks, and long-term financial sustainability is one of the major concerns on the future of 
tissue banking.353  There is a duty to respond to concerns of HBMs contributors in terms of 
good governance and accountability to foster continuous trust from patients and HBMs 
contributors.  Onora O’Neill supports the view that trustworthy institutions will have to 
incorporate user-friendly ways, in which donors can check what is done to their HBMs, and 
whether they accord both with publicly agreed systems of protection and with the content 
of consent they have given.354 Being accountable and transparent is thus a social 
responsibility of tissue banks. 
 
However, tissue banks in general do not view providing transparency to the public as a 
priority over closed and restricted communications and discussions with scientific 
researchers, clinician scientists and surgeons, who have helped to build up and subsequently 
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utilized the stored specimens.355  The closed culture of communication was also described in 
Japan by Triendl and Gottweis,356 who noted that the governance of Biobank Japan Inc. took 
the form of “governance by stealth”.  Most tissue banks adopted a closed culture of 
communications, which took place only amongst established players such as scientists, 
hospital administrators and clinicians, with no involvement of the public and thus the 
existing tissue banking framework lacked transparency to the public. 
 
Presently, tissue banks resist engaging in open discussion with HBMs contributors and the 
public for fear that the communication could attract scrutiny and criticism resulting in the 
withdrawal of participation.357  For the same reason, some opinion leaders even 
recommended that withdrawal of participation from tissue banks should not be allowed 
once a patient has agreed to donate or abandon tissues.358  Where NUHTR is concerned, I 
am of the view that since patients may not have had the full information on the usage and 
risk of HBMs at point of consent and subsequently reconsidered and decided to change their 
minds, they should be allowed to withdraw their permission.  This is especially relevant in 
cases when research participants do not agree that their stored residual HBMs can be used 
for certain types of research that are against their values - like cloning or genetic 
manipulation, which they would not have supported if they had known earlier.  These 
contributors as research participants should be allowed to withdraw further participation 
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when they have been informed about research that are against deep-seated values or when 
the trust is broken.   
 
The unused portion of stored HBMs should then be destroyed since it would not be feasible 
to physically return them to donors and no new research should be carried out.  In research 
ethics documentation as stated in the Helsinki Declaration359  and Nuremburg Code 
(principle 9), the research subject Nuremburg 360 should be at liberty to withdraw permission 
for the research or withdraw consent to participate at any time without reprisal.361  Since no 
specific informed consent was given for any specific type of research and only generic 
consent was taken at the point of collection, patients should be allowed to withdraw 
permission for continual use of their samples at any time when they feel that their rights and 
motivations for donation were violated.362  Thus, the refusal to allow donors to withdraw 
would create bad publicity for the tissue bank and erode public trust, even when it is legally 
justifiable to refuse such withdrawal.  Further, some tissue banks felt that providing either 
too much or unnecessary information may cause scepticism and “disturb the water”, thus 
creating greater confusion and suspicion.363  Iwae reported that in her interview with people 
involved in Biobank Japan Inc., one interviewee commented that BioBank Japan Project 
could not have collected 287,929 specimens in 5 years if it had adopted open 
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communication, which would come with additional administrative complications and 
bureaucracy.  This was one of the reasons given in justification of their “closed culture of 
communication” or “governance by stealth”.364   Some European authors, however, 
suggested that increased media attention and debate could contribute to greater public 
knowledge and interest in tissue banks.365  Gaskell and Gottweis stated, “Controversies don't 
seem to lead people to reject the idea of tissue bank research per se. Instead they facilitate 
the spread of information, and improve understanding and sharing of views on what is 
appropriate and acceptable use of samples.” They concluded that: “What is needed is a 
dialogue with the public, to explain the purposes of tissue banks and how they operate, and 
to give people an opportunity to voice their concerns and conditions for their support and 
participation.”366  There may be a difference in cultural preference in terms of open 
communication and determination of sufficient transparency and this requires further 
investigation. 
 
According to Onora O’Neill, the need for transparency on performance information should 
not only be made available to stakeholders, government departments and auditors, funding 
agencies and governing boards, but also to the wider public.367  Whilst it is important to 
increase awareness and utilization of the collected specimens to the research community for 
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the survival of a tissue bank, 368 I am of the view that tissue banks should focus on 
communicating with the public and patients who have contributed their HBMs.  In Singapore, 
there is neither public debate nor discussion on tissue banking, and Singapore’s tissue banks 
do not provide information to update their HBMs contributors on the use of donated HBMs 
in research and the types of research involved. 
 
Tissue repositories rely heavily on consent nurses to communicate with patients when 
requesting permission to collect their residual HBMs.  After collection, there is either little or 
no communication between tissue banks and HBMs contributors, until the next collection of 
specimen from the same person subsequent to hospital admission. My research data 
(reported in Chapter 3) showed that most local patients were unaware of the existence, of 
tissue banks, the objectives of tissue banking, and the related risks (like implications on 
privacy and confidentiality), until they were approached by a consent nurse.  Most 
participants donated their residual HBMs trusting that future research would generate 
public good and they were unaware of any risks associated with this donation.  The patients’ 
lack of awareness was also observed by Gaskell and Gottweis, who noted that “most 
Europeans haven't heard of their nation's repositories of human blood and tissue 
samples.” 369  The European Commission reported that there was a low level of knowledge 
on tissue banks and genetic research in different countries,370 and that the fact that most 
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people had not heard about tissue banks might make them suspicious of donating.  My 
qualitative research showed that local patients, despite not understanding the nature of 
tissue banking and risks, ‘trusted’ the hospital and researchers, and had faith that research 
would generate future public good.  However, this trust should be attributable to 
experiences so that one can form a judgment on trustworthiness to make a decision.  
Baroness O’Neill indicated: “To live our lives, we have to make decisions in the absence of 
full information or guarantees; it is pointless to sulk when the evidence is not perfect.”371  
Trust, therefore, is not based on perfect knowledge and understanding of everything, and if 
we have complete proof or complete control of the variables, our decision will solely be 
based on facts, and trust will then be redundant.   
 
O’Neill further stated that any “unscrupulous or unacceptable use of human tissue, even by 
a handful of researchers or doctors, might bring important medical and scientific activities 
into ill repute, and could lead to public demand for restrictions on less problematic uses of 
human tissue.”372  Thus, any misuse of human tissues would be considered a betrayal of 
trust given by the contributors and the general public.  It is thus important to keep an active 
communication channel with HBMs contributors to maintain a balanced perspective of 
tissue banking and research, as opposed to hearing only bad news through the press when 
unscrupulous or unacceptable use of human tissue occurs.  
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Both my qualitative and quantitative research showed that a huge proportion of patients 
(more than 70% of the 167329 patients in 10 years) were willing to donate their residual 
HBMs for research without the requirement of much information. Hence transparency 
should not be only about providing a lot of information, where the public have neither 
understanding nor interest in reading.  Members of the public may lack the knowledge 
capacity to comprehend or time to understand “a cornucopia of disclosed documents”.373  
Baroness Onora O’Neill supported genuine mediated communication that did not involve 
complicated scientific and technical terms and the provision of information specifically 
tailored for the public to understand; without deception, concealment and coercion.374  The 
concept of mediated communication came from communication theories referring to 
communication carried out by the use of information communication technology, in contrast 
to face-to-face communication.375  Mediated communication could be employed to maintain 
relationships with donors to allow transparency to be articulated in this connection.  O’Neill 
further stated that providing more information during a face-to-face informed consent 
discussion would not necessarily improve accountability to patients and more disclosed 
information does not necessary fulfil obligations to be 'transparent' when compared to 
genuine communication.376  Mediated communication in this case, refers to making 
information readily available for the patients when they needed it and allowing the donors 
access to the information at their own convenience, without emotional or physical duress. It 
engages the use of information communication technology such as websites, social media 
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(e.g. Facebook and blogs), as well as mobile telephones or instant messaging, in place of 
conventional face-to-face communications. 
 
Information that the tissue bank should make transparent includes future use of the stored 
residual HBMs, declaration of intellectual property, income generation and royalties, and 
conflict of interest, which must be transparent to all relevant parties, including research 
participants.  Relevant information can be made available at their website or brochures for 
public access when required.  Failure of transparency, through deception and concealment 
will be detrimental when the public discover such information via the press or other means.  
 
In this thesis, I have argued for continuous mediated communication, as it is impossible for 
full information to be available at the point of requesting for permission to collect residual 
HBMs.  To be transparent, communication should go beyond a one-off dissemination of 
information in a participation information sheet provided only at the point of consent.  
Mediated communication could act as a means of explaining the objectives of tissue banks 
and their operations, and providing an opportunity for people to voice their interests, 
concerns and promote transparency.  Information should be made freely available as and 
when the patients need it and this could be done through the web portal.   Transparency 
through mediated communication will shape the attitudes of potential donors and fosters 
support and trust in their future participation, together with a moral institution as 





Chapter 5. Conclusion 
In Chapter 1, I set out the objectives of this thesis and outlined the value of tissue bank 
research.  The thesis presented some definitions of the common terms used in tissue 
banking and the current consent paradigm used in tissue banking.  I have also discussed 
BAC’s guidelines on Human Tissues Research and the need for governance in Singapore. 
 
In Chapter 2, I discussed the problems and inadequacies (even impossibility) of defining 
precise informational parameters in different informed consent regimes (set out in Chapter 
1), and especially that of specific consent.  Where residual HBMs are concerned, I have 
argued that there are clear justifications for the use of general or broad consent rather than 
specific consent.  In fact, I have gone further to distinguish donation from a contribution of 
tissue through general (or broad) consent, and to argue that the former is to be preferred 
over the latter.  Specific informed consent operates on the assumption that patients will 
understand and carefully deliberate on the information that is given to them, and then 
decide if they will participate in the tissue banking project. In consent taking generally, the 
focus is on keeping patients ’informed’.  It is typically assumed that factors like 
demographics (like gender, religious belief and age), intention and purposes of research 
participation, and trust and governance, do not matter.  
 
My empirical research reported in Chapter 3 shows that such assumptions are not 
empirically supported, and at least for patients in Singapore, demographics, preferences and 
trust do matter.  While a long and detailed informational process could in theory be 
instructive for the potential research participant, this could discourage an altruistic person 
from contributing HBMs to research, as my empirical findings suggest.  A detailed informed 
consent process does not enhance the trust manifested by HBMs contributors and actually 
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undermines that trust while showing disrespect for those contributors.  Such a process fails 
to acknowledge the emotional distress that patients are likely to be experiencing before 
surgery.  In many cases, patients interviewed are also likely to lack the sophistication or the 
interest to persist in understanding a proposed research in all its intricate details.   Most 
patients did not want to know the specific details of the research, nor were they deterred by 
their failure to fully understand or anticipate the risks that were entailed, even with detailed 
explanation as part of the informed consent process.  These patients knew there were risks 
that they did not understand fully, and yet are willing to participate in the research.  A 
general understanding of ‘use for research’ was sufficient, and many donated HBMs to 
NUHTR based on altruism and trust.  A similar outcome has been achieved in the Surgical 
Consent Form with general or broad consent, where the consent sought is for the 
contribution of residual HBMs for a broad range of activities, including research.  By signing 
this broad consent form, patients agreed to the future use of their HBMs in medical research, 
education and study, as decided by NUH as a research institute.  Decrease in the reliance on 
‘full’ informed consent and the inability on the part of researchers to ensure full privacy 
protection for instance would imply a greater need for a more comprehensive and 
responsive system of tissue bank governance.377 
 
In chapter 4, I also argued that good governance requires tissue banks to be more than mere 
custodians of HBMs.  Instead, they must meet standards of accountability as stewards of 
HBMs that have been provided for the public good.  At a minimum level, there must be 
mechanisms to ensure ethical review of research proposals, fair allocation and optimal use 
of HBMs, appropriate supervision or control over HBMs that have been provided to 
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researchers (e.g. through material transfer agreements), effective safeguards through 
anonymisation of personal information, and transparency through mediated communication.  
I have also argued for all HBM contributors to have the right to withdraw participation at any 
time and without having to provide any reason.   
 
Good governance should enable tissue banks to serve as good stewards, or more generally, 
as a moral institution.  This is implicit in the altruistic nature of the donation of HBMs.  In fact, 
the BAC in Singapore encourages donation of HBMs as an ‘outright gift’, with no conditions 
attached.  However, a donation is predicated on a level of trust that the gift of HBMs will be 
applied to advance public good and that the donors will not suffer any harm as a 
consequence of making this gift.  For trust to subsist, I agree with Onora O’Neill that it 
should not be necessary for the tissue bank to specify all possible applications of the gift.  
However, the tissue bank should demonstrate that it is trustworthy.  A sound governance 
system should be directed at promoting and sustaining trust among donors and 
trustworthiness on the part of the tissue bank, by ensuring accountable and responsible 
handling and use of HBMs.378  Annette Baier sets out that trust is the attempts by the more 
powerful entity to equalise differences in power through a variety of means, including being 
accountable for the use of discretionary power379. According to the result of my research, 
contributors of HBMs are often ignorant of the value of their contributions, as well as the 
risks entailed.  In order to be trustworthy, tissue repositories and biobanks should ensure 
equalisation of power that arise from this asymmetric information and knowledge gaps. In 
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addition, they should demonstrate accountability for the discretion they have been 
entrusted with through broad consent that the contributors provided. 
 
 As the BAC has recommended, there are good reasons to include these values on trust 
through legislation, and to establish an independent body to oversee all tissue banks and 
tissue repositories in Singapore.  Ultimately, tissue banking is an enterprise of trust.  This is 
the ethical conclusion of this thesis, and is consistent with public perception and expectation, 
as the empirical evidence shows. 
 
Tissue repository and tissue banks are controversial due to the ethical, legal, and social 
implications (ESLI) surrounding utilization of HBMs and related data.380  These issues include: 
(i) Informed consent (e.g. how to inform participants about using banked samples for future 
research that has not yet been conceived), (ii) Confidentiality (e.g. increased risk of breaches 
owing to mandates of tissue banks to provide access to researchers and store samples and 
data for long periods of time), (iii) Secondary use of samples and data over time, (iv) Return 
of research results to donors, and (v) Data and Benefit sharing.  
 
This thesis presented empirical data on public attitudes, values, concerns, and interests 
underlying the donation of residual HBMs to tissue banks.  Policy makers, tissue bank 
operators and researchers who acknowledge the importance of public opinions will better 
able to maintain the trust of existing and new donors.  This acknowledgement is of utmost 
importance to ensure the success and continuity of tissue banks.  We have identified various 
themes underlying expressed objectives, preferences and concerns of patients regarding the 
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collection, storage and use of tissues in tissue bank research.  ESLI and associated challenges 
in tissue banking have been discussed extensively by lawyers and ethicists together with the 
scientific community.  The use of expert opinions must be coupled with and supported by 
public engagement and opinion polls to gain public trust and support. Public opinion should 
matter in the sense that a tissue bank should be accountable and public transparency should 
be fostered. In addition, as a moral institution, the decisions and actions of a tissue 
repository should be able to withstand ethical scrutiny.  
 
In the attempt to address these issues in tissue banks, we should take public perception and 
trust of tissue banks into consideration.  Public opinions and perceptions of tissue banks are 
important and if they either do not trust the biobank, or are doubtful or suspicious of tissue 
banks and their governance structures, biobank collection and research may be significantly 
hindered.  Understanding and considering public viewpoints and positions are thus a 
necessary component in ensuring public trust and support of biobank and its related 
research.381  The current research shows that most donors of tissue banks contributed for 
altruistic reasons with good intentions despite lack of understanding of the risk and harm 
that donation poses.  Even highly educated donors do not comprehend the privacy risk of 
their donation but yet are willing to contribute in good faith and for public good.  
Participants had donated based on trust in doctors, institutions and out of gratitude for their 
treatment.  The trust given to institutions, tissue banks and researchers implied that they 
were given stewardship of HBMs and related data.  Thus tissue banks and researchers must 
shoulder the duty to reduce risk to donors and protect them from harm.  An effective 
biobank governance system could hence provide the needed safeguards and controls if 
                                                          




executed with accountability and adequate transparency.  Further, governance and control 
of tissue banks must be sustainable and practicable in biobank operations.   
 
I have explained the value of public preferences, perceptions and expectations, which 
support my argument for relying on general (or broad) consent, and even outright donation, 
in obtaining HBMs for tissue banking and research purposes. My systematic literature review 
and empirical findings highlight that there is no clear consensus on the best ethical approach 
to consent taking.  Furthermore, I have explained why other forms of consent taking are 
inadequate, inappropriate or ineffective. However, my argument for general consent or 
donation will be ethically effective and consistent with public expectations and requirements 
only when there is good governance to support tissue banks to act as stewards (and not as 
mere custodians) of retained HBMs. I have set out a number of requirements for good 
governance, which included accountability, responsible use, safeguards, transparency and 
mediated communication. Most importantly, I support the right to withdrawal of 
participation from the biobank and argue that failure to allow withdrawal will result in a 
betrayal of trust.  
 
To conclude, I support the use of general (or broad) consent regime or for donation 
as ’outright gifts’. The same lexicon on ‘donation’ has also been proposed by the BAC, with 
recommendations to strengthen the governance and regulatory system in relation to tissue 
collections and uses. As discussed in Chapter 1 and 2, the BAC proposed legislation for 
management and use of legacy tissue and establishment of a regulatory body to oversee the 
collection, management and use of HBMs. The need for good governance was a reason that 
BAC considered research institutions, rather than individual researchers, to be appropriate 




My empirical findings in Chapter 3 are supportive of the BAC's recommendations to 
strengthen the governance framework, most likely through legislation. My findings give 
important content to the BAC's principle of ’respect for persons’ and on the types of consent 
to be used to fulfil this principle; whether through general consent or as a donation and; 
whether they should take into account their preferences, social and economic status (i.e. 
demographics), gender, intentions and values. The proposed regulatory framework requires 
tissue banks to take these into account. However, broader public discussion on what should 
be taken into account should then be the subject of public discussion. 
 
My empirical findings further support Onora O'Neill's argument that informed consent 
should be relied on as a means of promoting accountability and trust, rather than an end in 
itself or mere permission. In addition, donated residual HBMs should be taken to be like 
public goods as donors are often expected to give altruistically. I have argued in Chapter 4 
for research institutions and tissue banks to be responsible, not as mere custodians, but as 
stewards of these public goods. I am also supportive of the Nuffield Council's view that 
stewardship will require a biobank to do all that is necessary to promote public health and to 
safeguard the well-being of donors. I understand that my position differs from the BAC in 
requiring tissue banks to be stewards, rather than just mere custodians, although my final 
proposal may not ultimately be so different from the BAC's, as the BAC may have meant 
stewardship, when it used the term 'custodian'. 
 
For a system of governance that promotes trust, I have argued that tissue banks should 
respect the right of a contributor and allow donors’ withdrawal from participation at any 
time. The biobank should be transparent and have continuous communication channels with 
the donors. This could be provided as a form of 'mediated' communications, so that the trust 
has some basis and continuously maintained.  It is also a means of ensuring accountability 
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and to allow donors to appreciate the research use of their residual HBMs. Other forms of 
mechanisms to reinforce include HBMs research ethics and allocation committees; propose 
use of material transfer agreements, as well as mechanisms to ensure confidentiality and 
privacy safeguards (anonymisation and trusted third party) are in place.  
 
I propose an ethical governance system that will protect the residual HBMs, respect the 
expectations and provide safeguards for the concerns of patients who have donated their 
residual HBMs.  This supports my proposal on the use of broad consent, outright donation of 
residual HBMs for research (but with a continuing right to withdraw from participation at 
any time) and constituting the tissue repository and its moral institution as steward of 
residual HBMs.   A moral institution’s stewardship responsibilities will include the 
establishment of an ethics committee, HBMs governance board or council, HBMs utilisation 
steering committee and scientific advisory board with a view towards ensuring 
harmonization of its ethics governance with accepted international best practice.  Central to 
good governance of tissue banks is the requirement that confidentiality of donors is 






In order for my proposal of an effective biobank governance system to be implemented, 
additional manpower, effort and resources must be available to the research institutions and 
the tissue banks.  This additional effort will involve a paradigm change in the current tissue 
banking culture and practices. Tissue banking is an expensive investment for research 
institutions, where funds are channelled to specific research projects rather than to building 
a central collection and core storage facility.  Most research institutions are reluctant to bear 
the additional cost although they understand the need to encourage patients to continue 
donating their residual HBMs for research.  The BAC’s recommendations on statutory 
regulations on governance are still not implemented. My research supports the BAC’s 
recommendation to strengthen the governance regime for tissue repositories and tissue 
banks through legislation, although my research at this stage does not provide guidance on 
how much effort and resources should be committed to developing tissue banks as moral 
institutions (or good stewards of public goods). In the absence of a regulatory framework, 
my proposals would also be limited in execution. 
 
Implications for research 
Another limitation of my thesis relates to the empirical aspect of my study, and I would like 
to suggest ways of addressing these limitations in future research.  My quantitative research 
on the NUH Surgical Consent Form shows significant differences in consent rate, depending 
on demographics, religions, ethnics, etc.  More in-depth research can be conducted using 
focus groups in relation to each one of these demographic factors to better understand 
these differences.  In the qualitative research, we could only recruit patients who had 
donated their residual HBMs to NUH TR.   Those patients who refused donating also refused 
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to participate in our qualitative research.  We could only document their reasons informally.  
Future research may explore this group of patients to understand their concerns and 
preferences.   
 
Implications for Practice 
My paper on “Patients’ consent and donation of their residual biological samples: A 
systematic review”,   published by International Journal of Evidence-Based Healthcare, was 
accepted by The Joanna Briggs Institute as “Best Practice: evidence-based information 
sheets for health professional”.  The Joanna Briggs Institute (JBI) Library is a repository for 
publications and information for policy makers, health professionals, health scientists and 
others with a practical or academic interest in evidence based healthcare.  This evidence is 
collated and the results are appraised, synthesised and transferred to service delivery 
settings and health professionals who utilise it and evaluate its impact on health outcomes, 
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CONSENT FOR OPERATION / PROCEDURE BY PATIENT 
(For competent patients above 21 years of age or patients below 21 years who are assessed to have 
capacity to provide valid consent) 
 
PART I – To be Filled by Patient 
 
1. I,   (NRIC/Passport No.   ), 
 (Name of patient) 
 
 hereby consent to undergo the operation / procedure of   
  (State nature of operation / procedure) 
 
   the nature, effect and purpose, as well as benefits of the above proposed 
 
 
 operation / procedure and risks involved have been explained to me by Dr/Mr   
 (Name of medical practitioner) 
 
 I confirm that the potential risks of not carrying out the procedure, and alternative modalities have been discussed with me.  
 
2. I also consent to: 
(a) The administration of sedation, general, local or other forms of anaesthesia for this operation / procedure. The 
potential risks involved are illustrated overleaf. 
(b) The use of drugs and medicines as may be deemed advisable or necessary for the said operation / procedure. 
(c) Such further or alternative operative measures or procedures as may be found to be necessary during the course of 
the operation / procedure. 
(d) The transfusion of blood, blood components and other blood derived products as may be deemed necessary. 
(e) The taking of photographs / videographs for education /academic / research purposes, where my identity will not be 
revealed, if used. 
 
3. I acknowledge that no assurance has been given to me that the operation / procedure will be performed by any particular 
medical practitioner.  (to delete if not applicable) 
 
4. Note: This clause is only applicable if tissue is to be removed. Please tick here if it is not applicable  Not applicable 
 
I understand that in the course of the operation / procedure, tissues (which includes skin, bones, organs, blood and other 
body fluids) may be removed as part of the surgical procedure, and the remainder which otherwise be discarded, may 
prove valuable for medical research, education and study purposes. 
 
 I *agree / *do not agree to allow the remainder of any tissue removed not required for my medical management, to be 
used for medical research, education and study purposes. I understand that only excess tissue that remains after all the 
necessary medical tests are completed will be used, and no extra tissue will be taken for these purposes.  
  
5. I acknowledge that the following have been explained to me – 
(a) The potential risks involved with the administration of anaesthesia and sedation as illustrated overleaf, but not limited 
to the list. 
(b) The potential risks involved with blood transfusion as illustrated overleaf, but not limited to the list. 
(c) No guarantee has been made to me about the outcome of the blood transfusion. 
(d) The alternatives to the use of community blood supply which include pre-donation of my own blood (autologous blood 
donation). 
(e) The consequences of refusing to accept transfusion of blood or blood components, that include seriously jeopardizing 
my health or resulting in death. 
 
 
                  
  (Signature of patient) (Date) 
 
PART II – To be Filled by Medical Practitioner 
 
 
I,   confirm that I have explained to the patient the  
 (Name of medical practitioner) 
 




 _________________________________                      ______________________________                        ___________________       





*Delete accordingly                                                                               R5-11-11 
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 PART III – To be Filled by Interpreter (if applicable) 
 
 By Interpreter 
 
 * I,   confirm that I have explained to the patient the nature, effect and 
  (Name of Interpreter) 
   
       purpose, as well as benefits of the operation / procedure and risks involved, in   
 (Language / Dialect) 
 
 
     
    (Signature of Interpreter)                                                                                                                         (Date) 
 
 By Patient 
 
 * I,   the abovenamed patient, confirm that the nature, effect and 
  (Name of patient) 
  
       purpose, as well as benefits of the proposed operation / procedure and risks involved were explained to me by 
 
 Dr / Mr / Ms    in   . 




     
  (Signature of patient) (Date) 
 
 
Risks of Anaesthesia and Sedation   
Note: There may be other risks (depending on your medical condition and type of surgery) that have not been listed here. 
Please ask your DOCTOR IN CHARGE OF SEDATION OR ANAESTHETIST if you have any general or specific concerns.  
Anaesthesia (including Deep Sedation) Moderate Sedation 
Common (1:10 to 1:100) 
Giddiness, nausea and/or vomiting, sore throat and hoarse voice, physical 
trauma including eye abrasions, damage to teeth or dental work, lips or 
tongue, pain and inflammation of injection site, headache, muscle ache 
and/or backache, postural headache related to a spinal or epidural 
injection 
Common (1:10 to 1:100) 




Uncommon (1:1000 to 1:10 000) 
Respiratory depression, which may require ventilatory support, chest 
infection, awareness despite anaesthesia, serious allergy to drugs 
Uncommon (1:1000 to 1:10 000) 
Allergic reactions, inflammation of veins (phlebitis), 
respiratory depression 
 
Rare (1:10 000 to 1: 100 000) 
Permanent damage to the eyes (which may result in blindness), persistent 
nerve damage, resulting in transient / permanent numbness or weakness, 
cardiorespiratory arrest and death, equipment failure and related 
consequences 
Rare (1:10 000 to 1: 100 000) 
Cardiorespiratory arrest and death 
 
 
Risks of Various Potential Complication of Transfusion 
Common 
Skin reactions and rashes (1-2%), Fever (0.5-1%) 
Uncommon 
Bacterial contamination (platelet transfusion) (0.01-0.1%) 
Rare  
Mistransfusion (0.008%), viral transmission (Hepatitis B, C, HIV) (0.0001-0.001%), ABO related acute hemolytic reaction (0.0002%), 
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Consent to Donate Clinical Samples for Research to the NUH Tissue Repository 
 
The National University Hospital (NUH) Tissue Repository request your kind consideration to donate clinical samples, blood and 
leftover tissues removed during your surgery for use in research. These leftover tissues, if not donated, will be discarded. If you 
consent, the blood would be drawn additionally and exclusively for this donation. 
 
A detailed information pamphlet has been given and the nature of the donation explained to you. Your medical treatment will NOT be 
affected in any way by your decision.  
 
You will be given a copy of this signed consent form.  
I acknowledge that I have been given the Patient Information Pamphlet and the nature of this donation has been explained to me in 
the _______          language/ dialect* that I understand. I have had the opportunity to ask questions and have received satisfactory 
answers and information.  
 
I voluntarily consent to donate my clinical samples for future research: (Please tick (√) as appropriate)   
  
(i) My left over tissue and blood* (both)     Yes □   No □ 
(ii) My left over tissue (only)      Yes □    No □ 
(iii) My blood* (only)       Yes □    No □ 
            
( *I consent to a maximum amount of 30 ml of blood to be drawn based on the Duty Anaesthetist’s evaluation of my clinical condition 
and I consent to it being drawn during my surgery.)     Yes □   No □  
 
(iv) Other clinical samples ( viz, hair, nails, effusions, urine, faeces, saliva, left over blood), if applicable  {Refer to para 2 of Patient 
Information Pamphlet)       Yes □   No □ 
(a) Hair   Yes □  No □ 
(b) Nails   Yes □  No □ 
(c) Effusions  Yes □  No □  
(d) Urine   Yes □  No □ 
(e) Faeces   Yes □  No □ 
(f) Saliva   Yes □  No □  
(g) Left over blood
@
  Yes □  No □  (@left over from my routine blood examination in Dept of Lab Medicine) 
 
Please continue only if patient has ticked any of the ‘Yes’ box. 
 
I also give permission for information in my medical records to be used for research. I understand that this information will  not bear 
my name or other identifiers and that due care will be taken to preserve the confidentiality of this information.   
 
I understand and acknowledge that the donated clinical samples as well as any substance or material derived from it, or  modified 
versions of it, may be used for purposes relating to research and development, medical education, teaching, publications, diagnosis 
and possibly the treatment of medical conditions on a commercial basis or otherwise. I also understand that my samples and medical 
data will only be made available for future research studies, if those studies have first been approved by an Institutional Review 
Board to make sure they are ethical and scientifically sound. 
 
I agree that, as a voluntary donor, neither I nor my estate will receive any benefits, commercial or otherwise, from the use of my 
clinical samples or any substance or material derived from them, or modified versions thereof. 
 
My signature / thumbprint* below indicates my consent to the donation of clinical samples on the understanding indicated above.  
 
 Name Signature Date 
Patient    
Parent / Legal Guardian*, if appropriate
(1) 
   
Witness / Translators*    
Consenting Nurse/ Staff    
 
* Delete whichever is not applicable. 
(1) 
Signature of the parent or legal guardian is required if patient is under 21 years old or is incapable of understanding the nature of the donation as judged by the consenting nurse/staff. 
For any further assistance/ queries regarding this donation, you may  contact : Administrator, NUH Tissue Repository at tel 6772 2310 
For an independent opinion regarding the research and the rights of research participants, you may contact a staff member of the National University of Singapore Institutional Review Board 
(Attn: Mr Chan Tuck Wai, at telephone 6516 1234 or email at irb@nus.edu.sg). 
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Donating Clinical Samples for Research Through 
The NUH Tissue Repository 
 
Patient Information Pamphlet 
 
 
This pamphlet provides information on the use of clinical samples in research and development and what it means to 
be a donor of tissue and other patient samples. 
 
Where do left-over clinical samples (tissues and other patient samples) come from? 
During your surgery, some tissues may be removed from your body to help in the diagnosis and/or treatment of your 
condition. This tissue may be solid, semi-fluid (eg. bone marrow) or fluid (eg. blood left over from routine tests). Any 
such tissue removed from your body will always be used first and foremost to determine your medical condition, and 
how you can best be treated. Sometimes, not all the tissue removed from you is needed to diagnose and/or treat your 
condition. Leftover tissues, that are normally discarded or destroyed, are often useful material for research. Other 
clinical samples which may be useful for research include body fluids (eg. effusions), secretions (eg. saliva), 
excretions (eg. urine, faeces), hair, toenails, fingernails etc. Choosing to donate any such samples WILL NOT require 
removal of any extra tissue or change the care you will receive in any way.  
 
How would blood for research be collected from cancer patients? 
Blood, another important material for biomedical research, can be obtained from patients undergoing cancer surgery. 
If you consent to donating blood, a maximum amount of 30 ml of blood may be drawn. The amount of blood drawn 
would be decided by the Anaesthetist drawing blood, depending on your age, sex and your clinical condition but would 
not exceed 30 ml, at any cost.  This amount of blood is quickly replenished by human body. This blood would be 
drawn during your surgical procedure by a qualified Anaesthetist in operating theatre. The blood would be drawn when 
venous line is being inserted for inducing anaesthesia during the surgical process and you would not have to undergo 
any additional pricks for donating blood. Drawing of this blood would not entail any additional health risk to you, apart 
from those associated with your surgery and have already been explained to you by your consulting surgeon. 
 
Why should I donate clinical samples? 
Researchers at the National University Hospital (NUH) and National University of Singapore (NUS) or other 
institutions are trying to learn more about diseases. Clinical samples provide the materials for researchers to study 
different diseases. Your samples will be used together with samples from many other donors, in research studies 
related to your condition or to other conditions. Some of the research findings may help doctors and scientists develop 
new products, such as drugs and diagnostic tests leading to better prevention and treatment of diseases. 
 
Who can donate clinical samples?  
Anyone undergoing treatment at the NUH can donate patient samples. You will be asked to consider donation only if it 
can be done without affecting your health.  
 
What will happen if I agree to donate clinical samples? 
Left-over clinical samples will be transferred to the NUH Tissue Repository where they will be processed and stored 
until they are needed for a study. 
 
Who gets to use the donated clinical samples? 
Researchers at the NUH, NUS and other Singapore institutes and organizations must apply for formal approval from 
the NUH Tissue Repository to use clinical samples for research. Your samples will only be made available for future 
research studies, if those studies have been approved by an Institutional Review Board to make sure they are ethical 
and scientifically sound.  They will ask for a certain number of samples from a particular group of people (for example, 
for research study on diabetes, researchers may ask for research samples from men over age 65 who were 
diagnosed with diabetes). Samples that meet such requirements will be provided to the researchers. Researchers will 
not be able to ask for tissue samples from a specific person.  
 
Do commercial companies have access to my clinical samples? 
In addition to not-for-profit institutions, your donated clinical samples may also be provided to commercial 
organizations for their research and development purposes. It is also possible that your donated tissues might be used 
for commercial development, in ethically approved projects by the collecting agency. The approval process takes into 
consideration the expected future benefits of the proposed tissue usage, whether these be scientific, medical, or 
economic benefits, to Singapore as a whole. The process and criteria for approving requests from commercial 
companies will be at least as careful as for not-for-profit research. 
  




Will I find out results of the research? 
Neither you nor your doctor will receive the results of research done with your donated clinical samples. This is 
because research can take a long time and requires samples from many people before results are known.  Results 
from research using your samples may not be ready for many years and will probably not affect your care right now.  
 
Are there any risks to me from donating? 
There is no additional risk to you during your operative procedure. As the study results will not be entered into your 
medical records, your health insurance will not be affected in any way. 
 
Will researchers have access to my medical records?  
Certain information that forms part of your medical record may be required for interpreting research results.  Some 
examples include your age, gender, past health history, details of your present illness and family history of illnesses. 
Such information will be stored in tissue repository databases, and only approved researchers will be allowed access 
to the information.  Your medical data will only be made available for future research studies, if those studies have 
been approved by an Institutional Review Board to make sure they are ethical and scientifically sound. Rigorous 
measures have been introduced to protect your privacy and none of your personal identifiers (like your name, address 
and NRIC number) will be stored with the information or made available to the researchers.   
 
How will my privacy be protected? 
To ensure that your samples and medical information cannot be linked to you, the samples and medical information 
received by the tissue repository will not contain your identifiable personal data. Instead, these will be replaced by 
code numbers. It will only be possible to retrace the link between the personal data and the codes by a decoding step. 
This decoding only takes place under special circumstances and approval needs to be given by an official ethics 
committee or institutional review board that oversees the ethical aspects of the research.   
 
Does the donation cost me anything? 
There will be no cost to you if you agree to donate your clinical samples for research.  
 
Will I benefit from research done on my clinical samples? 
Your donation of clinical samples is regarded as wholly voluntary and is treated as an outright gift. There will be no 
medical or personal benefit to you arising from the donation of your tissue or from the results of the research 
conducted using such samples. You will not have access to the results of the research conducted on your tissue. The 
results of research may be beneficial to future patients. 
 
Can I change my mind if I do not want to donate my tissue after I have signed or donated? 
Yes. You can notify the hospital and it will terminate your donation process or contact the repository to destroy any 
unused clinical samples that you have already donated.  
 
What happens next? 
Once you have read this pamphlet, you will have an opportunity to speak with your doctor or nurse before/after your 
operative procedure to make sure that all your questions are answered. Your signature on a Consent Form is required 
if you agree to donate your clinical samples. The choice of whether or not to donate is up to you. Refusal to participate 
or withdrawal from participation will not affect your medical management or cause loss of benefits to which you are 
otherwise entitled. Whatever you choose to do, your medical care will not be affected. 
 
Can I contact anyone if I have further questions? 
You may call the NUH Tissue Repository (6772-2310) and ask for the Repository Administrator who will be able to 




For an independent opinion regarding research and the rights of research participants, you may contact a staff 
member of the National University of Singapore Institutional Review Board (Attn: Mr Chan Tuck Wai, at tel 6516 1234 




Thank you for your kind consideration. 
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Abstract
Aim This review aimed to critically appraise, synthesise and present the best available evidence related to the
experiences of patients who have donated their residual biological samples and the impact of this experience on the
type of consent given for future research use of these tissues.
Method The three-step search strategy aimed to find both published and unpublished studies published in English
between 1990 and 2010 in electronic databases (PubMed, CINAHL, Scopus, Embase, PsycINFO,Mednar, PROQUEST).
Using the standardised data extraction tool from the Joanna Briggs Institute, the Qualitative Assessment and
Review Instrument, 131 findings were extracted from the 18 papers included in this review. These findings generated
19 categories and four synthesised findings.
Results The synthesised findings generatedwere related to the different stages of the handling of leftover tissue. The
first synthesised finding: patient consent to the use of leftover tissue is a complex interaction betweenmany factors and
not solely driven by perceptions of benefits to self or others, relates to the collection of the leftover tissue – the initial
consent process. The second synthesised finding: healthcare institutions and regulatory authorities must provide clear
and transparent safeguards and controls, and communicate these to the patient prior to the consenting process,
outlines the issues affecting consent during the processing and storage of the tissues in biobanks or research
institutions. The third synthesised finding: views on ownership and rights to the further use of the leftover tissue varies
between individual patients and influences their willingness to consent to further use, demonstrates the concerns
relating to the safeguards on the collection and storage of leftover tissue. The fourth synthesised finding: patients have
opposing views on the use of their leftover tissue for commercial purposes, reflecting the differing community beliefs
around using leftover tissue for research whichmay provide a commercial benefit to some, but not all, the community.
Conclusion For leftover tissues to be used, patients must clearly understand: the type of consent they are providing
(opt in or opt out); the parameters for the future research use of their leftover tissues; the safeguards put into place to
protect the individual and the donated tissue from unethical use; and the commercial implications of their consent.
Implications for practice This review provides information on patient’s experiences on the collection, storage,
distribution and future use of leftover tissue. These preferences need to be understood when designing a prospective
model of consent regimen which respects patient’s confidentiality and wishes. The information in this review is
especially important for policy-makers designing a prospective model of consent regimen for the use of existing and
previously collected biological samples with no consent taken.
Implications for research Further research is needed to ascertain what factors specifically influence patient’s
willingness to consent for the use of leftover tissue. Factors for further exploration include the effects of culture,
Correspondence: Mr Tuck Wai CHAN, Clinical Research Centre,
National University of Singapore, Block MD 11, #03-02, 10
Medical Drive, Singapore 117597. Email: dprctw@nus.edu.sg
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religion and age. Additionally, further research is required to inform the development of specific consent regimes for
the use of leftover tissue for commercial, stem cell and genetic research.
Key words: ethics, leftover tissues, patient informed consent, residual tissues, tissue bank.
Background
During a patient’s surgery, some biological samples may be
removed from the body to aid in the diagnosis and/or treat-
ment of their medical condition. In a majority of these cases,
not all the tissues removed are needed for the primary use of
clinical diagnosis and treatment of the condition. These left-
over human biological materials, which are normally dis-
carded or destroyed, are useful samples for secondary uses
such as biomedical research, education and training.1,2
Current international statutory laws recognise the
autonomy of a patient’s decision over their body including
leftover or residual biological samples.3 Furthermore, it is
agreed that a patient’s informed consent should be obtained
for the secondary use of these leftover or residual biological
samples for research.4 However, many countries do not have
a standard procedure for obtaining a patient’s consent for
donating leftover biological samples.5 Additionally, the inter-
national regulatory regimes for research using residual tissue
differ widely between countries.6,7 Even where regulations
exist, consent regimens may range from highly project-
specific consent to ‘opt-out’ presumed consent or even no
consent at all.8 For example, the Dutch Medical Treatment
Act allows anonymous tissue samples obtained during
medical treatment to be used for medical research if the
patient has not previously objected. The United Kingdom
Human Tissue Act, however, requires the need to obtain
prior informed consent for the removal, storage and use of
tissues for scheduled purposes.6 Many countries in Asia,
including Singapore, do not have any regulation on this
issue.9
Current established informed consent regimens8,10 include
the following:
• Specific consent (where tissues requested are only used
for that specific project)
• Tiered consent (patients are presented with a menu of
options in their consent documents from which they can
choose the future use of tissue, time of storage, types of
research and whether the tissue can be commercialised)
• Open or blanket consent (a general consent for all future
use of tissues)
• Presumed consent or implicit consent (an implied consent
requiring patients to opt out if they do not wish to donate
their tissues)
There is ongoing discussion about which consent regi-
mens stated above will best comply with the patient’s pre-
ference.11 Some authors argue that presumed consent with
opt-out is sufficient,1,11,12 while others claim that ‘one-time
general’ consent for all future research will suffice.4,13 Addi-
tionally, some authors believe that a specific consent must be
requested from patients for any future use of each and every
sample as it provides more control over its use.14,15 The
implications for this latter model are that it can restrict
research,16 and will not be practicable in actual clinical prac-
tice, because of the additional resources such a consent
requires.17 Others claim that specific informed consent
cannot be obtained on the type of future research as patients
cannot be truly informed,13 because science advances with
time and the type of tissue research may also vary. Hence, it
is impossible for a patient to give informed consent for future
use, which may or may not eventuate. For example, 20 years
ago, no scientist would mention the use of tissues for genetic
sequencing and cloning nor were they able to predict the
future use of such tissues due to the advancement in science.
For the purpose of this review, the following definitions
were used.
Specific consent10,15,18
Specific consent is also known as Project Specific Consent,
where patients are asked to consent to donate for one spe-
cific research project and are re-contacted for each new use
of their specimens that is out of the scope of their original
consent.
Tiered consent8,9
Tiered consent is also known as broad consent (as compared
to specific consent), where patients agree to a menu of
options, which may include general or specific consent for
future use, whether related or non-related disease, time
period, commercial uses, genetic conditions and so on.
Open consent4,19
Open consent is also known as one-time general consent,
generic or blanket consent, where patients consent to an
unlimited range of options such as the types of future
research and time period/s. Patients are given the explicit
choice to opt out during the initial consent process or to
withdraw anytime after they have consented.
Presumed consent1,11
Presumed consent is also known as opt-out or implicit
consent, where patients are informed that their specimens
will be used for future research unless they deny permission
by opting out.
Human biological samples3,9
Human biological samples refer to all kinds of human tissues
derived from living or cadaveric patients, including solid
body tissue, organs, fetuses, blood and other body fluids and
10 TW Chan et al.
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their derivatives, cord blood, embryos, gametes (sperm or
eggs) or any part or derivatives including DNA and cells.
Tissues research3,20
The types of research requiring the used tissues include drug
or clinical trials, cancer research, genetic research, general
knowledge of the body tissue, testing medicine and genetic
cloning.
Aim
The aim of this review was to critically appraise, synthesise
and present the best available evidence related to the expe-
riences of patients who have donated their residual biologi-
cal samples and the impact of this experience on the type of
consent given for the future research use of these tissues.
Search strategy
The search strategy employed in this review was to identify
both published and unpublished studies published between
1990 and 2010 in the English language. These years were
chosen as informed consent for leftover tissues was not
reported earlier than 1990. The databases searched were
PubMed (MEDLINE), CINAHL, SCOPUS, EMBASE, PsycINFO,
Mednar and PROQUEST. The keywords used were: ‘tissue+’,
‘tissues’, ‘biological material’, ‘DNA’, ‘blood’, ‘bone’,
‘consent’, ‘opt-in’, ‘opt-out’, ‘presumed consent’, ‘informed
consent’, ‘research’, ‘biomedical research’, ‘qualitative
research’, ‘empirical research’, ‘biological Samples’, ‘biologi-
cal material’, ‘specimen’, presumed’, ‘samples’, ‘tissue
banking’ and ‘tissue bank’.
The Joanna Briggs Institute’s three-step search strategy
was utilised. An initial limited search of MEDLINE and
CINAHL was undertaken to identify previous systematic
reviews in this area, followed by analysis of the text words
contained in the title and abstract, and of the index terms
used to describe the article. A second search using all iden-
tified keywords and index terms was then undertaken across
all included databases. Third, the reference lists of all iden-
tified reports and articles were searched for additional
studies. The titles and abstracts of all papers identified were
reviewed independently by two of the reviewers against the
inclusion criteria. When the titles and abstracts were incon-
clusive, the full papers were retrieved and reviewed. Articles
that met the inclusion criteria were then reviewed indepen-
dently by two reviewers.
Inclusion criteria
This systematic review considered qualitative publications
and the qualitative mixed-method publications that
included patients, regardless of age or sex, who were
involved in the donation of their residual biological samples
for research. Specific inclusion criteria were: (i) all types of
tissues (namely cancer tissues, reproductive tissues, adult
stem cells, cord blood, gamete, eggs and sperm donation,
embryo and fetal tissue) that were donated or not donated
and were residual/leftover tissues after surgery, removed as
part of a treatment of an illness or were collected for a
medical diagnosis; (ii) tissue collected for research, educa-
tion and teaching; and (iii) tissues stored or used in biologi-
cal specimen banks, tissue banks and biobanking.
Exclusion criteria
As this review only focused on leftover tissues to be stored
for future research use, it excluded research focusing on
organ transplant and tissues collection for therapeutic pur-
poses.
Review method
This systematic review was carried out between September
2010 and March 2011 using the guidelines provided by the
Joanna Briggs Institute System for the Unified Management,
Assessment and Review of Information.
The review considered all published and unpublished
qualitative studies. It did not include opinion pieces or the
grey literature. Studies that focused on qualitative data
including, but not limited to, designs such as phenomenol-
ogy, grounded theory, ethnography, action research and
feminist research, and the qualitative data from mixed
method studies were considered. This review was not limited
by any geographical or cultural settings.
Qualitative papers selected for retrieval were assessed by
two independent reviewers for methodological validity prior
to inclusion in the review using the standardised critical
appraisal instruments from the Joanna Briggs Institute Quali-
tative Assessment and Review Instrument (JBI-QARI). Any
disagreements that arose between the reviewers were
resolved through discussion, or with the assistance of the
third reviewer. As there were 10 criteria for assessment in
JBI-QARI, a cut-off point of 6/10 was set for inclusion of the
studies in this review.
Qualitative research findings from each included paper
were pooled using the JBI-QARI. This involved the extraction
of findings, followed by an aggregation or synthesis of find-
ings on the basis of similarity in meaning (categories). These
categories were then subjected to a meta-synthesis to
produce a comprehensive set of synthesised findings (Level 3
findings), which may be used as the basis for evidence-based
practice.
Study characteristics
The review of initial potential papers (from abstracts and
titles and reference lists of retrieved papers) resulted in a
total of 153 papers. One hundred thirty-one papers were
then excluded following a review of the abstract, or full text
if an abstract was not available, against the inclusion criteria.
The twenty-two remaining papers were then assessed with
four papers excluded for the following reasons: (i) one of the
studies recruited their participants from organ transplants,
which was one of the exclusion criteria for this research21;
and (ii) either the two studies had not discussed the
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themes22 or the themes were not confirmed by the pre-
sented data in the paper.23 One of these latter papers used
the computer program NVivo computer program for analy-
sis23 and did not include any actual textual data from the
participants; thus, the findings were not able to be con-
firmed. The fourth study was not research, as it was a report
of a public consultation conducted by the researchers.24 A
total of 18 papers were included in the review.
Methodological quality
A description of the included studies is provided in Table 1.
In summary, the 18 papers comprised 10
studies25,29,31,32,34,37–40,42 that used focus group methods to
collect the different views and attitudes of patients who had
donated or were considering donating leftover clinical
tissues for research; five studies26–28,30,35,36 that conducted
semi-structured in-depth interviews with individual patients
or potential donors; two studies33,41 which used both focus
groups and semi-structured interviews; and one study which
used interviews and observational techniques35 for collecting
their research data. Among the 18 papers in this review,
eight papers scored 8/10, seven scored 7/10 and three
scored 6/10.
Congruity between research objectives, methods used to
collect data, representation, analysis and interpretation of
data were high in these 18 studies. However, based on
JBI-QARI evaluation methods for qualitative research analy-
sis, all of the authors failed to clearly describe the method-
ology and paradigm used in their research. All authors,
rather than describing the research paradigm and method-
ology, commenced their manuscript with an explanation of
the data collection methods (focus groups, open-ended
questions, semi-structured questions). This limitation was
apparent in both ‘qualitative’ and the ‘qualitative com-
ponent of mixed methods’ papers included in this review.
Thus, it was not possible to assess the methodological
quality of the papers for paradigm and methodology, based
on the JBI-QARI criteria, as the reviewers were unable to
assess the congruity (or otherwise) between the stated
philosophical perspectives and the research methodology
and the research objectives. Nevertheless, studies that dem-
onstrated congruity between the research method, research
questions, objectives, data collection and analysis were
included.
These 18 studies covered the collection of a variety of
different types of human biological samples and tissues from
the patients. These included blood,40,42 DNA,27,29,32,34 cancer
tissue samples,26,36 aborted fetus,38 residual newborn dried
blood,39 skin tissues,28 placental tissues,35 breast cancer and
normal tissues,30,33 post-mortem organs and tissues,41 non-
specific adults’ human biological samples for biobanking,25,37
and biological samples from children (non specific).31 Ethnic
groups included in these 18 studies included Chinese,
Malays, Indians,42 Japanese,25 Non-Hispanics Afro and Afro
Americans,32 Caucasians, English and Irish.26 The age groups
of the study participants ranged from teenagers (15 to
19 years old)31 to the elderly (65–69 years old).41
Results
The findings in the 18 studies were examined using the
three JBI levels of credibility (unequivocal [E], Credible [C] or
Unsupported [U]) (see Appendix I). The findings which did
not have any textual data to support them were considered
to be unsupported and were therefore excluded from the
study. The remaining 131 credible and unequivocal findings
were then clustered into 19 categories and further grouped
into four synthesised findings.
Synthesised finding 1: Patient consent to the use
of leftover tissue is a complex interaction between
many factors and not solely driven by perceptions
of benefits of self or others
More than half of the findings from the review, that is, 69
out of 131 findings explained the different reasons why
patients were willing to donate their leftover tissues for
research (Synthesised finding 1) (Table 2). This theme was
the dominant theme in the analysis and is, therefore, an
important consideration for researchers and policy-makers as
all 18 selected studies included some findings to support the
varied reasons that patients would consider when donating
their biological samples for research.
The most common category of this group of findings was
‘benefits to self’.23,25,27–30,33,36,39 In this category, some
patients donated tissues because they believed that there
was a direct or indirect benefit to themselves. For example,
they may have a medical condition for which further
research may be of direct benefit, either presently or in the
future. This group of patients would thus expect the out-
comes, conclusion and results of the research (whether
accidental findings of a specific individual’s tissue or an
important finding on the medical condition) to be commu-
nicated back to the participants25 in the future.
Trust in research, the medical researchers, the research
organisation and the governance of the donated tissues
was the next dominant category.25–27,30,33–36,38,40 Patients
claimed to have trust in the public good paradigm of
research for societal progress,35 and believed that research-
ers were generating public good in the diagnosis and
treatment of medical conditions. Patients trusted the pro-
fessionals, who gained their consent to use the tissue
samples for research.26 They also trusted that their tissues
would not be misused.40 Patients exhibited confidence in
the research process27 and the meaningfulness of the
research35 to generate new knowledge. Overall, trust is an
important factor in the decision on whether they will
donate their leftover tissues.
A similar category is that of ‘Benefits to others’, where
participants believed that their donated tissues would
benefit society.23,25–28,32,33,36,38,40 This category demonstrated
the altruistic and utilitarian characteristics of society where
patients decided to donate their tissues out of their own
kindness or gratitude. By donating their tissues to research,
some patients believed that they were contributing to
the development of medical science, contributing to the
public good and promoting public interest in the future.25
12 TW Chan et al.
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Whether it was a desire to do good27 or seeing donation
as an act of reciprocity for the years of research,36 some
patients were willing to donate their tissues for research
because of ‘the good’ that the research could bring to
others.36
Some people believed that donating their tissues was one
way to contribute to medical science25 and medical educa-
tion,28 and, thus, they considered this tissue donation as ‘a
gift’ to humanity. This evidence indicated an unconditional
gratitude, with some people not even having a specific
reason26,33,36 for donating their tissues.
A certain group of patients had based their decision on
whether or not to donate their residual tissues based on the
types of research34,36,38,39 to be conducted using their tissues.
For example, some patients objected to cloning,36 or non-
therapeutic research38 or research using stem cells38 and
viewed them as ‘weird’ research36 in which they would not
provide consent for leftover tissue use.
Many patients felt that as there was ‘no risk and harm’25–27
to the donor and as the residual tissues to be donated would
otherwise be discarded or destroyed (as it was considered a
‘waste’36 product of the surgery), they would consent to
further use. The latter group of patients donated because
they believed that they had a ‘dependent relationship’25,32
with the doctors requesting the tissues and consequently felt
obliged to donate.
Synthesised finding 2: Healthcare institutions
and regulatory authorities must provide clear
and transparent safeguards and controls and
communicate these to the patient prior to
the consenting process
A total of 27 findings were grouped into four categories to
support this synthesised finding (Table 3).
Patients believed that research institutions should
have strict controls and ethical safeguards29,34,38 on the col-
lection and storage of their leftover tissues and their related
genetic and medical information. Protection of privacy
and confidentiality25,33,34,39 were the main concerns of the
patients in terms of safeguards and control. Patients were
worried that their private and confidential medical records
and genetic information from the tissue identification
would be revealed to insurance agents and employers.33
This could result in economic and financial loss to patients
in the future. Furthermore, they were concerned about
social and financial discrimination once their medical
confidentiality was breached and thus believed that
there must be safeguards and controls on the medical or
genetic information retained by researchers and their
organisations.34
Mistrust in research organisations and their governance
was one of the main reasons for the refusal to donate their
leftover tissues for research.32,34 Others were also concerned
about the manner and timing in which patients were
approached for donation.30,36 It was important that they did
not feel coerced to donate, or were placed in a vulnerable
position where they felt forced to donate.38
Synthesised finding 3: Views on ownership and
rights to the future use of the leftover tissue
varies between individual patients and influences
their willingness to consent to further use
Eighteen of the 29 findings were related to the issue of
informed consent (Table 4). Most patients (14 out of 18
findings) agreed that leftover tissues should not be collected,
stored, distributed and used for research without the
consent of the patients.23,25,34,35,37,39–41 Other issues men-
tioned by patients were the question of who should give
consent (especially in the case of minors),42 the use of the
stored residual tissues for future research,36 the length of
time of storage37,40 and the type of research performed on
the tissues.26 The types of consent models, whether broad or
specific informed consent, were briefly discussed38 in two
papers,28,37,42 but the authors did not conclude which type of
consent models the interviewed patients preferred. Some
patients considered that they owned their tissue samples25 as
they were once part of their own body12 and they believed
that they had the right to know the fate of their tissues.28,39
These patients were not willing to give up this right of
ownership of their tissues25,30,36,42 when donating the tissues
to research institutions.25,28,33 In contrast, some patients
mentioned that informed consent was not required or nec-
essary,40 and informed consent was not an issue for them.
Some patients preferred that they had an option to opt out
of the donation or possibility to withdraw their donated
samples34 from the tissue repositories, even though they had
a sense of trust that the materials were not misused.29
Synthesised finding 4: Patients have opposing
views on the use of their leftover tissue for
commercial purposes
Patients had divided views on the use of their leftover tissues
by commercial companies to generate profit (Table 5). While
they may be willing to donate for altruistic reason to a
government-funded institution for research of public ben-
efit,36 they cautioned that such donation should not be used
for commercial purpose because they distrusted ‘for-profit’
organisations.12 They had a general suspicion2 of the profi-
teering motive of private companies compared to the
motive of a governmental- or public institution-funded
tissue bank. Others viewed commercial company involve-
ment and third party access and usage of the tissues as
necessary36 and as a part of the development of drugs – a
‘necessary evil’,1 since commercial companies may be able
to advance technology for research. Such patients also cau-
tioned that the use of the tissue must be closely monitored
or regulated.42
Discussion
Most scientists believe that leftover tissues from diagnostics
and procedures are important resources for research.2,36
These stored tissues are currently used for research to under-
stand disease aetiology, future prognosis, treatment or drug
responsiveness, genomics research and genetic testing.2,36
Collecting such tissues and their associated medical data
18 TW Chan et al.
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creates numerous ethical, legal, social, methodological
and technical problems2 at the different stages of tissue
handling.
The findings of this review indicate that most patients
want researchers to understand the various factors that will
impact upon their willingness to consent as well as the type
of consent they are willing to give with regard to the future
use of their leftover tissue. Researchers, research institutions
and statutory bodies have a responsibility to the patients for
the storage, distribution and use of leftover tissues. This duty
of care is particularly important as the tissue donation has
usually been given to progress science either for the indi-
vidual or common good. The refusal of patients to donate
their tissues could result in these tissues being discarded as
thrown away ‘waste’40 and their valuable research potential
would be lost.34
From the review, the most common reasons provided by
the patients when they donated the tissues included benefits
to themselves or others.27 Some patients hoped to have
some direct benefits for themselves and their disease condi-
tions and if not, they hoped that future research using their
tissues could benefit other patients, just like they had ben-
efited from the earlier research done.25 Many patients also
mentioned the ‘trust’ they have, for the researchers and the
research institutions that their tissues will not be exploited
and will be used for a good cause.40 Trust is an important
reason for patients to freely donate their leftover tissues for
research,34 and the betrayal of such trust can lead to lower
donation rates for such tissues.34,42 This ‘trust’ is important
in ensuring continual donations and once this trust is
‘betrayed’, the willingness to donate will decrease. This
‘betrayal of trust’32,34 was described in some of the studies
when the case of UK Alder Hey Hospital’s41 unauthorised
organs retention and other similar cases were men-
tioned.36,41 Commercial company access and uses of the
leftover tissues were discussed in some studies.21,28,34,40 And
the issue of ‘mistrust’ was also highlighted in the commo-
dification of human tissues.21
The findings of this review also indicate that patients are
willing to donate their leftover tissues for research as long as
there are proper safeguards on their confidentiality and pri-
vacy.37,40 Concerns over the use of the biological materials
for genetic research appear to be related to confidentiality
and privacy issues,39 risk to self and family, religious belief,42
potential discrimination32 and loss of employment or insur-
ance coverage.34
One of the secondary objectives of this review was to
examine the patient’s experience and preference on the
different consent models when donating their leftover
tissues. After reviewing the selected papers, no firm conclu-
sions could be reached as few research papers2,13,24 men-
tioned the various consent models. Murphy et al.37 noted
Table 5 Synthesised finding 4: Patients have opposing views on the use of their leftover tissues for commercial purposes
Category Finding Illustration from study
Against financial gains
from my tissues
Critical of a company controlling access for
profit (Levitt & Weldon)34 (U)
I think it is a moral question as well. We are not talking about a
Dyson Hoover here, we are talking about people’s health and
well-being here and I do not like to see it patented. (MG1)
page 315
Distrust was expressed of for-profit
organizations (Skolbekken et al.)40 (U)
If you can imagine that international corporations enter the scene,
and we know what that means . . . with cloning and gene
modification and all that. I am personally against it. That would
be abuse, in my view. (Woman, 60) page 340
General suspicion of the profit motive with
a marked perception of a public/private
divide (Levitt & Weldon)34 (U)
You cannot have a government institution with the taxpayers
paying for it and a private institution making profits out of that
information which is being supplied voluntarily by the public.
The two are not compatible. One is trying to make a profit out
of it, the other may be using it for specific government
purposes. (MG1) page 315
Most patients clearly rejected the idea of
receiving financial compensation for a
tissue donation (Felt et al.)28 (U)
Because we all benefit from it [the donated tissue] if, for example,
a drug against skin cancer will be found; everybody profits! And
why . . . just because I have consented [to donate tissue] . . .
should I cash in now? (P12). page 97
Pro-financial gain
from my tissues
Accept pharmaceutical involvement as a
‘necessary evil’ and suggested greater
personal motivation to participate
(Haddow et al.)29 (c)
People have obviously got, when you have got somebody that has
got a condition in the family then they are more inclined to
help. If you are talking to somebody sitting at the table who did
not have anybody in their family with anything wrong, ‘why
should I bother’, ‘I am not going to gain anything out of this’,
this sort of thing. We have obviously got more something to
gain somewhere down the line possibly, but somebody else
might not have (FG1 R3). page 273
Private company involvement and
third-party access (Morrell et al.)36 (U)
I can see there will be slip-ups; there will be people who do the
wrong thing for profit. I think it is a risk you have got to run.
page 4
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that the patient ‘could be given a choice of broad or study
specific consent at the beginning of a research’1,11,43 whereas
Skolbekken et al.40 noted that patients preferred ‘initial
consent to be active, the need for explicit, active consent for
each new research project was perceived as unnecessary’.20
Depending on whether the tissues are identifiable, coded or
anonymous (with no identifiable patient’s information), the
preference of consent model may differ.34 Some authors had
recommended that coded and anonymous tissues may not
require the same stringent specific consent as identifiable
tissues.3,5,6 Unfortunately, due to the limitation of qualitative
studies available on the models of informed consent, no
determination can be made on the basis of this review as to
exactly which consent model is most preferred by patients.
This suggests the need for such research in the future.2
Conclusion
The four meta-syntheses of the results emphasised that
patients had different concerns at different stages of the
handling of their leftover tissue by researchers and the
research institutions. The three stages of tissue handling are
collection, storage (includes processing) and future use of
the tissues. These stages were illustrated in the four synthe-
sised findings namely: during collection or donation of the
tissues (synthesised finding 1), the patients had expressed
that they have different reasons for donating their leftover
tissues; during the processing and storage of the tissues in
biobanks or research institutions (synthesised finding 2)
where patients had concerns on the safeguards and controls
on the collection and storage of their leftover tissues; and the
subsequent distribution or access the tissues and the subse-
quent usage of the tissues for future research (synthesised
findings 3 and 4) where patients have different views on
their ownership and rights on the ethical uses of their tissues,
and whether they would allow the commercial access and
use of their tissues.
From the analysis, we can conclude that institutions
requesting such a donation need to first establish good
governance systems for the collection and storage of the
tissues, as well as a system for protecting the rights and
confidentiality of the patients. Most patients wanted an
ethical and effective system for deciding on the future use of
their tissues, especially when a full informed consent was not
obtained from the donor at the point of donation. Institu-
tions and research organisations need to play an important
custodian role for these stored tissues to ensure that the
medical research is ethically conducted and will generate
public good. The results of this review may also be useful in
increasing the number of tissue donations, which is an
important and valuable source of samples for biomedical
research on any specific disease of future patients. Increasing
the patients’ acceptance and positive donation rate are
important because these leftover or residual tissues have no
direct cost to the patients and the research institutions, most
of which consider the tissues as surgical waste that are to be
discarded rather than used for research. Thus, understand-
ing patient experiences and attitudes could improve future
donation rates of these important medical resources.
Implications for practice
Several implications for practice may be derived from this
review. Each of these recommendations is assigned a level of
evidence according to JBI criteria (Appendix II).
1 Healthcare professionals should be aware that patient’s
consent to the use of their leftover tissues is a complex
interaction between many factors and not solely driven by
perceptions of benefits to self or others. (Level 1 Evidence)
2 Healthcare institutions and regulatory authorities must
provide clear and transparent safeguards and controls
and communicate these to the patient prior to the
consent process on the storage, subsequent distribution
and future use of the tissue. In particular, consent should
ensure the patients privacy and confidentiality are pro-
tected. (Level 1 evidence)
3 Healthcare professionals should be aware that the
views on ownership and rights to the future use of leftover
tissues will vary between individual patients and will
influence their willingness to consent to further use.
(Level 1 Evidence)
4 Healthcare professionals, institutions and regulatory
authorities should be aware that patients have opposing
views on the use of their leftover tissue for commercial
purposes. (Level 1 Evidence)
Implications for research
This systematic review has highlighted the paucity of good
quality research into the meaningfulness of being a donor
of leftover tissue. Further research studies should be under-
taken to ascertain:
• The patient’s preference on the different models of
informed consent, as these different models may increase
patient’s willingness to donate the leftover tissues. The
study should ascertain if there is a need for re-consent
when a new researcher requires the tissues
• Whether culture, age, ethnicity or religion affect patients’
willingness to donate their leftover tissues
• Whether informed consent models for donating tissues
should be based on the types of identifiable information
attached to the tissues
• The patients’ reasons to donate their leftover tissues and
how to gain patients’ trust in order to increase their
willingness to donate
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Appendix I
Level of evidence (JBI)
Joanna Briggs Institute level of evidence for qualitative studies
Degrees of
credibility
Unequivocal (U) Unequivocal relates to evidence beyond
reasonable doubt which may include
findings that are matter of fact, directly
reported/observed and not open to
challenge.
Credible (C ) Credible relates to those findings that are,
albeit interpretations, plausible in the light
of the data and theoretical framework.
They can be logically inferred from the
data. Because the findings are interpretive
they can be challenged.
Unsupported (S) Unsupported is when the findings are not
supported by the data.
Appendix II




1 Metasynthesis of research with unequivocal synthesised
findings
2 Metasynthesis of research with credible synthesised
findings.
3 (a) Methasynthesis of test/opinion with credible
synthesised findings
(b) One or more single research studies of high quality
4 Expert Opinion
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II. DECLARATION OF THE PRINCIPAL INVESTIGATOR 
The information provided in this form is correct. 
a. I will not initiate this research until I receive written notification of NUS-IRB 
approval and regulatory authority approval (if applicable). 
b. I will not initiate any change in protocol without prior written approval from NUS-
IRB except when it is necessary to reduce or el im inate risk to the subject. 
c. I will promptly report any unexpected or serious adverse events, unanticipated 
problems or incidents that may occur in the course of this research. 
d. I will ma intain all relevant documents and recognize that the NUS-IRB staff and 
regulatory authorities may inspect these records. 
e. I understand that failure to comply with all applicable regulations, institutional and 
NUS-IRB policies and requirements may result in the suspension or termination of 
this research. 
f. I declare that there is no existing or potential conflict of interest for any of the 
investigators participating in this research. 
Remarks (if any) : 
Eng Chon Boon 
Principal Investigator's signature Date 
Phone : 6772 2379 Fax 6772 2346 
Mailing Address: NUH/NUS Tissue Repository , National University Hospital, Department of 
Pathology, 5 Lower Kent Ridge Road, Singapore 119074 
Email : medecb@nus.edu.sg; 
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III. CO-INVESTIGATORS 
All co-investigators who have a responsibility for the consent process or direct data 
collection for this research should be listed below. Multiple copies of this form may be 
submitted as necessary. All co-investigators need not sian on the same form. 
Name : Chan Tuck Wai 
Position: PhD Student 
Department: Centre for Biomedical Ethics 
Institution: NUS 
Signature of Co-investigator 
Name: Dr Rajeev Singh 
Position: Deputy Head 
Department: NUH/NUS Tissue Repository 
Institution: NUS 
Signature of Co-investigator 
Name: Margaret Low Cheng Lian 
Position: Principal Consent Nurse 
Department: NUH/NUS Tissue Repository 
Institution: NUS 
Signature of Co-investigator 
Name: Lim Lay Pheng 
Position: Consent Nurse 
Department: NUH/NUS Tissue Repository 
Institution: NUS 
Signature of Co-investigator 
Name: Tee Suan Geok Felicia 
Position: Consent Nurse 
Department: NUH/NUS Tissue Repository 
Institution: NUS 
Signature of Co-investigator 
NUS-IRB Application Form for SBER 











Fax: 6772 2346 
Date 
Email: lay 12heng lim@nuhs.edu.sg 
Phone: 67722310 




Fax: 6772 2346 
Date 
Version 2, dated 27 July 2011 
IV. COMMENTS OF HEAD OF DEPARTMENT* (Please c1rcle accordingly) 
1. Significance: 
Does the research address an important problem? Will YES NO 
the research affect concepts and methods that drive 
the field? 
2. Approach: 
Is the conceptual framework adequately developed? YES NO 
Are the design, methods and analyses adequately 
developed and appropriate? 
3. Innovation: 
Does the research challenge existing paradigms? Does YES NO 
it employ novel concepts approaches and methods? 
4. Principal Investigator: 
Is the Principal Investigator appropriately trained to YES NO 
conduct this research? Does the Principal Investigator 
have evidence of commitment (e.g. previous track 
record)? 
5. Environment: 
Is the Principal Investigator's environment suited to YES NO 
perform the research? Is there an adequate 
patient/subject pool and are there adequate resources? 
6. Peer/ Scholarly/Scientific Review: 
Has this project undergone a peer/ scholarly/ scientific YES NO 
review? 
7. Budget (to be completed ONLY for funded 
projects): 
If this research is funded, are the projected costs YES NO 
appropriate (i.e. accurate)? 
Comments 
I acknowledge that this research is in keeping with standards set by the Principal 
Investigator's department. 
Signature of Head I Chief I Vice-Dean(Research)* 
Name: Teh Minq 
Date 
Position: Head of 
Title: Assoc Prof Department of 
Pathology 
*The Department Representative can be the Head I Chief I Research Head of the PI's Department. 
If the PI or co-investigators is the Head or Chief of PI's Department, this section should be completed by the Vice-Dean (Research) 
or Dean of the Faculty . 
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**IMPORTANT- Please complete Section V and VI, only if your existing 
research protocol submitted do not contain the relevant sections. 
V. ABSTRACT OF RESEARCH PROPOSAL 
In no more than 300 words, describe concisely the specific aims, hypotheses, 
methodology and approach of the application, indicating where appropriate the 
application's importance to science, existing knowledge and applications. The abstract 
must be self-contained so that it can serve as a succinct and accurate description of the 
application when separated from it. Please use lay terms. If this is not possible. the 
technical terms should be explained in simple language. 
Background: Residual or leftover clinical tissues are valuable resources for biomedical 
research. There is on-going discussion about the methodological, legal, and ethical 
issues on the collection, storage and use of these tissues for future research. This 
research will conduct qualitative interviews with human subjects who had previously 
agreed or not agreed to donate of their leftover tissues to NUH/NUS Tissue Repository. 
Objectives: The aim of this research is to understand potential or current donors' 
preferences, experiences and willingness to donate their leftover tissues. 
Data collection & analysis: The qualitative interviews will be conducted by the research 
team after the subjects have made their decisions as to whether they wished to donate 
their leftover tissues for research. The qualitative interview results will be analysed 
thematically. 
Implications for Practice: The results from this research can assist researchers and 
policy makers understand the experiences of donors and their attitudes and preferences 
on the collection, storage, distribution and use of their leftover tissue for research. 
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VI. PROTOCOL CHECKLIST 
Organise details of the research protocol under the following headings (in no more than 7 pages). 
1. Specific Aims: 
1.1 State concisely and realistically what the research described in this application is intended to 
accomplish and/or what hypothesis is to be tested. 
The aim of this research is to understand potential or current donors' preferences, 
experiences and willingness to donate their leftover tissues. 
2. Introduction: 
2.1 Briefly describe the background to the current proposal. 
Residual or leftover clinical tissues are valuable resources for biomedical research. There is on-
going discussion about the methodological, legal, and ethical issues on the collection, storage and 
use of these tissues for future research. This research w ill conduct qualitative interviews with 
subjects who have previously agreed or not agreed in the donation of their leftover tissues to 
NUH/NUS Tissue Repository. 
2.2 State concisely the importance of the research described in this application. 
Residual or leftover clinical tissues are valuable resources for biomedical research. The results from 
this research can assist researchers and policy makers understand the experiences of donors and 
their attitudes and preferences on the collection, storage, distribution and use of their leftover 
tissue for research. 
2.3 Relevant references 
1. Vermeulen E, Schmidt MK, Aaronson NK, Kuenen M, van der Valk P, Sietses C, et al. Opt-out plus, 
the donors' choice: preferences of cancer patients concerning information and consent regimen 
for future research with biological samples archived in the context of treatment. J Clin Pathol. 
2009 Mar;62(3):275-8. 
2. Oosterhuis JW, Coebergh JW, van Veen EB. Tumour banks: well-guarded treasures in the 
interest of patients. Nat Rev Cancer. 2003 Jan;3(1):73-7. 
3. Goodson ML, Vernon BG. A study of public opinion on the use of tissue samples from living 
subjects for clinical research. J Clin Pathol. 2004 Feb;57(2):135-8. 
4. Wendler D. One-time general consent for research on biological samples: is it compatible with 
the Health Insurance Portability and Accountability Act. Archives of Internal Medicine. 
2006;166(14):1449-52. 
3. Preliminary Studies: 




4.1 Discuss in detail the design and procedures to be used to accomplish the specific aims of the 
research. 
The qualitative interviews will be conducted by the research team after the potential donors 
(research subjects) had already decided whether or not they wanted to donate their leftover 
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tissues for research. The qualitative interview results will be analysed thematically. 
Subjects' verbal informed consent will be sought before the interviews begin. Each subject 
participates in one 30-minute interview at a time convenient for them. The interviewers are the 
NUH/NUS tissue Consent Nurses working in NUH, which is where the interviews will take place. The 
interviews will be conducted only in the English Language and audio-recorded if the subjects 
consent to it. 
4.2 Include details on sample size calculation and the means by which data will be analysed and 
interpreted. 
Qualitative interview of 100 donors. 
4.3 List all subject-related procedures. Please also describe the subject research visits (frequency 
and procedures involved) .For studies with multiple visits, please attach visits schedule. 
Subjects will participate in one qualitative interview each that lasts about 30 minutes. Subjects will 
not be re-contacted after the interviews. 
4.4 What are the anticipated benefits and risks to human subjects participating in this research? 
There are no direct benefits to subjects. 
4.5 Discuss the potential difficulties and limitations of the proposed procedures and alternative 
approaches to achieve the aims. Please provide information on how these limitations/ difficulties 
faced may be minimized or overcome. 
Subjects may be reluctant to participate in the interviews. They do not need to answer any 
question that they feel uncomfortable with and can withdraw their participation at any time during 
the interview. 
4.6 Will any part of the procedures be placed on audiotape, film/video, or other electronic media? 
l:8l Yes D No 
If Yes, what is the media? Explain how the recorded information will be used? How long will the 
tapes, etc, be retained and how will they be disposed of? 
The interview will be recorded with the subjects' consent for the purpose of transcribing into field 
notes for analysis. The informed consent process will be recorded. No personal identifiable 
information will be recorded in the questionnaire and the recording. If subjects feel uncomfortable 
with the audio-recording, field notes will be taken instead. 
5. Additional Information on Methodology: 
5.1 If research involves creating new databases or making use of archived/ existing databases, 
please complete the sections below. In addition, if your research involves making use of archived/ 
existing databases, please furnish the necessary documentation, e.g., permissions to use those 
databases. 
5.1.1 Where will the data be stored? 
The database will be stored in a Password protected PC at the NUH/NUS tissues repository for seven years. 
5.1 .2 Who will have access to the data? 
The research team will have access. 
5.1.3 What will happen to the data after research completion? 
The data collected, including transcripts and audio-recordings, will be stored in a Password 
protected PC at the NUH/NUS tissues repository for a maximum period of seven years after the 
last publication, afterwhich it will be destroyed. 
5.1.4 Any other remarks? 
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6. Characteristics of Target subjects I Target Subject Data: 
6.1 What is the number of subjects to be enrolled? Give a breakdown by institution for multi-
center studies (if applicable). 
Institution/ Site of Recruitment Total Men Women Children 
NUH 100 50 50 
6.2 Lower Age Limit: 21 Upper Age Limit (if any): 80 
6.3 Total number of subjects targeted for enrolment worldwide (for international studies) : nil 
6.4 Are there any subject recruitment restrictions based on race of the subject? No. 
6.5 Inclusion criteria : Any donor who have been asked to donate their leftover tissues. English 
speaking only. 
6.6 Exclusion criteria: Any donors who are unable to speak English or understand the research . 
6.7 Are the subjects vulnerable or in a dependent relationship with the researchers? 
0 Yes !8:1 No 
If Yes please provide details. 
7. Participant Information Sheet and Written Informed Consent Form: 
7.1 The PI is responsible for ensuring that all research subjects give informed consent before 
enrolling into the research. Please submit a copy of the Participant Information Sheet and 
Consent Form. (A sample of Participant Information Sheet and Consent Form is available on the IRB 
website at http://www.nus.edu.sg/ irb/ Guide.htm) 
7.2 Summarise the consent procedure. Please specify how will informed consent be obtained and 
who will obtain consent. 
The NUH/NUS tissue consent nurse will routinely ask research subjects whether they wish to 
donate their leftover tissues before their scheduled surgery. After the nurses have noted their 
decisions on the donation, the subjects will then be invited to participate in this research . They will 
be visited by the research team after their surgery for the interview. 
7 .3 If waiver of consent is required, please justify how your research meets the following 
criteria : 
(The NUS-IRB may waive the requirement to obtain informed consent if the NUS-IRB finds that the research 
meets the following 4 criteria. Please note th{2t all studies involving_ deceg_tion must aQ.{2.1't. for waiver of 
informed consent. Sub[ects in these studies must be debriefed.) 
YE:2 A WAIVER OF DOtUMENTATION OF INFORMED tQ~~~NT IS R~QU!;STED, 
7.3.1 The research involves no more than m inimal risk to the subjects. 
This is a qualitative interview. Only demographic information, e.g., age, sex, etc, will be 
transferred from the initial Tissue Repository Consent Form to the researchers' records. Subjects' 
identities will be coded on the questionnaire and the Tissue Repository Consent Form. 
7.3.2 The waiver or alteration will not adversely affect the rights and welfare of the subjects. 
Yes, subjects can withdraw anytime they wish . 
7.3.3 Whenever appropriate, the subjects will be provided with additional pertinent information 
after participation. 
Yes. 
7.3.4 The research could not practicably be carried out without the waiver or alteration. 
Not applicable. 
8. Recruitment Process: 
8.1 Explain the process of recruitment in detail. For example state how the list of potential research 
subjects will be obtained. Please submit a copy of any advertisements/ posters that will be used. 
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The NUH/NUS tissue consent nurse routinely asks research subjects whether they wish to donate 
their leftover tissues to the NUH/NUH Tissue Repository before any surgical procedures. After 
subjects have made their decision on the donation, they will be given a short explanation of this 
research study and invited to participate. If the subject agrees to participate in the interview, they 
will be visited by the research team after their surgery. The researcher will first call on the research 
subjects 2 to 3 days post surgery to check with the donor that s/he feels well enough to be 
interviewed. In any case, the NUH/NUS tissue Consent Nurse are usually make their rounds 
routinely in the wards and will visit the subjects in any case. No advertisements will be used. 
If subject prefer to be interviewed during their clinical follow-up appointments or other visits, the 
research team will arrange with the subject for a suitable date for this interview, to the 
convenience of the research subjects. 
9. Timelines: 
9.1 What are the estimated start and end dates of the research? 
Start Date: Aug 2011 End Date: Aug 2012 
9.2 Indicate the duration of subject involvement in the research. Please also state the recruitment 
period. 
About 30 minutes. 
10. Financial Aspects/Conflicts of Interest: 
10.1 Who will be responsible for research related costs? For sponsored research, list the costs that 
will be borne by the sponsor. 
NIL 
10.2 For industry sponsored research, please complete the following. 
11.2.1 Name of the sponsor company? 
NIL 
11.2.2 Address of the sponsor? 
NIL 
11.2.3 Sponsor contact person? 
NIL 
11.2.4 Have any of the investigators received any financial support, sponsorship from the 
company supporting this research? 0 Yes [8J No 
11.2.5 Do any of the investigators hold any ownership interest, e.g. stock options in this 
company? 0 Yes t8J No 
11 .2.6 Is the sponsor offering any incentive connected with subject recruitment or 
completion of research (e.g. finders' fee, recruitment bonuses etc) that will be paid to 
the research staff? 0 Yes [8J No 
11.2.7 If you have answered 'yes' to Q 10.2.5, please elaborate. 
NA 
11 .2.8 Any other remarks? 
NIL 
10.3 Will subjects receive financial payment/ incentive for participation? If yes, please elaborate. 
No, subjects are not reimbursed for participating in the research. 
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VII. ATTACHMENT CHECKLIST: 
Document 
Research Protocol (latest version)*+ 
Grant Application Form 
Participant Information Sheet and Consent Form+ 
Investigator(s)' CV 
Survey Form(s)/Questionnaire(s) I Interview Guide+ 
Data Collection Form+ 
Advertisement for Recruitment of Subjects+ 
Letter of Invitation to Subjects+ 
Relevant Publications 
Subject Payment Details* 
Financial Agreement 

























*If information is not included in sections V and VI of the application form. 
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PARTICIPANT INFORMATION SHEET !!!~!:'~ ~ ofSingapore 
1. Project title : 
Patients' experiences towards the donation of their leftover tissues and the impact of 
these experiences on the type of consent given for secondary use. 
2. Principal Investigator and co-investigator(s), if any, with the contact number and 
organization. 
Dr Eng Chon Boon 
Dept of Pathology, National University of Singapore 
Phone: 6772 2379 Email: medecb@nus.edu .sg; 
Address: NUH/NUS Tissue Repository, 5 Lower Kent Ridge Road, Singapore 119074 
3. What is the purpose of this research? 
The aim of this research is to understand potential or current donors' preferences, 
experiences and willingness to donate their leftover tissues. 
You are invited to participate in a research. This information sheet provides you with 
information about the research. The Principal Investigator or his/her representative will 
also describe this research to you and answer all of your questions. Read the 
information below and ask questions about anything you don't understand before 
deciding whether or not to take part. 
4. Who can participate in the research? What is the expected duration of my 
participation? What is the duration of this research? 
Any English speaking potential or current donor who has been asked to donate their 
leftover tissue can participate in this interview research. 
The NUH/NUS tissue consent nurse will routinely ask research subjects whether they 
wish to donate their leftover tissues before their scheduled surgery. After the nurses 
have noted their decisions on the donation, the subjects will then be invited to 
participate in this research. They will be visited by the research team after their surgery 
for the interview. 
Subjects' verbal informed consent will be sought before the interviews begin. Each 
subject participates in one 30-minute interview at a time convenient for them. The 
interviewers are the NUH/NUS tissue Consent Nurses working in NUH, which is where 
the interviews will take place. The interviews will be conducted only in the English 
Language and audio-recorded if the subjects consent to it. 
5. What is the approximate number of participants involved? 
Approximately 100 research subjects will be involved in this research. 
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6. What will be done if I take part in this research? 
The qualitative interviews will be conducted by the research team after the potential or 
current donors (research subjects) had already decided whether or not they wanted to 
donate their leftover tissues for research . The qualitative interview results will be 
analysed thematically. 
7. How will my privacy and the confidentiality of my research records be protected? 
This is a 30 minutes qualitative interview. We will not collect any personal information 
from you. Only demographic information, e.g., age, sex, etc, will be transferred from 
the initial Tissue Repository Consent Form to the researchers' records. Subjects' 
identities will be coded on the questionnaire and the Tissue Repository Consent Form . 
The data collected, including transcripts and audio-recordings, will be stored in a Password 
protected PC at the NUH/NUS tissues repository for a maximum period of seven years after 
the last publication, afterwhich it will be destroyed. 
8. What are the possible discomforts and risks for participants? 
No risks or discomforts are expected for participants participating in th is research. 
9. What is the compensation for any injury? 
This is an interview. No injury is expected from participating in this research. Hence, 
there will be no compensation awarded. 
10. Will there be reimbursement for participation? 
Participants are not reimbursed for participating in this research. 
11. What are the possible benefits to me and to others? 
There is no direct benefit to you by participating in this research. The results from this 
research can assist researchers and policy makers understand the experiences of 
potential or current donors and their attitudes and preferences on the collection, 
storage, distribution and use of their leftover tissue for research. 
12. Can I refuse to participate in this research? 
Yes, you can. Your decision to participate in this research is voluntary and completely 
up to you. You can also withdraw from the research at any t ime without giving any 
reasons, by informing the principal investigator and all your data collected will be 
discarded. 
13. Whom should I call if I have any questions or problems? 
Please contact the Principal Investigator, Dr Eng Chon Boon at telephone 65- 6772 2379 
and email medecb@nus.edu.sg for all research-related matters and in the event of 
research-related injuries. 
For an independent opinion regarding the research and the rights of research 
participants, you may contact a staff member of the National University of Singapore 
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Institutional Review Board (Attn: Ms Tan Hui Cheng, at telephone 65- 6516 7359 or 
email at irb@nus.edu.sg). 
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Tissue Consent- Interview Guide 
Code 
Highest Educational Level : 
1. University/Post Graduate 
2. Diploma 
3. A Level 
4. 0 Level 
5. Others _______ _ 
Reason for donation 
1. Can you tell me why you have or have not consented or given permission to the donation of your tissues? 
Do you know of any benefits and risk in this donation and the uses of your tissues? (Prompt: Example of risk and Benefits) 
What would influence your decision? 
Do you think you would have given consent if it was a different organ? For example, the brain versus the skin? Why? 
Types of consent models 
2. Do you remember that you have earlier agreed to donate your leftover tissues in the surgical consent form? 
(Prompt: show surgical consent) 
Do you think that is sufficient information or do you think you need more detailed information on such donation? Why? 
(Prompt: show NUHS TR detailed consent) 
Pre or Post surgery Consent 
3. When is the best time for someone to approach you to get your consent or permission to donate the leftover tissue? 
Prompts: 
I. Before admission at the clinic when told (ask why or why not) 
II. On admission (ask why or why not) 
Ill. After the surgery procedure (ask why or why not) 
IV. After the tissue has been fully analyzed (ask why or why not) 
Who would be the most appropriate person to ask for this consent or permission? Why? 
(Prompts: The doctors, the nurse or the researchers?) 
Withdrawal and Rights 
4. If you change your mind to this donation, what do you think would be the best way to do this? Under what circumstances would 
you want to change your decision whether to donate your tissues or not? 
Medical records and privacy 
5. Do you object, if the researchers, who are carrying out research on your donated specimen, know about your name and IC number 
etc., and medical records for their purpose of the research if you knew they would keep such information confidential? 
{Prompts: If they object, why. Or If they don' t object, why) 
Governance, safeguard and controls 
6. Can you tell me who you think should monitor the use of your leftover tissues and the consent? Are you aware of any safeguards 
and controls available for your tissues, and what governance would you expect? 
(Prompts: IRB, Government, Insti tution, Doctors, Researcher. And explore why/why not?) 
Access and uses of tissues 
7. Do you have any objection if the following groups of researchers have access your tissues for their research? (e.g. How do you feel 
about the commercial use or __ of donated left over tissue?) 
• Hospital researchers, University scientists, and students (and why) 
• Government funded agency (and why) 
• Commercial laboratories and Drugs companies (and why) 
• researchers and 
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Tissue Consent- Interview Guide 
Code Number: 
Highest Educational Level : 
1. University/Post Graduate 
2. Diploma 
3. A Level 
4. 0 Level 
5. Others _______ _ 
Reason for donation 
1. Can you tell me why you have or have not consented or given permission to the donation of your 
tissues? 
Do you know of any benefits and risk in this donation and the uses of your tissues? {Prompt: Example of 
risk and Benefits} 
What would influence your decision? 
Do you think you wou ld have given consent if it was a different organ? For example, the brain versus 
the skin? Why? 
Types of consent models 
2. Do you remember that you have earlier agreed to donate your leftover tissues in the surgical 
consent form? {Prompt: show surgical consent) 
Do you think that is sufficient information or do you think you need more detailed information on such 
donation? Why? {Prompt: show NUHS TR detailed consent} 
Pre or Post surgery Consent 
3. When is the best time for someone to approach you to get your consent or permission to donate 
the leftover tissue? 
I. Before admission at the clinic when told (ask why or why not) 
II. On admission (ask why or why not) 
Ill. After the surgery procedure (ask why or why not) 
IV. After the tissue has been fully analyzed (ask why or why not) 
Who would be the most appropriate person to ask for this consent or permission? Why?(Prompts: The 
doctors, the nurse or the researchers?) 
Withdrawal and Rights 
4. If you change your mind to this donation, what do you think would be the best way to do this? 
Under what circumstances would you want to change your decision whether to donate your tissues or not? 
Medical records and privacy 
5. Do you object, if the researchers, who are carrying out research on your donated specimen, know 
about your name and IC number etc., and medical records for their purpose of the research if you knew they would 
keep such information confidential? {Prompts: if they object, why. Or If they don't object, why) 
Governance, safeguard and controls 
6. Can you tell me who you think should monitor the use of your leftover tissues and the consent? 
Are you aware of any safeguards and controls available for your tissues, and what governance would you expect? 
(Prompts: IRB, Government, Institution, Doctors, Researcher. And explore why/why not?) 
Access and uses of tissues 
7. Do you have any objection if the following groups of researchers have access your tissues for their 
research? (e.g. How do you feel about the commercial use or __ of donated left over tissue?) 
• Hospital researchers, University scientists, and students (and why) 
• Government funded agency (and why) 
• Commercial laboratories and Drugs companies (and why) 
• Foreign researchers and foreign institutions (and why) 
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Appendix 6:  Statistical Analysis 
 
Research Ethics and Consent on the Collection and Use of Human Biological Materials: A 
Singapore Perspective 
 
gender * response Crosstabulation 
 
response 
Total No Yes 
gender Female Count 28389 67020 95409 
% within gender 29.8% 70.2% 100.0% 
Male Count 15819 56097 71916 
% within gender 22.0% 78.0% 100.0% 
Total Count 44208 123117 167325 
% within gender 26.4% 73.6% 100.0% 
 
The odds of males in willing to donate the human biological materials is significantly higher 





race * response Crosstabulation 
 
response 
Total No Yes 
race Chinese Count 29070 86207 115277 
% within race 25.2% 74.8% 100.0% 
Malay Count 5633 12831 18464 
% within race 30.5% 69.5% 100.0% 
Indian Count 4362 9570 13932 
% within race 31.3% 68.7% 100.0% 
Eurasian Count 113 309 422 
% within race 26.8% 73.2% 100.0% 
Sikh Count 1287 3770 5057 
% within race 25.4% 74.6% 100.0% 
Other Races Count 3744 10433 14177 
% within race 26.4% 73.6% 100.0% 
Total Count 44209 123120 167329 
% within race 26.4% 73.6% 100.0% 
p < 0.001 
 
a) Chinese compared with Malay: The odds of Chinese in willing to donate the human 
biological materials is significantly higher compared with Malay (OR = 1.30, 95% CI 
1.25 to 1.36, p < 0.001). 
b) Chinese compared with Indian: The odds of Chinese in willing to donate the human 
biological materials is significantly higher compared with Indian (OR = 1.35, 95% CI 
1.29 to 1.42, p < 0.001). 
c) Chinese compared with Eurasian: OR = 1.08, 95% CI 0.82 to 1.44, p = 1 
d) Chinese compared with Sikh: OR = 1.01, 95% CI 0.93 to 1.10, p = 1 
e) Chinese compared with Other Races: The odds of Chinese in willing to donate the human 
biological materials is significantly higher compared with other races (OR = 1.06, 95% CI 






religion * response Crosstabulation 
 
response 
Total No Yes 
religion Buddhism Count 9907 28827 38734 
% within religion 25.6% 74.4% 100.0% 
Christianity Count 3508 9937 13445 
% within religion 26.1% 73.9% 100.0% 
Hinduism Count 2023 4497 6520 
% within religion 31.0% 69.0% 100.0% 
Islam Count 5551 12782 18333 
% within religion 30.3% 69.7% 100.0% 
Roman Catholicism Count 68 189 257 
% within religion 26.5% 73.5% 100.0% 
Sikhism Count 191 446 637 
% within religion 30.0% 70.0% 100.0% 
Non-Denomination Count 2860 8790 11650 
% within religion 24.5% 75.5% 100.0% 
Other Religion Count 20101 57652 77753 
% within religion 25.9% 74.1% 100.0% 
Total Count 44209 123120 167329 
% within religion 26.4% 73.6% 100.0% 
p < 0.001 
 
a) Buddhism compared with Christianity: OR = 1.03, 95% CI 0.97 to 1.09, p = 1 
b) Buddhism compared with Hinduism: The odds of Buddhism in willing to donate the 
human biological materials is significantly higher compared with Hinduism (OR = 1.31, 
95% CI 1.21 to 1.42, p < 0.001). 
c) Buddhism compared with Islam: The odds of Buddhism in willing to donate the human 
biological materials is significantly higher compared with Islam (OR = 1.26, 95% CI 1.20 
to 1.33, p < 0.001). 
d) Buddhism compared with Roman Catholicism: OR = 1.05, 95% CI 0.71 to 1.53, p = 1 
e) Buddhism compared with Sikhism: OR = 1.25, 95% CI 0.98 to 1.58, p = 0.082 
f) Buddhism compared with Non-Denomination: OR = 0.95, 95% CI 0.89 to 1.01, p = 0.178 




age group * response Crosstabulation 
 
response 
Total No Yes 
age group 0 to 49 Count 19986 48050 68036 
% within age group 29.4% 70.6% 100.0% 
50 and above 50 Count 24223 75070 99293 
% within age group 24.4% 75.6% 100.0% 
Total Count 44209 123120 167329 
% within age group 26.4% 73.6% 100.0% 
The odds of patients who were 50 and above 50 years old in willingness to donate the human 
biological materials were significantly higher compared with those who were below 50 years 
old (OR = 1.29, 95% CI = 1.26 to 1.32, p < 0.001). 
 
 
fee * response Crosstabulation 
 
response 
Total No Yes 
fee Private Count 14033 44378 58411 
% within fee 24.0% 76.0% 100.0% 
Subsidised Count 30150 78685 108835 
% within fee 27.7% 72.3% 100.0% 
Other Fee Schedule Count 26 57 83 
% within fee 31.3% 68.7% 100.0% 
Total Count 44209 123120 167329 
% within fee 26.4% 73.6% 100.0% 
p < 0.001 
 
a) Private compared with Subsidised: The odds of those who had private fee schedule in 
willingness to donate the human biological materials were significantly higher compared 
with those who had subsidised fee schedule (OR = 1.21, 95% CI 1.18 to 1.24, p < 0.001). 





Rate of increase per year 
 
Coefficientsa
-34 50.7 00 12 32.98 5 -2.799 .02 7 -63 66.2 46 -53 5.15 4





B Std. Erro r




t Sig. Lo wer Bound Up per Bound
95 % Co nfidence Interv al for
B
Dependent Variable: percenta. 
 
rate of increase per year = 1.76% (95% CI 0.30% to 3.21%), p = 0.024 
 
Slide 31. Comparison by gender 
gender * response Crosstabulation
60 409 25 038 85 447
70 .7% 29 .3% 10 0.0%
49 020 13 757 62 777
78 .1% 21 .9% 10 0.0%
10 9429 38 795 14 8224
73 .8% 26 .2% 10 0.0%
Co unt
% within  gen der
Co unt
% within  gen der
Co unt













102 2.34 3b 1 .00 0
102 1.96 0 1 .00 0
103 4.79 9 1 .00 0
.00 0 .00 0
102 2.33 6 1 .00 0
148 224
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 16430.77.b. 
 
 
  total yes % 
lower 95% 
CI upper 95% CI 
female 85447 60409 70.70 70.39 71.00 




Comparison by race 
 
Combining Eurasian, Japanese & others 
 
race * response Crosstabulation
770 05 256 73 102 678
75.0% 25.0% 100 .0%
115 35 498 3 165 18
69.8% 30.2% 100 .0%
885 40 306 56 119 196
74.3% 25.7% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










198 .591b 1 .00 0
198 .321 1 .00 0
192 .915 1 .00 0
.00 0 .00 0
198 .590 1 .00 0
119 196
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 4248.26.b. 
 
race * response Crosstabulation
770 05 256 73 102 678
75.0% 25.0% 100 .0%
853 0 380 7 123 37
69.1% 30.9% 100 .0%
855 35 294 80 115 015
74.4% 25.6% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt












198 .071b 1 .00 0
197 .764 1 .00 0
191 .162 1 .00 0
.00 0 .00 0
198 .070 1 .00 0
115 015
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 3162.15.b. 
 
race * response Crosstabulation
770 05 256 73 102 678
75.0% 25.0% 100 .0%
373 4 127 1 500 5
74.6% 25.4% 100 .0%
807 39 269 44 107 683
75.0% 25.0% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










.38 9b 1 .53 3
.36 9 1 .54 4
.38 8 1 .53 3
.53 7 .27 2
.38 9 1 .53 3
107 683
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 




race * response Crosstabulation
770 05 256 73 102 678
75.0% 25.0% 100 .0%
862 8 306 2 116 90
73.8% 26.2% 100 .0%
856 33 287 35 114 368
74.9% 25.1% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










7.8 99b 1 .00 5
7.8 36 1 .00 5
7.8 35 1 .00 5
.00 5 .00 3
7.8 99 1 .00 5
114 368
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 2937.12.b. 
 
race * response Crosstabulation
115 35 498 3 165 18
69.8% 30.2% 100 .0%
853 0 380 7 123 37
69.1% 30.9% 100 .0%
200 65 879 0 288 55
69.5% 30.5% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt












1.5 93b 1 .20 7
1.5 61 1 .21 2
1.5 92 1 .20 7
.21 0 .10 6
1.5 93 1 .20 7
288 55
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 3758.18.b. 
 
race * response Crosstabulation
115 35 498 3 165 18
69.8% 30.2% 100 .0%
373 4 127 1 500 5
74.6% 25.4% 100 .0%
152 69 625 4 215 23
70.9% 29.1% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










42.441b 1 .00 0
42.210 1 .00 0
43.247 1 .00 0
.00 0 .00 0
42.439 1 .00 0
215 23
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 




race * response Crosstabulation
115 35 498 3 165 18
69.8% 30.2% 100 .0%
862 8 306 2 116 90
73.8% 26.2% 100 .0%
201 63 804 5 282 08
71.5% 28.5% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










53.023b 1 .00 0
52.829 1 .00 0
53.313 1 .00 0
.00 0 .00 0
53.021 1 .00 0
282 08
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 3334.02.b. 
 
race * response Crosstabulation
853 0 380 7 123 37
69.1% 30.9% 100 .0%
373 4 127 1 500 5
74.6% 25.4% 100 .0%
122 64 507 8 173 42
70.7% 29.3% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt












51.331b 1 .00 0
51.067 1 .00 0
52.214 1 .00 0
.00 0 .00 0
51.328 1 .00 0
173 42
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 1465.54.b. 
 
race * response Crosstabulation
853 0 380 7 123 37
69.1% 30.9% 100 .0%
862 8 306 2 116 90
73.8% 26.2% 100 .0%
171 58 686 9 240 27
71.4% 28.6% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










63.985b 1 .00 0
63.757 1 .00 0
64.096 1 .00 0
.00 0 .00 0
63.982 1 .00 0
240 27
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 




race * response Crosstabulation
373 4 127 1 500 5
74.6% 25.4% 100 .0%
862 8 306 2 116 90
73.8% 26.2% 100 .0%
123 62 433 3 166 95
74.0% 26.0% 100 .0%
Co unt
% within  race
Co unt
% within  race
Co unt










1.1 63b 1 .28 1
1.1 22 1 .28 9
1.1 67 1 .28 0
.28 9 .14 5
1.1 63 1 .28 1
166 95
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 1298.99.b. 
 
 
  total yes % 
lower 95% 
CI upper 95% CI 
chinese 102678 77005 75.00 74.73 75.26 
malay 16518 11535 69.83 69.13 70.53 
indian 12337 8530 69.14 68.33 69.96 
sikh 5005 3734 74.61 73.40 75.81 









477 19 100 .0% 0 .0% 477 19 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
26 543 90 20 35 563
74 .6% 25 .4% 10 0.0%
90 02 31 54 12 156
74 .1% 25 .9% 10 0.0%
35 545 12 174 47 719
74 .5% 25 .5% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt










1.6 18b 1 .20 3
1.5 88 1 .20 8
1.6 14 1 .20 4
.20 6 .10 4
1.6 18 1 .20 3
477 19
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 







414 72 100 .0% 0 .0% 414 72 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
409 0 181 9 590 9
69.2% 30.8% 100 .0%
306 33 108 39 414 72
73.9% 26.1% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt










77.109b 1 .00 0
76.828 1 .00 0
74.892 1 .00 0
.00 0 .00 0
77.107 1 .00 0
414 72
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





521 35 100 .0% 0 .0% 521 35 100 .0%religion * resp onse
N Percent N Percent N Percent





rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
116 27 494 5 165 72
70.2% 29.8% 100 .0%
381 70 139 65 521 35
73.2% 26.8% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt










115 .486b 1 .00 0
115 .258 1 .00 0
114 .137 1 .00 0
.00 0 .00 0
115 .484 1 .00 0
521 35
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





358 20 100 .0% 0 .0% 358 20 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
189 68 257
73.5% 26.5% 100 .0%
267 32 908 8 358 20
74.6% 25.4% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.16 2b 1 .68 8
.10 9 1 .74 1
.16 0 1 .68 9
.67 1 .37 1
.16 2 1 .68 8
358 20
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





361 42 100 .0% 0 .0% 361 42 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
407 172 579
70.3% 29.7% 100 .0%
269 50 919 2 361 42
74.6% 25.4% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












5.6 66b 1 .01 7
5.4 39 1 .02 0
5.4 79 1 .01 9
.01 8 .01 0
5.6 66 1 .01 7
361 42
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





461 86 100 .0% 0 .0% 461 86 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
345 77 116 09 461 86
74.9% 25.1% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
buddhism










4.2 76b 1 .03 9
4.2 23 1 .04 0
4.2 96 1 .03 8
.03 9 .02 0
4.2 76 1 .03 9
461 86
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





102 132 100 .0% 0 .0% 102 132 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
265 43 902 0 355 63
74.6% 25.4% 100 .0%
495 40 170 29 665 69
74.4% 25.6% 100 .0%
760 83 260 49 102 132
74.5% 25.5% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.57 7b 1 .44 7
.56 6 1 .45 2
.57 8 1 .44 7
.45 1 .22 6
.57 7 1 .44 7
102 132
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





180 65 100 .0% 0 .0% 180 65 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
90 02 31 54 12 156
74 .1% 25 .9% 10 0.0%
40 90 18 19 59 09
69 .2% 30 .8% 10 0.0%
13 092 49 73 18 065
72 .5% 27 .5% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












46.640b 1 .00 0
46.398 1 .00 0
46.114 1 .00 0
.00 0 .00 0
46.638 1 .00 0
180 65
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





287 28 100 .0% 0 .0% 287 28 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
90 02 31 54 12 156
74 .1% 25 .9% 10 0.0%
11 627 49 45 16 572
70 .2% 29 .8% 10 0.0%
20 629 80 99 28 728
71 .8% 28 .2% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












52.509b 1 .00 0
52.317 1 .00 0
52.769 1 .00 0
.00 0 .00 0
52.507 1 .00 0
287 28
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





124 13 100 .0% 0 .0% 124 13 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
900 2 315 4 121 56
74.1% 25.9% 100 .0%
189 68 257
73.5% 26.5% 100 .0%
919 1 322 2 124 13
74.0% 26.0% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.03 4b 1 .85 3
.01 3 1 .90 9
.03 4 1 .85 3
.83 4 .45 5
.03 4 1 .85 3
124 13
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





127 35 100 .0% 0 .0% 127 35 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
90 02 31 54 12 156
74 .1% 25 .9% 10 0.0%
40 7 17 2 57 9
70 .3% 29 .7% 10 0.0%
94 09 33 26 12 735
73 .9% 26 .1% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












4.0 50b 1 .04 4
3.8 58 1 .05 0
3.9 45 1 .04 7
.04 6 .02 5
4.0 50 1 .04 4
127 35
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





227 79 100 .0% 0 .0% 227 79 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
900 2 315 4 121 56
74.1% 25.9% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
170 36 574 3 227 79
74.8% 25.2% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
chr istian ity










7.4 52b 1 .00 6
7.3 69 1 .00 7
7.4 60 1 .00 6
.00 6 .00 3
7.4 52 1 .00 6
227 79
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





787 25 100 .0% 0 .0% 787 25 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
90 02 31 54 12 156
74 .1% 25 .9% 10 0.0%
49 540 17 029 66 569
74 .4% 25 .6% 10 0.0%
58 542 20 183 78 725
74 .4% 25 .6% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.71 9b 1 .39 7
.70 0 1 .40 3
.71 7 1 .39 7
.39 7 .20 1
.71 9 1 .39 7
787 25
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





224 81 100 .0% 0 .0% 224 81 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
409 0 181 9 590 9
69.2% 30.8% 100 .0%
116 27 494 5 165 72
70.2% 29.8% 100 .0%
157 17 676 4 224 81
69.9% 30.1% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












1.8 46b 1 .17 4
1.8 01 1 .18 0
1.8 40 1 .17 5
.17 5 .09 0
1.8 45 1 .17 4
224 81
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





616 6 100 .0% 0 .0% 616 6 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
409 0 181 9 590 9
69.2% 30.8% 100 .0%
189 68 257
73.5% 26.5% 100 .0%
427 9 188 7 616 6
69.4% 30.6% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












2.1 69b 1 .14 1
1.9 70 1 .16 0
2.2 26 1 .13 6
.14 7 .07 9
2.1 68 1 .14 1
616 6
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





648 8 100 .0% 0 .0% 648 8 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
409 0 181 9 590 9
69.2% 30.8% 100 .0%
407 172 579
70.3% 29.7% 100 .0%
449 7 199 1 648 8
69.3% 30.7% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.28 8b 1 .59 2
.23 9 1 .62 5
.28 9 1 .59 1
.60 4 .31 4
.28 8 1 .59 2
648 8
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





165 32 100 .0% 0 .0% 165 32 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
409 0 181 9 590 9
69.2% 30.8% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
121 24 440 8 165 32
73.3% 26.7% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
hin duism










79.831b 1 .00 0
79.504 1 .00 0
78.843 1 .00 0
.00 0 .00 0
79.826 1 .00 0
165 32
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





724 78 100 .0% 0 .0% 724 78 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
409 0 181 9 590 9
69.2% 30.8% 100 .0%
495 40 170 29 665 69
74.4% 25.6% 100 .0%
536 30 188 48 724 78
74.0% 26.0% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












76.341b 1 .00 0
76.071 1 .00 0
73.854 1 .00 0
.00 0 .00 0
76.340 1 .00 0
724 78
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





168 29 100 .0% 0 .0% 168 29 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
116 27 494 5 165 72
70.2% 29.8% 100 .0%
189 68 257
73.5% 26.5% 100 .0%
118 16 501 3 168 29
70.2% 29.8% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












1.3 83b 1 .24 0
1.2 26 1 .26 8
1.4 14 1 .23 4
.27 2 .13 4
1.3 83 1 .24 0
168 29
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





171 51 100 .0% 0 .0% 171 51 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
11 627 49 45 16 572
70 .2% 29 .8% 10 0.0%
40 7 17 2 57 9
70 .3% 29 .7% 10 0.0%
12 034 51 17 17 151
70 .2% 29 .8% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.00 5b 1 .94 5
.00 1 1 .98 2
.00 5 1 .94 5
.96 1 .49 1
.00 5 1 .94 5
171 51
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





271 95 100 .0% 0 .0% 271 95 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
116 27 494 5 165 72
70.2% 29.8% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
196 61 753 4 271 95
72.3% 27.7% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
islam










96.630b 1 .00 0
96.357 1 .00 0
97.631 1 .00 0
.00 0 .00 0
96.626 1 .00 0
271 95
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





831 41 100 .0% 0 .0% 831 41 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
11 627 49 45 16 572
70 .2% 29 .8% 10 0.0%
49 540 17 029 66 569
74 .4% 25 .6% 10 0.0%
61 167 21 974 83 141
73 .6% 26 .4% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












123 .752b 1 .00 0
123 .533 1 .00 0
121 .392 1 .00 0
.00 0 .00 0
123 .750 1 .00 0
831 41
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





836 100 .0% 0 .0% 836 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
189 68 257
73.5% 26.5% 100 .0%
407 172 579
70.3% 29.7% 100 .0%
596 240 836
71.3% 28.7% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.91 7b 1 .33 8
.76 5 1 .38 2
.92 6 1 .33 6
.36 3 .19 1
.91 6 1 .33 9
836
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





108 80 100 .0% 0 .0% 108 80 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
189 68 257
73.5% 26.5% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
822 3 265 7 108 80
75.6% 24.4% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
rom an catholicism










.59 2b 1 .44 1
.48 5 1 .48 6
.58 2 1 .44 6
.46 4 .24 3
.59 2 1 .44 2
108 80
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





668 26 100 .0% 0 .0% 668 26 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
189 68 257
73.5% 26.5% 100 .0%
495 40 170 29 665 69
74.4% 25.6% 100 .0%
497 29 170 97 668 26
74.4% 25.6% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












.10 4b 1 .74 7
.06 3 1 .80 2
.10 3 1 .74 8
.77 9 .40 1
.10 4 1 .74 7
668 26
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





112 02 100 .0% 0 .0% 112 02 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
407 172 579
70.3% 29.7% 100 .0%
803 4 258 9 106 23
75.6% 24.4% 100 .0%
844 1 276 1 112 02
75.4% 24.6% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion
sik hism










8.4 14b 1 .00 4
8.1 29 1 .00 4
8.0 87 1 .00 4
.00 4 .00 2
8.4 13 1 .00 4
112 02
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





671 48 100 .0% 0 .0% 671 48 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
40 7 17 2 57 9
70 .3% 29 .7% 10 0.0%
49 540 17 029 66 569
74 .4% 25 .6% 10 0.0%
49 947 17 201 67 148
74 .4% 25 .6% 10 0.0%
Co unt
% within  religion
Co unt
% within  religion
Co unt












5.1 27b 1 .02 4
4.9 13 1 .02 7
4.9 65 1 .02 6
.02 4 .01 3
5.1 27 1 .02 4
671 48
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 





771 92 100 .0% 0 .0% 771 92 100 .0%religion * resp onse
N Percent N Percent N Percent
Valid Missing To tal
Cases
 
rel igion * response Crosstabulation
803 4 258 9 106 23
75.6% 24.4% 100 .0%
495 40 170 29 665 69
74.4% 25.6% 100 .0%
575 74 196 18 771 92
74.6% 25.4% 100 .0%
Co unt
% within  religion
Co unt
% within  religion
Co unt
% within  religion











7.0 68b 1 .00 8
7.0 04 1 .00 8
7.1 23 1 .00 8
.00 8 .00 4
7.0 68 1 .00 8
771 92
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 






  total yes % 
lower 95% 
CI upper 95% CI 
BUDDHISM 35563 26543 74.64 74.18 75.09 
CHRISTIANITY 12156 9002 74.05 73.27 74.83 
HINDUISM 5909 4090 69.22 68.04 70.39 
ISLAM 16572 11627 70.16 69.46 70.86 
ROMAN 
CATHOLICISM 257 189 73.54 68.15 78.93 
SIKHISM 579 407 70.29 66.57 74.02 
NON-
DENOMINATION 10623 8034 75.63 74.81 76.44 
OTHERS 66569 49540 74.42 74.09 74.75 
 





70 .576 1.4 68 48 .078 .00 0 67 .191 73 .961





B Std. Erro r




t Sig. Lo wer Bound Up per Bound
95 % Co nfidence Interv al for
B
Dependent Variable: percenta. 
 
trend = 0.5% (95% -0.4% to 1.05%),p = 0.066 
 
slide 35. comparison by fee 
 
fee * response Cross tabulation
390 86 123 39 514 25
76.0% 24.0% 100 .0%
702 89 264 31 967 20
72.7% 27.3% 100 .0%
57 26 83
68.7% 31.3% 100 .0%
109 432 387 96 148 228
73.8% 26.2% 100 .0%
Co unt
% within  fee
Co unt
% within  fee
Co unt
% within  fee
Co unt











194 .181a 2 .00 0
195 .903 2 .00 0
194 .161 1 .00 0
148 228
Pearson  Chi-Square
Lik eliho od Ratio
Lin ear-by-Lin ear Association











fee * response Crosstabulation
390 86 123 39 514 25
76.0% 24.0% 100 .0%
702 89 264 31 967 20
72.7% 27.3% 100 .0%
109 375 387 70 148 145
73.8% 26.2% 100 .0%
Co unt
% within  fee
Co unt
% within  fee
Co unt










193 .054b 1 .00 0
192 .882 1 .00 0
194 .806 1 .00 0
.00 0 .00 0
193 .053 1 .00 0
148 145
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 13458.08.b. 
 
fee * response Crosstabulation
39 086 12 339 51 425
76 .0% 24 .0% 10 0.0%
57 26 83
68 .7% 31 .3% 10 0.0%
39 143 12 365 51 508
76 .0% 24 .0% 10 0.0%
Co unt
% within  fee
Co unt
% within  fee
Co unt












2.4 41b 1 .11 8
2.0 56 1 .15 2
2.2 97 1 .13 0
.12 0 .07 6
2.4 41 1 .11 8
515 08
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 19.92.b. 
 
fee * response Crosstabulation
702 89 264 31 967 20
72.7% 27.3% 100 .0%
57 26 83
68.7% 31.3% 100 .0%
703 46 264 57 968 03
72.7% 27.3% 100 .0%
Co unt
% within  fee
Co unt
% within  fee
Co unt










.66 7b 1 .41 4
.48 1 1 .48 8
.64 9 1 .42 1
.46 2 .24 4
.66 7 1 .41 4
968 03
Pearson  Chi-Square
Co ntinuity Co rrect iona
Lik eliho od Ratio
Fisher's Exact  Test
Lin ear-by-Lin ear Association








Computed only for a 2x2 tablea. 
0 cells (.0%) have expected count  less t han 5.  The minimum expected count is 22.68.b. 
 
  total yes % 
lower 95% 
CI upper 95% CI 
Private 51425 39086 76.01 75.64 76.37 
Subsidised 96720 70289 72.67 72.39 72.95 
Others 83 57 68.67 58.70 78.65 
 
